U.S. patent application number 14/320413 was filed with the patent office on 2015-02-12 for methods for identifying a target site of a cas9 nuclease.
This patent application is currently assigned to President and Fellows of Harvard College. The applicant listed for this patent is President and Fellows of Harvard College. Invention is credited to David R. Liu, Vikram Pattanayak.
Application Number | 20150044192 14/320413 |
Document ID | / |
Family ID | 52448835 |
Filed Date | 2015-02-12 |
United States Patent
Application |
20150044192 |
Kind Code |
A1 |
Liu; David R. ; et
al. |
February 12, 2015 |
METHODS FOR IDENTIFYING A TARGET SITE OF A CAS9 NUCLEASE
Abstract
Some aspects of this disclosure provide strategies, methods, and
reagents for selecting a site-specific endonuclease based on
determining its target site preferences and specificity. Methods
and reagents for determining target site preference and specificity
are also provided.
Inventors: |
Liu; David R.; (Lexington,
MA) ; Pattanayak; Vikram; (Cambridge, MA) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
President and Fellows of Harvard College |
Cambridge |
MA |
US |
|
|
Assignee: |
President and Fellows of Harvard
College
Cambridge
MA
|
Family ID: |
52448835 |
Appl. No.: |
14/320413 |
Filed: |
June 30, 2014 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
61864289 |
Aug 9, 2013 |
|
|
|
Current U.S.
Class: |
424/94.6 ;
435/196; 506/2 |
Current CPC
Class: |
C12Q 1/44 20130101; C12Q
1/6883 20130101; C12Q 1/6816 20130101; C12Q 1/6874 20130101; C12Q
2600/156 20130101; A61P 35/00 20180101; C12N 9/22 20130101; A61P
31/18 20180101; C12Q 1/6869 20130101; A61K 38/465 20130101; C12Y
301/00 20130101; C12Q 1/6816 20130101; C12Q 2521/301 20130101; C12Q
2522/101 20130101; C12Q 2535/122 20130101; C12Q 2563/131 20130101;
C12Q 2563/149 20130101; C12Q 1/6869 20130101; C12Q 2521/301
20130101; C12Q 2522/101 20130101; C12Q 2535/122 20130101; C12Q
2563/131 20130101; C12Q 2563/149 20130101 |
Class at
Publication: |
424/94.6 ; 506/2;
435/196 |
International
Class: |
C12Q 1/68 20060101
C12Q001/68; C12N 9/22 20060101 C12N009/22 |
Goverment Interests
GOVERNMENT SUPPORT
[0002] This invention was made with U.S. Government support under
grant numbers HR0011-11-2-0003 and N66001-12-C-4207, awarded by the
Defense Advanced Research Projects Agency. The U.S. Government has
certain rights in the invention.
Claims
1. A method of selecting an RNA-programmable nuclease that
specifically cuts a consensus target site from a plurality of
nucleases, the method comprising (a) providing a plurality of
candidate nucleases that cut the same consensus sequence; (b) for
each of the candidate nucleases of step (a), identifying a nuclease
target site cleaved by the candidate nuclease that differ from the
consensus target site; and (c) selecting a nuclease based on the
nuclease target site(s) identified in step (b).
2. The method of claim 1, wherein identifying a nuclease target
site comprises (i) contacting the nuclease with a library of
candidate nucleic acid molecules, wherein each nucleic acid
molecule comprises a concatemer of a sequence comprising a
candidate nuclease target site and a constant insert sequence,
under conditions suitable for the nuclease to cut a candidate
nucleic acid molecule comprising a target site of the nuclease; and
(ii) identifying nuclease target sites cut by the nuclease in (i)
by determining the sequence of an uncut nuclease target site on the
nucleic acid strand that was cut by the nuclease in step (i).
3. The method of claim 1, wherein the nuclease selected in step (c)
is the nuclease that cleaves the consensus target site with the
highest specificity.
4. The method of claim 3, wherein the nuclease that cleaves the
consensus target site with the highest specificity is the candidate
nuclease that cleaves the lowest number of target sites that differ
from the consensus site.
5. The method of claim 3, wherein the candidate nuclease that
cleaves the consensus target site with the highest specificity is
the candidate nuclease that cleaves the lowest number of target
sites that are different from the consensus site in the context of
a target genome.
6. The method of claim 1, wherein the candidate nuclease selected
in step (c) is a nuclease that does not cleave any target site
other than the consensus target site.
7. The method of claim 6, wherein the candidate nuclease selected
in step (c) is a nuclease that does not cleave any target site
other than the consensus target site within the genome of a subject
at a therapeutically effective concentration of the nuclease.
8. The method of claim 1 further comprising contacting a genome
with the nuclease selected in step (c).
9. The method of claim 8, wherein the genome is a vertebrate,
mammalian, human, non-human primate, rodent, mouse rat, hamster,
goat, sheep, cattle, dog, cat, reptile, amphibian, fish, nematode,
insect, or fly genome.
10. The method of claim 8, wherein the genome is within a living
cell.
11. The method of claim 8, wherein the genome is within a
subject.
12. The method of claim 1, wherein the consensus target site is
within an allele that is associated with a disease or disorder.
13. The method of claim 12, wherein cleavage of the consensus
target site results in treatment or prevention of the disease or
disorder.
14. The method of claim 12, wherein cleavage of the consensus
target site results in the alleviation of a symptom of the disease
or disorder.
15. The method of claim 12, wherein the disease is HIV/AIDS.
16. The method of claim 15, wherein the allele is a CCRS
allele.
17. The method of claim 12, wherein the disease is a proliferative
disease.
18. The method of claim 17, wherein the allele is a VEGFA
allele.
19. An isolated nuclease that has been selected according to claim
1.
20. The isolated nuclease of claim 19, wherein the nuclease has
been engineered to cleave a target site within a genome.
21. The isolated nuclease of claim 19, wherein the nuclease is a
Cas9 nuclease comprising an sgRNA that is complementary to the
target site within the genome.
22. The isolated nuclease of claim 19, wherein the nuclease has
been selected based on cutting no other candidate target site, not
more than one candidate target site, not more than two candidate
target sites, not more than three candidate target sites, not more
than four candidate target sites, not more than five candidate
target sites, not more than six candidate target sites, not more
than seven candidate target sites, not more than eight candidate
target sites, not more than eight candidate target sites, not more
than nine candidate target sites, or not more than 10 candidate
target sites in addition to its known nuclease target site.
Description
RELATED APPLICATION
[0001] This application claims priority under 35 U.S.C.
.sctn.119(e) to U.S. provisional patent application, U.S. Ser. No.
61/864,289, filed Aug. 9, 2013, the entire contents of which are
incorporated herein by reference.
BACKGROUND OF THE INVENTION
[0003] Site-specific endonucleases theoretically allow for the
targeted manipulation of a single site within a genome and are
useful in the context of gene targeting as well as for therapeutic
applications. In a variety of organisms, including mammals,
site-specific endonucleases have been used for genome engineering
by stimulating either non-homologous end joining or homologous
recombination. In addition to providing powerful research tools,
site-specific nucleases also have potential as gene therapy agents,
and two site-specific endonucleases have recently entered clinical
trials: one, CCR5-2246, targeting a human CCR-5 allele as part of
an anti-HIV therapeutic approach (NCT00842634, NCT01044654,
NCT01252641), and the other one, VF24684, targeting the human
VEGF-A promoter as part of an anti-cancer therapeutic approach
(NCT01082926).
[0004] Specific cleavage of the intended nuclease target site
without or with only minimal off-target activity is a prerequisite
for clinical applications of site-specific endonuclease, and also
for high-efficiency genomic manipulations in basic research
applications, as imperfect specificity of engineered site-specific
binding domains has been linked to cellular toxicity and undesired
alterations of genomic loci other than the intended target. Most
nucleases available today, however, exhibit significant off-target
activity, and thus may not be suitable for clinical applications.
Technology for evaluating nuclease specificity and for engineering
nucleases with improved specificity are therefore needed.
SUMMARY OF THE INVENTION
[0005] Some aspects of this disclosure are based on the recognition
that the reported toxicity of some engineered site-specific
endonucleases is based on off-target DNA cleavage, rather than on
off-target binding alone. Some aspects of this disclosure provide
strategies, compositions, systems, and methods to evaluate and
characterize the sequence specificity of site-specific nucleases,
for example, RNA-programmable endonucleases, such as Cas9
endonucleases, zinc finger nucleases (ZNFs), homing endonucleases,
or transcriptional activator-like element nucleases (TALENs).
[0006] The strategies, methods, and reagents of the present
disclosure represent, in some aspects, an improvement over previous
methods for assaying nuclease specificity. For example, some
previously reported methods for determining nuclease target site
specificity profiles by screening libraries of nucleic acid
molecules comprising candidate target sites relied on a "two-cut"
in vitro selection method which requires indirect reconstruction of
target sites from sequences of two half-sites resulting from two
adjacent cuts of the nuclease of a library member nucleic acid (see
e.g., PCT Application WO 2013/066438; and Pattanayak, V., Ramirez,
C. L., Joung, J. K. & Liu, D. R. Revealing off-target cleavage
specificities of zinc-finger nucleases by in vitro selection.
Nature methods 8, 765-770 (2011), the entire contents of each of
which are incorporated herein by reference). In contrast to such
"two-cut" strategies, the methods of the present disclosure utilize
an optimized "one cut" screening strategy, which allows for the
identification of library members that have been cut at least once
by the nuclease. As explained in more detail elsewhere herein, the
"one-cut" selection strategies provided herein are compatible with
single end high-throughput sequencing methods and do not require
computational reconstruction of cleaved target sites from cut
half-sites, thus streamlining the nuclease profiling process.
[0007] Some aspects of this disclosure provide in vitro selection
methods for evaluating the cleavage specificity of endonucleases
and for selecting nucleases with a desired level of specificity.
Such methods are useful, for example, for characterizing an
endonuclease of interest and for identifying a nuclease exhibiting
a desired level of specificity, for example, for identifying a
highly specific endonuclease for clinical applications.
[0008] Some aspects of this disclosure provide methods of
identifying suitable nuclease target sites that are sufficiently
different from any other site within a genome to achieve specific
cleavage by a given nuclease without any or at least minimal
off-target cleavage. Such methods are useful for identifying
candidate nuclease target sites that can be cleaved with high
specificity on a genomic background, for example, when choosing a
target site for genomic manipulation in vitro or in vivo.
[0009] Some aspects of this disclosure provide methods of
evaluating, selecting, and/or designing site-specific nucleases
with enhanced specificity as compared to current nucleases. For
example, provided herein are methods that are useful for selecting
and/or designing site-specific nucleases with minimal off-target
cleavage activity, for example, by designing variant nucleases with
binding domains having decreased binding affinity, by lowering the
final concentration of the nuclease, by choosing target sites that
differ by at least three base pairs from their closest sequence
relatives in the genome, and, in the case of RNA-programmable
nucleases, by selecting a guide RNA that results in the fewest
off-target sites being bound and/or cut.
[0010] Compositions and kits useful in the practice of the methods
described herein are also provided.
[0011] Some aspects of this disclosure provide methods for
identifying a target site of a nuclease. In some embodiments, the
method comprises (a) providing a nuclease that cuts a
double-stranded nucleic acid target site, wherein cutting of the
target site results in cut nucleic acid strands comprising a 5'
phosphate moiety; (b) contacting the nuclease of (a) with a library
of candidate nucleic acid molecules, wherein each nucleic acid
molecule comprises a concatemer of a sequence comprising a
candidate nuclease target site and a constant insert sequence,
under conditions suitable for the nuclease to cut a candidate
nucleic acid molecule comprising a target site of the nuclease; and
(c) identifying nuclease target sites cut by the nuclease in (b) by
determining the sequence of an uncut nuclease target site on the
nucleic acid strand that was cut by the nuclease in step (b). In
some embodiments, the nuclease creates blunt ends. In some
embodiments, the nuclease creates a 5' overhang. In some
embodiments, the determining of step (c) comprises ligating a first
nucleic acid adapter to the 5' end of a nucleic acid strand that
was cut by the nuclease in step (b) via 5'-phosphate-dependent
ligation. In some embodiments, the nucleic acid adapter is provided
in double-stranded form. In some embodiments, the
5'-phosphate-dependent ligation is a blunt end ligation. In some
embodiments, the method comprises filling in the 5'-overhang before
ligating the first nucleic acid adapter to the nucleic acid strand
that was cut by the nuclease. In some embodiments, the determining
of step (c) further comprises amplifying a fragment of the
concatemer cut by the nuclease that comprises an uncut target site
via a PCR reaction using a PCR primer that hybridizes with the
adapter and a PCR primer that hybridizes with the constant insert
sequence. In some embodiments, the method further comprises
enriching the amplified nucleic acid molecules for molecules
comprising a single uncut target sequence. In some embodiments, the
step of enriching comprises a size fractionation. In some
embodiments, the determining of step (c) comprises sequencing the
nucleic acid strand that was cut by the nuclease in step (b), or a
copy thereof obtained via PCR. In some embodiments, the library of
candidate nucleic acid molecules comprises at least 10.sup.8, at
least 10.sup.9, at least 10.sup.10, at least 10.sup.11, or at least
10.sup.12 different candidate nuclease cleavage sites. In some
embodiments, the nuclease is a therapeutic nuclease which cuts a
specific nuclease target site in a gene associated with a disease.
In some embodiments, the method further comprises determining a
maximum concentration of the therapeutic nuclease at which the
therapeutic nuclease cuts the specific nuclease target site, and
does not cut more than 10, more than 5, more than 4, more than 3,
more than 2, more than 1, or no additional nuclease target sites.
In some embodiments, the method further comprises administering the
therapeutic nuclease to a subject in an amount effective to
generate a final concentration equal or lower than the maximum
concentration. In some embodiments, the nuclease is an
RNA-programmable nuclease that forms a complex with an RNA
molecule, and wherein the nuclease:RNA complex specifically binds a
nucleic acid sequence complementary to the sequence of the RNA
molecule. In some embodiments, the RNA molecule is a single-guide
RNA (sgRNA). In some embodiments, the sgRNA comprises 5-50
nucleotides, 10-30 nucleotides, 15-25 nucleotides, 18-22
nucleotides, 19-21 nucleotides, e.g., 10, 11, 12, 13, 14, 15, 16,
17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30
nucleotides. In some embodiments, the nuclease is a Cas9 nuclease.
In some embodiments, the nuclease target site comprises a
[sgRNA-complementary sequence]-[protospacer adjacent motif (PAM)]
structure, and the nuclease cuts the target site within the
sgRNA-complementary sequence. In some embodiments, the
sgRNA-complementary sequence comprises 10, 11, 12, 13, 14, 15, 16,
17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30
nucleotides. In some embodiments, the nuclease comprises an
unspecific nucleic acid cleavage domain. In some embodiments, the
nuclease comprises a FokI cleavage domain. In some embodiments, the
nuclease comprises a nucleic acid cleavage domain that cleaves a
target sequence upon cleavage domain dimerization. In some
embodiments, the nuclease comprises a binding domain that
specifically binds a nucleic acid sequence. In some embodiments,
the binding domain comprises a zinc finger. In some embodiments,
the binding domain comprises at least 2, at least 3, at least 4, or
at least 5 zinc fingers. In some embodiments, the nuclease is a
Zinc Finger Nuclease. In some embodiments, the binding domain
comprises a Transcriptional Activator-Like Element. In some
embodiments, the nuclease is a Transcriptional Activator-Like
Element Nuclease (TALEN). In some embodiments, the nuclease is an
organic compound. In some embodiments, the nuclease comprises an
enediyne functional group. In some embodiments, the nuclease is an
antibiotic. In some embodiments, the compound is dynemicin,
neocarzinostatin, calicheamicin, esperamicin, bleomycin, or a
derivative thereof. In some embodiments, the nuclease is a homing
endonuclease.
[0012] Some aspects of this disclosure provide libraries of nucleic
acid molecules, in which each nucleic acid molecule comprises a
concatemer of a sequence comprising a candidate nuclease target
site and a constant insert sequence of 10-100 nucleotides. In some
embodiments, the constant insert sequence is at least 15, at least
20, at least 25, at least 30, at least 35, at least 40, at least
45, at least 50, at least 55, at least 60, at least 65, at least
70, at least 75, at least 80, or at least 95 nucleotides long. In
some embodiments, the constant insert sequence is not more than 15,
not more than 20, not more than 25, not more than 30, not more than
35, not more than 40, not more than 45, not more than 50, not more
than 55, not more than 60, not more than 65, not more than 70, not
more than 75, not more than 80, or not more than 95 nucleotides
long. In some embodiments, the candidate nuclease target sites are
sites that can be cleaved by an RNA-programmable nuclease, a Zinc
Finger Nuclease (ZFN), a Transcription Activator-Like Effector
Nuclease (TALEN), a homing endonuclease, an organic compound
nuclease, or an enediyne antibiotic (e.g., dynemicin,
neocarzinostatin, calicheamicin, esperamicin, bleomycin). In some
embodiments, the candidate nuclease target site can be cleaved by a
Cas9 nuclease. In some embodiments, the library comprises at least
10.sup.5, at least 10.sup.6, at least 10.sup.7, at least 10.sup.8,
at least 10.sup.9, at least 10.sup.10, at least 10.sup.11, or at
least 10.sup.12 different candidate nuclease target sites. In some
embodiments, the library comprises nucleic acid molecules of a
molecular weight of at least 0.5 kDa, at least 1 kDa, at least 2
kDa, at least 3 kDa, at least 4 kDa, at least 5 kDa, at least 6
kDa, at least 7 kDa, at least 8 kDa, at least 9 kDa, at least 10
kDa, at least 12 kDa, or at least 15 kDa. In some embodiments, the
library comprises candidate nuclease target sites that are
variations of a known target site of a nuclease of interest. In
some embodiments, the variations of a known nuclease target site
comprise 10 or fewer, 9 or fewer, 8 or fewer, 7 or fewer, 6 or
fewer, 5 or fewer, 4 or fewer, 3 or fewer, or 2 or fewer mutations
as compared to a known nuclease target site. In some embodiments,
the variations differ from the known target site of the nuclease of
interest by more than 5%, more than 10%, more than 15%, more than
20%, more than 25%, or more than 30% on average, distributed
binomially. In some embodiments, the variations differ from the
known target site by no more than 10%, no more than 15%, no more
than 20%, no more than 25%, nor more than 30%, no more than 40%, or
no more than 50% on average, distributed binomially. In some
embodiments, the nuclease of interest is a Cas9 nuclease, a zinc
finger nuclease, a TALEN, a homing endonuclease, an organic
compound nuclease, or an enediyne antibiotic (e.g., dynemicin,
neocarzinostatin, calicheamicin, esperamicin, bleomycin). In some
embodiments, the candidate nuclease target sites are Cas9 nuclease
target sites that comprise a [sgRNA-complementary sequence]-[PAM]
structure, wherein the sgRNA-complementary sequence comprises 10,
11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27,
28, 29, or 30 nucleotides.
[0013] Some aspects of this disclosure provide methods for
selecting a nuclease that specifically cuts a consensus target site
from a plurality of nucleases. In some embodiments, the method
comprises (a) providing a plurality of candidate nucleases that cut
the same consensus sequence; (b) for each of the candidate
nucleases of step (a), identifying a nuclease target site cleaved
by the candidate nuclease that differ from the consensus target
site using a method provided herein; (c) selecting a nuclease based
on the nuclease target site(s) identified in step (b). In some
embodiments, the nuclease selected in step (c) is the nuclease that
cleaves the consensus target site with the highest specificity. In
some embodiments, the nuclease that cleaves the consensus target
site with the highest specificity is the candidate nuclease that
cleaves the lowest number of target sites that differ from the
consensus site. In some embodiments, the candidate nuclease that
cleaves the consensus target site with the highest specificity is
the candidate nuclease that cleaves the lowest number of target
sites that are different from the consensus site in the context of
a target genome. In some embodiments, the candidate nuclease
selected in step (c) is a nuclease that does not cleave any target
site other than the consensus target site. In some embodiments, the
candidate nuclease selected in step (c) is a nuclease that does not
cleave any target site other than the consensus target site within
the genome of a subject at a therapeutically effective
concentration of the nuclease. In some embodiments, the method
further comprises contacting a genome with the nuclease selected in
step (c). In some embodiments, the genome is a vertebrate,
mammalian, human, non-human primate, rodent, mouse, rat, hamster,
goat, sheep, cattle, dog, cat, reptile, amphibian, fish, nematode,
insect, or fly genome. In some embodiments, the genome is within a
living cell. In some embodiments, the genome is within a subject.
In some embodiments, the consensus target site is within an allele
that is associated with a disease or disorder. In some embodiments,
cleavage of the consensus target site results in treatment or
prevention of a disease or disorder, e.g., amelioration or
prevention of at least one sign and/or symptom of the disease or
disorder. In some embodiments, cleavage of the consensus target
site results in the alleviation of a sign and/or symptom of the
disease or disorder. In some embodiments, cleavage of the consensus
target site results in the prevention of the disease or disorder.
In some embodiments, the disease is HIV/AIDS. In some embodiments,
the allele is a CCR5 allele. In some embodiments, the disease is a
proliferative disease. In some embodiments, the disease is cancer.
In some embodiments, the allele is a VEGFA allele.
[0014] Some aspects of this disclosure provide isolated nucleases
that have been selected according to a method provided herein. In
some embodiments, the nuclease has been engineered to cleave a
target site within a genome. In some embodiments, the nuclease is a
Cas9 nuclease comprising an sgRNA that is complementary to the
target site within the genome. In some embodiments, the nuclease is
a Zinc Finger Nuclease (ZFN) or a Transcription Activator-Like
Effector Nuclease (TALEN), a homing endonuclease, or an organic
compound nuclease (e.g., an enediyne, an antibiotic nuclease,
dynemicin, neocarzinostatin, calicheamicin, esperamicin, bleomycin,
or a derivative thereof). In some embodiments, the nuclease has
been selected based on cutting no other candidate target site, not
more than one candidate target site, not more than two candidate
target sites, not more than three candidate target sites, not more
than four candidate target sites, not more than five candidate
target sites, not more than six candidate target sites, not more
than seven candidate target sites, not more than eight candidate
target sites, not more than eight candidate target sites, not more
than nine candidate target sites, or not more than ten candidate
target sites in addition to its known nuclease target site.
[0015] Some aspects of this disclosure provide kits comprising a
library of nucleic acid molecules comprising candidate nuclease
target sites as provided herein. Some aspects of this disclosure
provide kits comprising an isolated nuclease as provided herein. In
some embodiments, the nuclease is a Cas9 nuclease. In some
embodiments, the kit further comprises a nucleic acid molecule
comprising a target site of the isolated nuclease. In some
embodiments, the kit comprises an excipient and instructions for
contacting the nuclease with the excipient to generate a
composition suitable for contacting a nucleic acid with the
nuclease. In some embodiments, the composition is suitable for
contacting a nucleic acid within a genome. In some embodiments, the
composition is suitable for contacting a nucleic acid within a
cell. In some embodiments, the composition is suitable for
contacting a nucleic acid within a subject. In some embodiments,
the excipient is a pharmaceutically acceptable excipient.
[0016] Some aspects of this disclosure provide pharmaceutical
compositions that are suitable for administration to a subject. In
some embodiments, the composition comprises an isolated nuclease as
provided herein. In some embodiments, the composition comprises a
nucleic acid encoding such a nuclease. In some embodiments, the
composition comprises a pharmaceutically acceptable excipient.
[0017] Other advantages, features, and uses of the invention will
be apparent from the detailed description of certain non-limiting
embodiments of the invention; the drawings, which are schematic and
not intended to be drawn to scale; and the claims.
BRIEF DESCRIPTION OF THE DRAWINGS
[0018] FIGS. 1A-B. In vitro selection overview. (a) Cas9 complexed
with a short guide RNA (sgRNA) recognizes .about.20 bases of a
target DNA substrate that is complementary to the sgRNA sequence
and cleaves both DNA strands. The white triangles represent
cleavage locations. (b) A modified version of our previously
described in vitro selection was used to comprehensively profile
Cas9 specificity. A concatemeric pre-selection DNA library in which
each molecule contains one of 10.sup.12 distinct variants of a
target DNA sequence (white rectangles) was generated from synthetic
DNA oligonucleotides by ligation and rolling-circle amplification.
This library was incubated with a Cas9:sgRNA complex of interest.
Cleaved library members contain 5' phosphate groups (circles) and
therefore are substrates for adapter ligation and PCR. The
resulting amplicons were subjected to high-throughput DNA
sequencing and computational analysis.
[0019] FIGS. 2A-H. In vitro selection results for Cas9:CLTA1 sgRNA.
Heat maps.sup.21 show the specificity profiles of Cas9:CLTA1 sgRNA
v2.1 under enzyme-limiting conditions (a, b), Cas9:CLTA1 sgRNA v1.0
under enzyme-saturating conditions (c, d), and Cas9:CLTA1 sgRNA
v2.1 under enzyme-saturating conditions (e, f). Heat maps show all
post-selection sequences (a, c, e) or only those sequences
containing a single mutation in the 20-base pair sgRNA-specified
target site and two-base pair PAM (b, d, f). Specificity scores of
1.0 and -1.0 corresponds to 100% enrichment for and against,
respectively, a particular base pair at a particular position.
Black boxes denote the intended target nucleotides. (g) Effect of
Cas9:sgRNA concentration on specificity. Positional specificity
changes between enzyme-limiting (200 nM DNA, 100 nM Cas9:sgRNA
v2.1) and enzyme-saturating (200 nM DNA, 1000 nM Cas9:sgRNA v2.1)
conditions, normalized to the maximum possible change in positional
specificity, are shown for CLTA1. (h) Effect of sgRNA architecture
on specificity. Positional specificity changes between sgRNA v1.0
and sgRNA v2.1 under enzyme-saturating conditions, normalized to
the maximum possible change in positional specificity, are shown
for CLTA1. See FIGS. 6-8, 25, and 26 for corresponding data for
CLTA2, CLTA3, and CLTA4.
[0020] FIGS. 3A-D. Target sites profiled in this study. (A) The 5'
end of the sgRNA has 20 nucleotides that are complementary to the
target site. The target site contains an NGG motif (PAM) adjacent
to the region of RNA:DNA complementarity. (B) Four human clathrin
gene (CLTA) target sites are shown. (C, D) Four human clathrin gene
(CLTA) target sites are shown with sgRNAs. sgRNA v1.0 is shorter
than sgRNA v2.1. The PAM is shown for each site. The non-PAM end of
the target site corresponds to the 5' end of the sgRNA.
[0021] FIG. 4. Cas9:guide RNA cleavage of on-target DNA sequences
in vitro. Discrete DNA cleavage assays on an approximately 1-kb
linear substrate were performed with 200 nM on-target site and 100
nM Cas9:v1.0 sgRNA, 100 nM Cas9:v2.1 sgRNA, 1000 nM Cas9:v1.0
sgRNA, and 1000 nM Cas9:v2.1 sgRNA for each of four CLTA target
sites. For CLTA1, CLTA2, and CLTA4, Cas9:v2.1 sgRNA shows higher
activity than Cas9:v1.0 sgRNA. For CLTA3, the activities of the
Cas9:v1.0 sgRNA and Cas9:v2.1 sgRNA were comparable.
[0022] FIGS. 5A-E. In vitro selection results for four target
sites. In vitro selections were performed on 200 nM pre-selection
library with 100 nM Cas9:sgRNA v2.1, 1000 nM Cas9:sgRNA v1.0, or
1000 nM Cas9:sgRNA v2.1. (A) Post-selection PCR products are shown
for the 12 selections performed. DNA containing 1.5 repeats were
quantified for each selection and pooled in equimolar amounts
before gel purification and sequencing. (B-E) Distributions of
mutations are shown for pre-selection (black) and post-selection
libraries (colored). The post-selection libraries are enriched for
sequences with fewer mutations than the pre-selection libraries.
Mutations are counted from among the 20 base pairs specified by the
sgRNA and the two-base pair PAM. P-values are <0.01 for all
pairwise comparisons between distributions in each panel. P-values
were calculated using t-tests, assuming unequal size and unequal
variance.
[0023] FIGS. 6A-F. In vitro selection results for Cas9:CLTA2 sgRNA.
Heat maps.sup.24 show the specificity profiles of Cas9:CLTA2 sgRNA
v2.1 under enzyme-limiting conditions (A, B), Cas9:CLTA2 sgRNA v1.0
under enzyme-excess conditions (C, D), and Cas9:CLTA2 sgRNA v2.1
under enzyme-excess conditions (E, F). Heat maps show all
post-selection sequences (A, C, E) or only those sequences
containing a single mutation in the 20-base pair sgRNA-specified
target site and two-base pair PAM (B, D, F). Specificity scores of
1.0 and -1.0 corresponds to 100% enrichment for and against,
respectively, a particular base pair at a particular position.
Black boxes denote the intended target nucleotides.
[0024] FIGS. 7A-F. In vitro selection results for Cas9:CLTA3 sgRNA.
Heat maps.sup.24 show the specificity profiles of Cas9:CLTA3 sgRNA
v2.1 under enzyme-limiting conditions (A, B), Cas9:CLTA3 sgRNA v1.0
under enzyme-excess conditions (C, D), and Cas9:CLTA3 sgRNA v2.1
under enzyme-saturating conditions (E, F). Heat maps show all
post-selection sequences (A, C, E) or only those sequences
containing a single mutation in the 20-base pair sgRNA-specified
target site and two-base pair PAM (B, D, F). Specificity scores of
1.0 and -1.0 corresponds to 100% enrichment for and against,
respectively, a particular base pair at a particular position.
Black boxes denote the intended target nucleotides.
[0025] FIGS. 8A-F. In vitro selection results for Cas9:CLTA4 sgRNA.
Heat maps.sup.24 show the specificity profiles of Cas9:CLTA4 sgRNA
v2.1 under enzyme-limiting conditions (A, B), Cas9:CLTA4 sgRNA v1.0
under enzyme-excess conditions (C, D), and Cas9:CLTA4 sgRNA v2.1
under enzyme-saturating conditions (E, F). Heat maps show all
post-selection sequences (A, C, E) or only those sequences
containing a single mutation in the 20-base pair sgRNA-specified
target site and two-base pair PAM (B, D, F). Specificity scores of
1.0 and -1.0 corresponds to 100% enrichment for and against,
respectively, a particular base pair at a particular position.
Black boxes denote the intended target nucleotides.
[0026] FIGS. 9A-D. In vitro selection results as sequence logos.
Information content is plotted.sup.25 for each target site position
(1-20) specified by CLTA1 (A), CLTA2 (B), CLTA3 (C), and CLTA4 (D)
sgRNA v2.1 under enzyme-limiting conditions. Positions in the PAM
are labelled "P1," "P2," and "P3." Information content is plotted
in bits. 2.0 bits indicates absolute specificity and 0 bits
indicates no specificity.
[0027] FIGS. 10A-L. Tolerance of mutations distal to the PAM for
CLTA1. The maximum specificity scores at each position are shown
for the Cas9:CLTA1 v2.1 sgRNA selections when considering only
those sequences with on-target base pairs in gray, while allowing
mutations in the first 1-12 base pairs (a-l). The positions that
are not constrained to on-target base pairs are indicated by dark
bars. Higher specificity score values indicate higher specificity
at a given position. The positions that were not allowed to contain
any mutations (gray) were plotted with a specificity score of +1.
For all panels, specificity scores were calculated from
pre-selection library sequences and post-selection library
sequences with an n.gtoreq.5,130 and n.gtoreq.74,538,
respectively.
[0028] FIGS. 11A-L. Tolerance of mutations distal to the PAM for
CLTA2. The maximum specificity scores at each position are shown
for the Cas9:CLTA2 v2.1 sgRNA selections when considering only
those sequences with on-target base pairs in gray, while allowing
mutations in the first 1-12 base pairs (a-l). The positions that
are not constrained to on-target base pairs are indicated by dark
bars. Higher specificity score values indicate higher specificity
at a given position. The positions that were not allowed to contain
any mutations (gray) were plotted with a specificity score of +1.
For all panels, specificity scores were calculated from
pre-selection library sequences and post-selection library
sequences with an n.gtoreq.3,190 and n.gtoreq.25,365,
respectively.
[0029] FIGS. 12A-L. Tolerance of mutations distal to the PAM for
CLTA3. The maximum specificity scores at each position are shown
for the Cas9:CLTA3 v2.1 sgRNA selections when considering only
those sequences with on-target base pairs in gray, while allowing
mutations in the first 1-12 base pairs (a-l). The positions that
are not constrained to on-target base pairs are indicated by dark
bars. Higher specificity score values indicate higher specificity
at a given position. The positions that were not allowed to contain
any mutations (gray) were plotted with a specificity score of +1.
For all panels, specificity scores were calculated from
pre-selection library sequences and post-selection library
sequences with an n.gtoreq.5,604 and n.gtoreq.158,424,
respectively.
[0030] FIGS. 13A-I. Tolerance of mutations distal to the PAM for
CLTA4. The maximum specificity scores at each position are shown
for the Cas9:CLTA4 v2.1 sgRNA selections when considering only
those sequences with on-target base pairs in gray, while allowing
mutations in the first 1-12 base pairs (a-i). The positions that
are not constrained to on-target base pairs are indicated by dark
bars. Higher specificity score values indicate higher specificity
at a given position. The positions that were not allowed to contain
any mutations (gray) were plotted with a specificity score of +1.
For all panels, specificity scores were calculated from
pre-selection library sequences and post-selection library
sequences with an n.gtoreq.2,323 and n.gtoreq.21,819,
respectively.
[0031] FIGS. 14A-L. Tolerance of mutations distal to the PAM in
CLTA1 target sites. Distributions of mutations are shown for in
vitro selection on 200 nM pre-selection library with 1000 nM
Cas9:CLTA1 sgRNA v2.1. The number of mutations shown are in a 1-12
base pair target site subsequence farthest from the PAM (a-l) when
the rest of the target site, including the PAM, contains only
on-target base pairs. The pre-selection and post-selection
distributions are similar for up to three base pairs, demonstrating
tolerance for target sites with mutations in the three base pairs
farthest from the PAM when the rest of the target sites have
optimal interactions with the Cas9:sgRNA. For all panels, graphs
were generated from pre-selection library sequences and
post-selection library sequences with an n.gtoreq.5,130 and
n.gtoreq.74,538, respectively.
[0032] FIGS. 15A-L. Tolerance of mutations distal to the PAM in
CLTA2 target sites. Distributions of mutations are shown for in
vitro selection on 200 nM pre-selection library with 1000 nM
Cas9:CLTA2 sgRNA v2.1. The number of mutations shown are in a 1-12
base pair target site subsequence farthest from the PAM (a-l) when
the rest of the target site, including the PAM, contains only
on-target base pairs. The pre-selection and post-selection
distributions are similar for up to three base pairs, demonstrating
tolerance for target sites with mutations in the three base pairs
farthest from the PAM when the rest of the target sites have
optimal interactions with the Cas9:sgRNA. For all panels, graphs
were generated from pre-selection library sequences and
post-selection library sequences with an n.gtoreq.3,190 and
n.gtoreq.21,265, respectively.
[0033] FIGS. 16A-L. Tolerance of mutations distal to PAM in CLTA3
target sites. Distributions of mutations are shown for in vitro
selection on 200 nM pre-selection library with 1000 nM Cas9:CLTA3
sgRNA v2.1. The number of mutations shown are in a 1-12 base pair
target site subsequence farthest from the PAM (a-l) when the rest
of the target site, including the PAM, contains only on-target base
pairs. The pre-selection and post-selection distributions are
similar for up to three base pairs, demonstrating tolerance for
target sites with mutations in the three base pairs farthest from
the PAM when the rest of the target sites have optimal interactions
with the Cas9:sgRNA. For all panels, graphs were generated from
pre-selection library sequences and post-selection library
sequences with an n.gtoreq.5,604 and n.gtoreq.158,424,
respectively.
[0034] FIGS. 17A-L. Tolerance of mutations distal to PAM in CLTA4
target sites. Distributions of mutations are shown for in vitro
selection on 200 nM pre-selection library with 1000 nM Cas9:CLTA4
sgRNA v2.1. The number of mutations shown are in a 1-12 base pair
target site subsequence farthest from the PAM (a-l) when the rest
of the target site, including the PAM, contains only on-target base
pairs. The pre-selection and post-selection distributions are
similar for up to three base pairs, demonstrating tolerance for
target sites with mutations in the three base pairs farthest from
the PAM when the rest of the target sites have optimal interactions
with the Cas9:sgRNA. For all panels, graphs were generated from
pre-selection library sequences and post-selection library
sequences with an n.gtoreq.2,323 and n.gtoreq.21,819,
respectively.
[0035] FIGS. 18A-D. Positional specificity patterns for 100 nM
Cas9:sgRNA v2.1. Positional specificity, defined as the sum of the
magnitude of the specificity score for each of the four possible
base pairs recognized at a certain position in the target site, is
plotted for each target site under enzyme-limiting conditions for
sgRNA v2.1 (A-D). The positional specificity is shown as a value
normalized to the maximum positional specificity value of the
target site. Positional specificity is highest at the end of the
target site proximal to the PAM and is lowest in the middle of the
target site and in the several nucleotides most distal to the
PAM.
[0036] FIGS. 19A-D. Positional specificity patterns for 1000 nM
Cas9:sgRNA v1.0. Positional specificity, defined as the sum of the
magnitude of the specificity score for each of the four possible
base pairs recognized at a certain position in the target site, is
plotted for each target site under enzyme-excess conditions with
sgRNA v1.0 (A-D). The positional specificity is shown as a value
normalized to the maximum positional specificity value of the
target site. Positional specificity is relatively constant across
the target site but is lowest in the middle of the target site and
in the several nucleotides most distal to the PAM.
[0037] FIGS. 20A-D. Positional specificity patterns for 1000 nM
Cas9:sgRNA v2.1. Positional specificity, defined as the sum of the
magnitude of the specificity score for each of the four possible
base pairs recognized at a certain position in the target site, is
plotted for each target site under enzyme-excess conditions with
sgRNA v2.1 (A-D). The positional specificity is shown as a value
normalized to the maximum positional specificity value of the
target site. Positional specificity is relatively constant across
the target site but is lowest in the middle of the target site and
in the several nucleotides most distal to the PAM.
[0038] FIGS. 21A-D. PAM nucleotide preferences. The abundance in
the pre-selection library and post-selection libraries under
enzyme-limiting or enzyme-excess conditions are shown for all 16
possible PAM dinucleotides for selections with CLTA1 (a), CLTA2
(b), CLTA3 (c), and CLTA4 (d) sgRNA v2.1. GG dinucleotides
increased in abundance in the post-selection libraries, while the
other possible PAM dinucleotides decreased in abundance after the
selection.
[0039] FIGS. 22A-D. PAM nucleotide preferences for on-target sites.
Only post-selection library members containing no mutations in the
20 base pairs specified by the guide RNAs were included in this
analysis. The abundance in the pre-selection library and
post-selection libraries under enzyme-limiting and enzyme-excess
conditions are shown for all 16 possible PAM dinucleotides for
selections with CLTA1 (A), CLTA2 (B), CLTA3 (C), and CLTA4 (D)
sgRNA v2.1. GG dinucleotides increased in abundance in the
post-selection libraries, while the other possible PAM
dinucleotides generally decreased in abundance after the selection,
although this effect for the enzyme-excess concentrations of
Cas9:sgRNA was modest or non-existent for many dinucleotides.
[0040] FIGS. 23A-D. PAM dinucleotide specificity scores. The
specificity scores under enzyme-limiting and enzyme-excess
conditions are shown for all 16 possible PAM dinucleotides
(positions 2 and 3 of the three-nucleotide NGG PAM) for selections
with CLTA1 (A), CLTA2 (B), CLTA3 (C), and CLTA4 (D) sgRNA v2.1. The
specificity score indicates the enrichment of the PAM dinucleotide
in the post-selection library relative to the pre-selection
library, normalized to the maximum possible enrichment of that
dinucleotide. A specificity score of +1.0 indicates that a
dinucleotide is 100% enriched in the post-selection library, and a
specificity score of -1.0 indicates that a dinucleotide is 100%
de-enriched. GG dinucleotides were the most enriched in the
post-selection libraries, and AG, GA, GC, GT, and TG show less
relative de-enrichment compared to the other possible PAM
dinucleotides.
[0041] FIGS. 24A-D. PAM dinucleotide specificity scores for
on-target sites. Only post-selection library members containing no
mutations in the 20 base pairs specified by the guide RNAs were
included in this analysis. The specificity scores under
enzyme-limiting and enzyme-excess conditions are shown for all 16
possible PAM dinucleotides (positions 2 and 3 of the
three-nucleotide NGG PAM) for selections with CLTA1 (A), CLTA2 (B),
CLTA3 (C), and CLTA4 (D) sgRNA v2.1. The specificity score
indicates the enrichment of the PAM dinucleotide in the
post-selection library relative to the pre-selection library,
normalized to the maximum possible enrichment of that dinucleotide.
A specificity score of +1.0 indicates that a dinucleotide is 100%
enriched in the post-selection library, and a specificity score of
-1.0 indicates that a dinucleotide is 100% de-enriched. GG
dinucleotides were the most enriched in the post-selection
libraries, AG and GA nucleotides were neither enriched or
de-enriched in at least one selection condition, and GC, GT, and TG
show less relative de-enrichment compared to the other possible PAM
dinucleotides.
[0042] FIGS. 25A-D. Effects of Cas9:sgRNA concentration on
specificity. Positional specificity changes between enzyme-limiting
(200 nM DNA, 100 nM Cas9:sgRNA v2.1) and enzyme-excess (200 nM DNA,
1000 nM Cas9:sgRNA v2.1) conditions are shown for selections with
sgRNAs targeting CLTA1 (A), CLTA2 (B), CLTA3 (C), and CLTA4 (D)
target sites. Lines indicate the maximum possible change in
positional specificity for a given position. The highest changes in
specificity occur proximal to the PAM as enzyme concentration is
increased.
[0043] FIGS. 26A-D. Effects of sgRNA architecture on specificity.
Positional specificity changes between Cas9:sgRNA v1.0 and
Cas9:sgRNA v2.1 under enzyme-excess (200 nM DNA, 1000 nM Cas9:sgRNA
v2.1) conditions are shown for selections with sgRNAs targeting
CLTA1 (A), CLTA2 (B), CLTA3 (C), and CLTA4 (D) target sites. Lines
indicate the maximum possible change in positional specificity for
a given position.
[0044] FIG. 27. Cas9:guide RNA cleavage of off-target DNA sequences
in vitro. Discrete DNA cleavage assays on a 96-bp linear substrate
were performed with 200 nM DNA and 1000 nM Cas9:CLTA4 v2.1 sgRNA
for the on-target CLTA4 site (CLTA4-0) and five CLTA4 off-target
sites identified by in vitro selection. Enrichment values shown are
from the in vitro selection with 1000 nM Cas9:CLTA4 v2.1 sgRNA.
CLTA4-1 and CLTA4-3 were the most highly enriched sequences under
these conditions. CLTA4-2a, CLTA4-2b, and CLTA4-2c are two-mutation
sequences that represent a range of enrichment values from high
enrichment to no enrichment to high de-enrichment. Lowercase
letters indicate mutations relative to the on-target CLTA4 site.
The enrichment values are qualitatively consistent with the
observed amount of cleavage in vitro.
[0045] FIG. 28. Effect of guide RNA architecture and Cas9:sgRNA
concentration on in vitro cleavage of an off-target site. Discrete
DNA cleavage assays on a 96-bp linear substrate were performed with
200 nM DNA and 100 nM Cas9:v1.0 sgRNA, 100 nM Cas9:v2.1 sgRNA, 1000
nM Cas9:v1.0 sgRNA, or 1000 nM Cas9:v2.1 sgRNA for the CLTA4-3
off-target site (5' GggGATGTAGTGTTTCCACtGGG--mutations are shown in
lowercase letters). DNA cleavage is observed under all four
conditions tested, and cleavage rates are higher under
enzyme-excess conditions, or with v2.1 sgRNA compared with v1.0
sgRNA.
DEFINITIONS
[0046] As used herein and in the claims, the singular forms "a,"
"an," and "the" include the singular and the plural reference
unless the context clearly indicates otherwise. Thus, for example,
a reference to "an agent" includes a single agent and a plurality
of such agents.
[0047] The term "Cas9" or "Cas9 nuclease" refers to an RNA-guided
nuclease comprising a Cas9 protein, or a fragment thereof. A Cas9
nuclease is also referred to sometimes as a casnI nuclease or a
CRISPR (clustered regularly interspaced short palindromic
repeat)-associated nuclease. CRISPR is an adaptive immune system
that provides protection against mobile genetic elements (e.g.,
viruses, transposable elements and conjugative plasmids). CRISPR
clusters contain spacers, sequences complementary to antecedent
mobile elements, and target invading nucleic acids. CRISPR clusters
are transcribed and processed into CRISPR RNA (crRNA). In type II
CRISPR systems correct processing of pre-crRNA requires a
trans-encoded small RNA (tracrRNA), endogenous ribonuclease 3 (mc)
and a Cas9 protein. The tracrRNA serves as a guide for ribonuclease
3-aided processing of pre-crRNA. Subsequently, Cas9/crRNA/tracrRNA
endonucleolytically cleaves linear or circular dsDNA target
complementary to the spacer. The target strand not complementary to
crRNA is first cut endonucleolytically, then trimmed 3'-5'
exonucleolytically. In nature, DNA-binding and cleavage typically
requires protein and both RNA species. However, single guide RNAs
("sgRNA", or simply "gNRA") can be engineered so as to incorporate
aspects of both the crRNA and tracrRNA into a single RNA molecule.
See, e.g., Jinek M., Chylinski K., Fonfara I., Hauer M., Doudna J.
A., Charpentier E. Science 337:816-821(2012), the entire contents
of which is hereby incorporated by reference. Cas9 recognizes a
short motif in the CRISPR repeat sequences (the PAM or protospacer
adjacent motif) to help distinguish self versus non-self. Cas9
nuclease sequences and structures are well known to those of skill
in the art (see, e.g., "Complete genome sequence of an M1 strain of
Streptococcus pyogenes." Ferretti J. J., McShan W. M., Ajdic D. J.,
Savic D. J., Savic G., Lyon K., Primeaux C., Sezate S., Suvorov A.
N., Kenton S., Lai H. S., Lin S. P., Qian Y., Jia H. G., Najar F.
Z., Ren Q., Zhu H., Song L. expand/collapse author list McLaughlin
R. E., Proc. Natl. Acad. Sci. U.S.A. 98:4658-4663(2001); "CRISPR
RNA maturation by trans-encoded small RNA and host factor RNase
III." Deltcheva E., Chylinski K., Sharma C. M., Gonzales K., Chao
Y., Pirzada Z. A., Eckert M. R., Vogel J., Charpentier E., Nature
471:602-607(2011); and "A programmable dual-RNA-guided DNA
endonuclease in adaptive bacterial immunity." Jinek M., Chylinski
K., Fonfara I., Hauer M., Doudna J. A., Charpentier E. Science
337:816-821(2012), the entire contents of each of which are
incorporated herein by reference). Cas9 orthologs have been
described in various species, including, but not limited to, S.
pyogenes and S. thermophilus. Additional suitable Cas9 nucleases
and sequences will be apparent to those of skill in the art based
on this disclosure, and such Cas9 nucleases and sequences include
Cas9 sequences from the organisms and loci disclosed in Chylinski,
Rhun, and Charpentier, "The tracrRNA and Cas9 families of type II
CRISPR-Cas immunity systems" (2013) RNA Biology 10:5, 726-737; the
entire contents of which are incorporated herein by reference. In
some embodiments, proteins comprising Cas9 or fragments thereof
proteins are referred to as "Cas9 variants." A Cas9 variant shares
homology to Cas9, or a fragment thereof. For example a Cas9 variant
is at least about 70% identical, at least about 80% identical, at
least about 90% identical, at least about 95% identical, at least
about 98% identical, at least about 99% identical, at least about
99.5% identical, or at least about 99.9% to wild type Cas9. In some
embodiments, the Cas9 variant comprises a fragment of Cas9 (e.g., a
gRNA binding domain or a DNA-cleavage domain), such that the
fragment is at least about 70% identical, at least about 80%
identical, at least about 90% identical, at least about 95%
identical, at least about 98% identical, at least about 99%
identical, at least about 99.5% identical, or at least about 99.9%
to the corresponding fragment of wild type Cas9. In some
embodiments, wild type Cas9 corresponds to Cas9 from Streptococcus
pyogenes (NCBI Reference Sequence: NC.sub.--017053.1, SEQ ID NO:40
(nucleotide); SEQ ID NO:41 (amino acid)).
TABLE-US-00001 (SEQ ID NO: 40)
ATGGATAAGAAATACTCAATAGGCTTAGATATCGGCACAAATAGCGTCGG
ATGGGCGGTGATCACTGATGATTATAAGGTTCCGTCTAAAAAGTTCAAGG
TTCTGGGAAATACAGACCGCCACAGTATCAAAAAAAATCTTATAGGGGCT
CTTTTATTTGGCAGTGGAGAGACAGCGGAAGCGACTCGTCTCAAACGGAC
AGCTCGTAGAAGGTATACACGTCGGAAGAATCGTATTTGTTATCTACAGG
AGATTTTTTCAAATGAGATGGCGAAAGTAGATGATAGTTTCTTTCATCGA
CTTGAAGAGTCTTTTTTGGTGGAAGAAGACAAGAAGCATGAACGTCATCC
TATTTTTGGAAATATAGTAGATGAAGTTGCTTATCATGAGAAATATCCAA
CTATCTATCATCTGCGAAAAAAATTGGCAGATTCTACTGATAAAGCGGAT
TTGCGCTTAATCTATTTGGCCTTAGCGCATATGATTAAGTTTCGTGGTCA
TTTTTTGATTGAGGGAGATTTAAATCCTGATAATAGTGATGTGGACAAAC
TATTTATCCAGTTGGTACAAATCTACAATCAATTATTTGAAGAAAACCCT
ATTAACGCAAGTAGAGTAGATGCTAAAGCGATTCTTTCTGCACGATTGAG
TAAATCAAGACGATTAGAAAATCTCATTGCTCAGCTCCCCGGTGAGAAGA
GAAATGGCTTGTTTGGGAATCTCATTGCTTTGTCATTGGGATTGACCCCT
AATTTTAAATCAAATTTTGATTTGGCAGAAGATGCTAAATTACAGCTTTC
AAAAGATACTTACGATGATGATTTAGATAATTTATTGGCGCAAATTGGAG
ATCAATATGCTGATTTGTTTTTGGCAGCTAAGAATTTATCAGATGCTATT
TTACTTTCAGATATCCTAAGAGTAAATAGTGAAATAACTAAGGCTCCCCT
ATCAGCTTCAATGATTAAGCGCTACGATGAACATCATCAAGACTTGACTC
TTTTAAAAGCTTTAGTTCGACAACAACTTCCAGAAAAGTATAAAGAAATC
TTTTTTGATCAATCAAAAAACGGATATGCAGGTTATATTGATGGGGGAGC
TAGCCAAGAAGAATTTTATAAATTTATCAAACCAATTTTAGAAAAAATGG
ATGGTACTGAGGAATTATTGGTGAAACTAAATCGTGAAGATTTGCTGCGC
AAGCAACGGACCTTTGACAACGGCTCTATTCCCCATCAAATTCACTTGGG
TGAGCTGCATGCTATTTTGAGAAGACAAGAAGACTTTTATCCATTTTTAA
AAGACAATCGTGAGAAGATTGAAAAAATCTTGACTTTTCGAATTCCTTAT
TATGTTGGTCCATTGGCGCGTGGCAATAGTCGTTTTGCATGGATGACTCG
GAAGTCTGAAGAAACAATTACCCCATGGAATTTTGAAGAAGTTGTCGATA
AAGGTGCTTCAGCTCAATCATTTATTGAACGCATGACAAACTTTGATAAA
AATCTTCCAAATGAAAAAGTACTACCAAAACATAGTTTGCTTTATGAGTA
TTTTACGGTTTATAACGAATTGACAAAGGTCAAATATGTTACTGAGGGAA
TGCGAAAACCAGCATTTCTTTCAGGTGAACAGAAGAAAGCCATTGTTGAT
TTACTCTTCAAAACAAATCGAAAAGTAACCGTTAAGCAATTAAAAGAAGA
TTATTTCAAAAAAATAGAATGTTTTGATAGTGTTGAAATTTCAGGAGTTG
AAGATAGATTTAATGCTTCATTAGGCGCCTACCATGATTTGCTAAAAATT
ATTAAAGATAAAGATTTTTTGGATAATGAAGAAAATGAAGATATCTTAGA
GGATATTGTTTTAACATTGACCTTATTTGAAGATAGGGGGATGATTGAGG
AAAGACTTAAAACATATGCTCACCTCTTTGATGATAAGGTGATGAAACAG
CTTAAACGTCGCCGTTATACTGGTTGGGGACGTTTGTCTCGAAAATTGAT
TAATGGTATTAGGGATAAGCAATCTGGCAAAACAATATTAGATTTTTTGA
AATCAGATGGTTTTGCCAATCGCAATTTTATGCAGCTGATCCATGATGAT
AGTTTGACATTTAAAGAAGATATTCAAAAAGCACAGGTGTCTGGACAAGG
CCATAGTTTACATGAACAGATTGCTAACTTAGCTGGCAGTCCTGCTATTA
AAAAAGGTATTTTACAGACTGTAAAAATTGTTGATGAACTGGTCAAAGTA
ATGGGGCATAAGCCAGAAAATATCGTTATTGAAATGGCACGTGAAAATCA
GACAACTCAAAAGGGCCAGAAAAATTCGCGAGAGCGTATGAAACGAATCG
AAGAAGGTATCAAAGAATTAGGAAGTCAGATTCTTAAAGAGCATCCTGTT
GAAAATACTCAATTGCAAAATGAAAAGCTCTATCTCTATTATCTACAAAA
TGGAAGAGACATGTATGTGGACCAAGAATTAGATATTAATCGTTTAAGTG
ATTATGATGTCGATCACATTGTTCCACAAAGTTTCATTAAAGACGATTCA
ATAGACAATAAGGTACTAACGCGTTCTGATAAAAATCGTGGTAAATCGGA
TAACGTTCCAAGTGAAGAAGTAGTCAAAAAGATGAAAAACTATTGGAGAC
AACTTCTAAACGCCAAGTTAATCACTCAACGTAAGTTTGATAATTTAACG
AAAGCTGAACGTGGAGGTTTGAGTGAACTTGATAAAGCTGGTTTTATCAA
ACGCCAATTGGTTGAAACTCGCCAAATCACTAAGCATGTGGCACAAATTT
TGGATAGTCGCATGAATACTAAATACGATGAAAATGATAAACTTATTCGA
GAGGTTAAAGTGATTACCTTAAAATCTAAATTAGTTTCTGACTTCCGAAA
AGATTTCCAATTCTATAAAGTACGTGAGATTAACAATTACCATCATGCCC
ATGATGCGTATCTAAATGCCGTCGTTGGAACTGCTTTGATTAAGAAATAT
CCAAAACTTGAATCGGAGTTTGTCTATGGTGATTATAAAGTTTATGATGT
TCGTAAAATGATTGCTAAGTCTGAGCAAGAAATAGGCAAAGCAACCGCAA
AATATTTCTTTTACTCTAATATCATGAACTTCTTCAAAACAGAAATTACA
CTTGCAAATGGAGAGATTCGCAAACGCCCTCTAATCGAAACTAATGGGGA
AACTGGAGAAATTGTCTGGGATAAAGGGCGAGATTTTGCCACAGTGCGCA
AAGTATTGTCCATGCCCCAAGTCAATATTGTCAAGAAAACAGAAGTACAG
ACAGGCGGATTCTCCAAGGAGTCAATTTTACCAAAAAGAAATTCGGACAA
GCTTATTGCTCGTAAAAAAGACTGGGATCCAAAAAAATATGGTGGTTTTG
ATAGTCCAACGGTAGCTTATTCAGTCCTAGTGGTTGCTAAGGTGGAAAAA
GGGAAATCGAAGAAGTTAAAATCCGTTAAAGAGTTACTAGGGATCACAAT
TATGGAAAGAAGTTCCTTTGAAAAAAATCCGATTGACTTTTTAGAAGCTA
AAGGATATAAGGAAGTTAAAAAAGACTTAATCATTAAACTACCTAAATAT
AGTCTTTTTGAGTTAGAAAACGGTCGTAAACGGATGCTGGCTAGTGCCGG
AGAATTACAAAAAGGAAATGAGCTGGCTCTGCCAAGCAAATATGTGAATT
TTTTATATTTAGCTAGTCATTATGAAAAGTTGAAGGGTAGTCCAGAAGAT
AACGAACAAAAACAATTGTTTGTGGAGCAGCATAAGCATTATTTAGATGA
GATTATTGAGCAAATCAGTGAATTTTCTAAGCGTGTTATTTTAGCAGATG
CCAATTTAGATAAAGTTCTTAGTGCATATAACAAACATAGAGACAAACCA
ATACGTGAACAAGCAGAAAATATTATTCATTTATTTACGTTGACGAATCT
TGGAGCTCCCGCTGCTTTTAAATATTTTGATACAACAATTGATCGTAAAC
GATATACGTCTACAAAAGAAGTTTTAGATGCCACTCTTATCCATCAATCC
ATCACTGGTCTTTATGAAACACGCATTGATTTGAGTCAGCTAGGAGGTGA CTGA (SEQ ID NO:
41) MDKKYSIGLDIGTNSVGWAVITDDYKVPSKKFKVLGNTDRHSIKKNLIGA
LLFGSGETAEATRLKRTARRRYTRRKNRICYLQEIFSNEMAKVDDSFFHR
LEESFLVEEDKKHERHPIFGNIVDEVAYHEKYPTIYHLRKKLADSTDKAD
LRLIYLALAHMIKFRGHFLIEGDLNPDNSDVDKLFIQLVQIYNQLFEENP
INASRVDAKAILSARLSKSRRLENLIAQLPGEKRNGLFGNLIALSLGLTP
NFKSNFDLAEDAKLQLSKDTYDDDLDNLLAQIGDQYADLFLAAKNLSDAI
LLSDILRVNSEITKAPLSASMIKRYDEHHQDLTLLKALVRQQLPEKYKEI
FFDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELLVKLNREDLLR
KQRTFDNGSIPHQIHLGELHAILRRQEDFYPFLKDNREKIEKILTFRIPY
YVGPLARGNSRFAWMTRKSEETITPWNFEEVVDKGASAQSFIERMTNFDK
NLPNEKVLPKHSLLYEYFTVYNELTKVKYVTEGMRKPAFLSGEQKKAIVD
LLFKTNRKVTVKQLKEDYFKKIECFDSVEISGVEDRFNASLGAYHDLLKI
IKDKDFLDNEENEDILEDIVLTLTLFEDRGMIEERLKTYAHLFDDKVMKQ
LKRRRYTGWGRLSRKLINGIRDKQSGKTILDFLKSDGFANRNFMQLIHDD
SLTFKEDIQKAQVSGQGHSLHEQIANLAGSPAIKKGILQTVKIVDELVKV
MGHKPENIVIEMARENQTTQKGQKNSRERMKRIEEGIKELGSQILKEHPV
ENTQLQNEKLYLYYLQNGRDMYVDQELDINRLSDYDVDHIVPQSFIKDDS
IDNKVLTRSDKNRGKSDNVPSEEVVKKMKNYWRQLLNAKLITQRKFDNLT
KAERGGLSELDKAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIR
EVKVITLKSKLVSDFRKDFQFYKVREINNYHHAHDAYLNAVVGTALIKKY
PKLESEFVYGDYKVYDVRKMIAKSEQEIGKATAKYFFYSNIMNFFKTEIT
LANGEIRKRPLIETNGETGEIVWDKGRDFATVRKVLSMPQVNIVKKTEVQ
TGGFSKESILPKRNSDKLIARKKDWDPKKYGGFDSPTVAYSVLVVAKVEK
GKSKKLKSVKELLGITIMERSSFEKNPIDFLEAKGYKEVKKDLIIKLPKY
SLFELENGRKRMLASAGELQKGNELALPSKYVNFLYLASHYEKLKGSPED
NEQKQLFVEQHKHYLDEIIEQISEFSKRVILADANLDKVLSAYNKHRDKP
IREQAENIIHLFTLTNLGAPAAFKYFDTTIDRKRYTSTKEVLDATLIHQS
ITGLYETRIDLSQLGGD
[0048] The term "concatemer," as used herein in the context of
nucleic acid molecules, refers to a nucleic acid molecule that
contains multiple copies of the same DNA sequences linked in a
series. For example, a concatemer comprising ten copies of a
specific sequence of nucleotides (e.g., [XYZ].sub.10), would
comprise ten copies of the same specific sequence linked to each
other in series, e.g., 5'-XYZXYZXYZXYZXYZXYZXYZXYZXYZXYZ-3'. A
concatemer may comprise any number of copies of the repeat unit or
sequence, e.g., at least 2 copies, at least 3 copies, at least 4
copies, at least 5 copies, at least 10 copies, at least 100 copies,
at least 1000 copies, etc. An example of a concatemer of a nucleic
acid sequence comprising a nuclease target site and a constant
insert sequence would be [(target site)-(constant insert
sequence)].sub.300. A concatemer may be a linear nucleic acid
molecule, or may be circular.
[0049] The terms "conjugating," "conjugated," and "conjugation"
refer to an association of two entities, for example, of two
molecules such as two proteins, two domains (e.g., a binding domain
and a cleavage domain), or a protein and an agent, e.g., a protein
binding domain and a small molecule. In some aspects, the
association is between a protein (e.g., RNA-programmable nuclease)
and a nucleic acid (e.g., a guide RNA). The association can be, for
example, via a direct or indirect (e.g., via a linker) covalent
linkage or via non-covalent interactions. In some embodiments, the
association is covalent. In some embodiments, two molecules are
conjugated via a linker connecting both molecules. For example, in
some embodiments where two proteins are conjugated to each other,
e.g., a binding domain and a cleavage domain of an engineered
nuclease, to form a protein fusion, the two proteins may be
conjugated via a polypeptide linker, e.g., an amino acid sequence
connecting the C-terminus of one protein to the N-terminus of the
other protein.
[0050] The term "consensus sequence," as used herein in the context
of nucleic acid sequences, refers to a calculated sequence
representing the most frequent nucleotide residues found at each
position in a plurality of similar sequences. Typically, a
consensus sequence is determined by sequence alignment in which
similar sequences are compared to each other and similar sequence
motifs are calculated. In the context of nuclease target site
sequences, a consensus sequence of a nuclease target site may, in
some embodiments, be the sequence most frequently bound, or bound
with the highest affinity, by a given nuclease. With respect to
RNA-programmable nuclease (e.g., Cas9) target site sequences, the
consensus sequence may, in some embodiments, be the sequence or
region to which a gRNA, or a plurality of gRNAs, is expected or
designed to bind, e.g., based on complementary base pairing.
[0051] The term "effective amount," as used herein, refers to an
amount of a biologically active agent that is sufficient to elicit
a desired biological response. For example, in some embodiments, an
effective amount of a nuclease may refer to the amount of the
nuclease that is sufficient to induce cleavage of a target site
specifically bound and cleaved by the nuclease. As will be
appreciated by the skilled artisan, the effective amount of an
agent, e.g., a nuclease, a hybrid protein, or a polynucleotide, may
vary depending on various factors as, for example, on the desired
biological response, the specific allele, genome, target site,
cell, or tissue being targeted, and the agent being used.
[0052] The term "enediyne," as used herein, refers to a class of
bacterial natural products characterized by either nine- and
ten-membered rings containing two triple bonds separated by a
double bond (see, e.g., K. C. Nicolaou; A. L. Smith; E. W. Yue
(1993). "Chemistry and biology of natural and designed enediynes".
PNAS 90 (13): 5881-5888; the entire contents of which are
incorporated herein by reference). Some enediynes are capable of
undergoing Bergman cyclization, and the resulting diradical, a
1,4-dehydrobenzene derivative, is capable of abstracting hydrogen
atoms from the sugar backbone of DNA which results in DNA strand
cleavage (see, e.g., S. Walker; R. Landovitz; W. D. Ding; G. A.
Ellestad; D. Kahne (1992). "Cleavage behavior of calicheamicin
gamma 1 and calicheamicin T". Proc Natl Acad Sci U.S.A. 89 (10):
4608-12; the entire contents of which are incorporated herein by
reference). Their reactivity with DNA confers an antibiotic
character to many enediynes, and some enediynes are clinically
investigated as anticancer antibiotics. Nonlimiting examples of
enediynes are dynemicin, neocarzinostatin, calicheamicin,
esperamicin (see, e.g., Adrian L. Smith and K. C. Bicolaou, "The
Enediyne Antibiotics" J. Med. Chem., 1996, 39 (11), pp 2103-2117;
and Donald Borders, "Enediyne antibiotics as antitumor agents,"
Informa Healthcare; 1.sup.st edition (Nov. 23, 1994, ISBN-10:
0824789385; the entire contents of which are incorporated herein by
reference).
[0053] The term "homing endonuclease," as used herein, refers to a
type of restriction enzymes typically encoded by introns or inteins
Edgell D R (February 2009). "Selfish DNA: homing endonucleases find
a home". Curr Biol 19 (3): R115-R117; Jasin M (June 1996). "Genetic
manipulation of genomes with rare-cutting endonucleases". Trends
Genet 12 (6): 224-8; Burt A, Koufopanou V (December 2004). "Homing
endonuclease genes: the rise and fall and rise again of a selfish
element". Curr Opin Genet Dev 14 (6): 609-15; the entire contents
of which are incorporated herein by reference. Homing endonuclease
recognition sequences are long enough to occur randomly only with a
very low probability (approximately once every 7.times.10.sup.10
bp), and are normally found in only one instance per genome.
[0054] The term "library," as used herein in the context of nucleic
acids or proteins, refers to a population of two or more different
nucleic acids or proteins, respectively. For example, a library of
nuclease target sites comprises at least two nucleic acid molecules
comprising different nuclease target sites. In some embodiments, a
library comprises at least 10.sup.1, at least 10.sup.2, at least
10.sup.3, at least 10.sup.4, at least 10.sup.5, at least 10.sup.6,
at least 10.sup.7, at least 10.sup.8, at least 10.sup.9, at least
10.sup.10, at least 10.sup.11, at least 10.sup.12, at least
10.sup.13, at least 10.sup.14, or at least 10.sup.15 different
nucleic acids or proteins. In some embodiments, the members of the
library may comprise randomized sequences, for example, fully or
partially randomized sequences. In some embodiments, the library
comprises nucleic acid molecules that are unrelated to each other,
e.g., nucleic acids comprising fully randomized sequences. In other
embodiments, at least some members of the library may be related,
for example, they may be variants or derivatives of a particular
sequence, such as a consensus target site sequence.
[0055] The term "linker," as used herein, refers to a chemical
group or a molecule linking two adjacent molecules or moieties,
e.g., a binding domain and a cleavage domain of a nuclease.
Typically, the linker is positioned between, or flanked by, two
groups, molecules, or other moieties and connected to each one via
a covalent bond, thus connecting the two. In some embodiments, the
linker is an amino acid or a plurality of amino acids (e.g., a
peptide or protein). In some embodiments, the linker is an organic
molecule, group, polymer, or chemical moiety.
[0056] The term "nuclease," as used herein, refers to an agent, for
example a protein or a small molecule, capable of cleaving a
phosphodiester bond connecting nucleotide residues in a nucleic
acid molecule. In some embodiments, a nuclease is a protein, e.g.,
an enzyme that can bind a nucleic acid molecule and cleave a
phosphodiester bond connecting nucleotide residues within the
nucleic acid molecule. A nuclease may be an endonuclease, cleaving
a phosphodiester bonds within a polynucleotide chain, or an
exonuclease, cleaving a phosphodiester bond at the end of the
polynucleotide chain. In some embodiments, a nuclease is a
site-specific nuclease, binding and/or cleaving a specific
phosphodiester bond within a specific nucleotide sequence, which is
also referred to herein as the "recognition sequence," the
"nuclease target site," or the "target site." In some embodiments,
a nuclease is a RNA-guided (i.e., RNA-programmable) nuclease, which
complexes with (e.g., binds with) an RNA having a sequence that
complements a target site, thereby providing the sequence
specificity of the nuclease. In some embodiments, a nuclease
recognizes a single stranded target site, while in other
embodiments, a nuclease recognizes a double-stranded target site,
for example a double-stranded DNA target site. The target sites of
many naturally occurring nucleases, for example, many naturally
occurring DNA restriction nucleases, are well known to those of
skill in the art. In many cases, a DNA nuclease, such as EcoRI,
HindIII, or BamHI, recognize a palindromic, double-stranded DNA
target site of 4 to 10 base pairs in length, and cut each of the
two DNA strands at a specific position within the target site. Some
endonucleases cut a double-stranded nucleic acid target site
symmetrically, i.e., cutting both strands at the same position so
that the ends comprise base-paired nucleotides, also referred to
herein as blunt ends. Other endonucleases cut a double-stranded
nucleic acid target sites asymmetrically, i.e., cutting each strand
at a different position so that the ends comprise unpaired
nucleotides. Unpaired nucleotides at the end of a double-stranded
DNA molecule are also referred to as "overhangs," e.g., as
"5'-overhang" or as "3'-overhang," depending on whether the
unpaired nucleotide(s) form(s) the 5' or the 3' end of the
respective DNA strand. Double-stranded DNA molecule ends ending
with unpaired nucleotide(s) are also referred to as sticky ends, as
they can "stick to" other double-stranded DNA molecule ends
comprising complementary unpaired nucleotide(s). A nuclease protein
typically comprises a "binding domain" that mediates the
interaction of the protein with the nucleic acid substrate, and
also, in some cases, specifically binds to a target site, and a
"cleavage domain" that catalyzes the cleavage of the phosphodiester
bond within the nucleic acid backbone. In some embodiments a
nuclease protein can bind and cleave a nucleic acid molecule in a
monomeric form, while, in other embodiments, a nuclease protein has
to dimerize or multimerize in order to cleave a target nucleic acid
molecule. Binding domains and cleavage domains of naturally
occurring nucleases, as well as modular binding domains and
cleavage domains that can be fused to create nucleases binding
specific target sites, are well known to those of skill in the art.
For example, zinc fingers or transcriptional activator like
elements can be used as binding domains to specifically bind a
desired target site, and fused or conjugated to a cleavage domain,
for example, the cleavage domain of FokI, to create an engineered
nuclease cleaving the target site.
[0057] The terms "nucleic acid" and "nucleic acid molecule," as
used herein, refer to a compound comprising a nucleobase and an
acidic moiety, e.g., a nucleoside, a nucleotide, or a polymer of
nucleotides. Typically, polymeric nucleic acids, e.g., nucleic acid
molecules comprising three or more nucleotides are linear
molecules, in which adjacent nucleotides are linked to each other
via a phosphodiester linkage. In some embodiments, "nucleic acid"
refers to individual nucleic acid residues (e.g. nucleotides and/or
nucleosides). In some embodiments, "nucleic acid" refers to an
oligonucleotide chain comprising three or more individual
nucleotide residues. As used herein, the terms "oligonucleotide"
and "polynucleotide" can be used interchangeably to refer to a
polymer of nucleotides (e.g., a string of at least three
nucleotides). In some embodiments, "nucleic acid" encompasses RNA
as well as single and/or double-stranded DNA. Nucleic acids may be
naturally occurring, for example, in the context of a genome, a
transcript, an mRNA, tRNA, rRNA, siRNA, snRNA, a plasmid, cosmid,
chromosome, chromatid, or other naturally occurring nucleic acid
molecule. On the other hand, a nucleic acid molecule may be a
non-naturally occurring molecule, e.g., a recombinant DNA or RNA,
an artificial chromosome, an engineered genome, or fragment
thereof, or a synthetic DNA, RNA, DNA/RNA hybrid, or including
non-naturally occurring nucleotides or nucleosides. Furthermore,
the terms "nucleic acid," "DNA," "RNA," and/or similar terms
include nucleic acid analogs, i.e. analogs having other than a
phosphodiester backbone. Nucleic acids can be purified from natural
sources, produced using recombinant expression systems and
optionally purified, chemically synthesized, etc. Where
appropriate, e.g., in the case of chemically synthesized molecules,
nucleic acids can comprise nucleoside analogs such as analogs
having chemically modified bases or sugars, and backbone
modifications. A nucleic acid sequence is presented in the 5' to 3'
direction unless otherwise indicated. In some embodiments, a
nucleic acid is or comprises natural nucleosides (e.g. adenosine,
thymidine, guanosine, cytidine, uridine, deoxyadenosine,
deoxythymidine, deoxyguanosine, and deoxycytidine); nucleoside
analogs (e.g., 2-aminoadenosine, 2-thiothymidine, inosine,
pyrrolo-pyrimidine, 3-methyl adenosine, 5-methylcytidine,
2-aminoadenosine, C5-bromouridine, C5-fluorouridine,
C5-iodouridine, C5-propynyl-uridine, C5-propynyl-cytidine,
C5-methylcytidine, 2-aminoadenosine, 7-deazaadenosine,
7-deazaguanosine, 8-oxoadenosine, 8-oxoguanosine,
O(6)-methylguanine, and 2-thiocytidine); chemically modified bases;
biologically modified bases (e.g., methylated bases); intercalated
bases; modified sugars (e.g., 2'-fluororibose, ribose,
2'-deoxyribose, arabinose, and hexose); and/or modified phosphate
groups (e.g., phosphorothioates and 5'-N-phosphoramidite
linkages).
[0058] The term "pharmaceutical composition," as used herein,
refers to a composition that can be administrated to a subject in
the context of treatment of a disease or disorder. In some
embodiments, a pharmaceutical composition comprises an active
ingredient, e.g., a nuclease or a nucleic acid encoding a nuclease,
and a pharmaceutically acceptable excipient.
[0059] The term "proliferative disease," as used herein, refers to
any disease in which cell or tissue homeostasis is disturbed in
that a cell or cell population exhibits an abnormally elevated
proliferation rate. Proliferative diseases include
hyperproliferative diseases, such as pre-neoplastic hyperplastic
conditions and neoplastic diseases. Neoplastic diseases are
characterized by an abnormal proliferation of cells and include
both benign and malignant neoplasias. Malignant neoplasia is also
referred to as cancer.
[0060] The terms "protein," "peptide," and "polypeptide" are used
interchangeably herein, and refer to a polymer of amino acid
residues linked together by peptide (amide) bonds. The terms refer
to a protein, peptide, or polypeptide of any size, structure, or
function. Typically, a protein, peptide, or polypeptide will be at
least three amino acids long. A protein, peptide, or polypeptide
may refer to an individual protein or a collection of proteins. One
or more of the amino acids in a protein, peptide, or polypeptide
may be modified, for example, by the addition of a chemical entity
such as a carbohydrate group, a hydroxyl group, a phosphate group,
a farnesyl group, an isofarnesyl group, a fatty acid group, a
linker for conjugation, functionalization, or other modification,
etc. A protein, peptide, or polypeptide may also be a single
molecule or may be a multi-molecular complex. A protein, peptide,
or polypeptide may be just a fragment of a naturally occurring
protein or peptide. A protein, peptide, or polypeptide may be
naturally occurring, recombinant, or synthetic, or any combination
thereof. A protein may comprise different domains, for example, a
nucleic acid binding domain and a nucleic acid cleavage domain. In
some embodiments, a protein comprises a proteinaceous part, e.g.,
an amino acid sequence constituting a nucleic acid binding domain,
and an organic compound, e.g., a compound that can act as a nucleic
acid cleavage agent. In some embodiments, a protein is in a complex
with, or is in association with, a nucleic acid, e.g., RNA.
[0061] The term "randomized," as used herein in the context of
nucleic acid sequences, refers to a sequence or residue within a
sequence that has been synthesized to incorporate a mixture of free
nucleotides, for example, a mixture of all four nucleotides A, T,
G, and C. Randomized residues are typically represented by the
letter N within a nucleotide sequence. In some embodiments, a
randomized sequence or residue is fully randomized, in which case
the randomized residues are synthesized by adding equal amounts of
the nucleotides to be incorporated (e.g., 25% T, 25% A, 25% G, and
25% C) during the synthesis step of the respective sequence
residue. In some embodiments, a randomized sequence or residue is
partially randomized, in which case the randomized residues are
synthesized by adding non-equal amounts of the nucleotides to be
incorporated (e.g., 79% T, 7% A, 7% G, and 7% C) during the
synthesis step of the respective sequence residue. Partial
randomization allows for the generation of sequences that are
templated on a given sequence, but have incorporated mutations at a
desired frequency. For example, if a known nuclease target site is
used as a synthesis template, partial randomization in which at
each step the nucleotide represented at the respective residue is
added to the synthesis at 79%, and the other three nucleotides are
added at 7% each, will result in a mixture of partially randomized
target sites being synthesized, which still represent the consensus
sequence of the original target site, but which differ from the
original target site at each residue with a statistical frequency
of 21% for each residue so synthesized (distributed binomially). In
some embodiments, a partially randomized sequence differs from the
consensus sequence by more than 5%, more than 10%, more than 15%,
more than 20%, more than 25%, or more than 30% on average,
distributed binomially. In some embodiments, a partially randomized
sequence differs from the consensus site by no more than 10%, no
more than 15%, no more than 20%, no more than 25%, nor more than
30%, no more than 40%, or no more than 50% on average, distributed
binomially.
[0062] The term "RNA-programmable nuclease," and "RNA-guided
nuclease" are used interchangeably herein and refer to a nuclease
that forms a complex with (e.g., binds or associates with) one or
more RNA that is not a target for cleavage. In some embodiments, an
RNA-programmable nuclease, when in a complex with an RNA, may be
referred to as a nuclease:RNA complex. Typically, the bound RNA(s)
is referred to as a guide RNA (gRNA) or a single-guide RNA (sgRNA).
The gRNA/sgRNA comprises a nucleotide sequence that complements a
target site, which mediates binding of the nuclease/RNA complex to
said target site and providing the sequence specificity of the
nuclease:RNA complex. In some embodiments, the RNA-programmable
nuclease is the (CRISPR-associated system) Cas9 endonuclease, for
example Cas9 (Csn1) from Streptococcus pyogenes (see, e.g.,
"Complete genome sequence of an M1 strain of Streptococcus
pyogenes." Ferretti J. J., McShan W. M., Ajdic D. J., Savic D. J.,
Savic G., Lyon K., Primeaux C., Sezate S., Suvorov A. N., Kenton
S., Lai H. S., Lin S. P., Qian Y., Jia H. G., Najar F. Z., Ren Q.,
Zhu H., Song L. expand/collapse author list McLaughlin R. E., Proc.
Natl. Acad. Sci. U.S.A. 98:4658-4663(2001); "CRISPR RNA maturation
by trans-encoded small RNA and host factor RNase III." Deltcheva
E., Chylinski K., Sharma C. M., Gonzales K., Chao Y., Pirzada Z.
A., Eckert M. R., Vogel J., Charpentier E., Nature
471:602-607(2011); and "A programmable dual-RNA-guided DNA
endonuclease in adaptive bacterial immunity." Jinek M., Chylinski
K., Fonfara I., Hauer M., Doudna J. A., Charpentier E. Science
337:816-821(2012), the entire contents of each of which are
incorporated herein by reference
[0063] Because RNA-programmable nucleases (e.g., Cas9) use RNA:DNA
hybridization to determine target DNA cleavage sites, these
proteins are able to cleave, in principle, any sequence specified
by the guide RNA. Methods of using RNA-programmable nucleases, such
as Cas9, for site-specific cleavage (e.g., to modify a genome) are
known in the art (See e.g., Cong, L. et al. Multiplex genome
engineering using CRISPR/Cas systems. Science 339, 819-823 (2013);
Mali, P. et al. RNA-guided human genome engineering via Cas9.
Science 339, 823-826 (2013); Hwang, W. Y. et al. Efficient genome
editing in zebrafish using a CRISPR-Cas system. Nature
biotechnology 31, 227-229 (2013); Jinek, M. et al. RNA-programmed
genome editing in human cells. eLife 2, e00471 (2013); Dicarlo, J.
E. et al. Genome engineering in Saccharomyces cerevisiae using
CRISPR-Cas systems. Nucleic acids research (2013); Jiang, W. et al.
RNA-guided editing of bacterial genomes using CRISPR-Cas systems.
Nature biotechnology 31, 233-239 (2013); the entire contents of
each of which are incorporated herein by reference).
[0064] The terms "small molecule" and "organic compound" are used
interchangeably herein and refer to molecules, whether
naturally-occurring or artificially created (e.g., via chemical
synthesis) that have a relatively low molecular weight. Typically,
an organic compound contains carbon. An organic compound may
contain multiple carbon-carbon bonds, stereocenters, and other
functional groups (e.g., amines, hydroxyl, carbonyls, or
heterocyclic rings). In some embodiments, organic compounds are
monomeric and have a molecular weight of less than about 1500
g/mol. In certain embodiments, the molecular weight of the small
molecule is less than about 1000 g/mol or less than about 500
g/mol. In certain embodiments, the small molecule is a drug, for
example, a drug that has already been deemed safe and effective for
use in humans or animals by the appropriate governmental agency or
regulatory body. In certain embodiments, the organic molecule is
known to bind and/or cleave a nucleic acid. In some embodiments,
the organic compound is an enediyne. In some embodiments, the
organic compound is an antibiotic drug, for example, an anticancer
antibiotic such as dynemicin, neocarzinostatin, calicheamicin,
esperamicin, bleomycin, or a derivative thereof.
[0065] The term "subject," as used herein, refers to an individual
organism, for example, an individual mammal. In some embodiments,
the subject is a human. In some embodiments, the subject is a
non-human mammal In some embodiments, the subject is a non-human
primate. In some embodiments, the subject is a rodent. In some
embodiments, the subject is a sheep, a goat, a cattle, a cat, or a
dog. In some embodiments, the subject is a vertebrate, an
amphibian, a reptile, a fish, an insect, a fly, or a nematode.
[0066] The terms "target nucleic acid," and "target genome," as
used herein in the context of nucleases, refer to a nucleic acid
molecule or a genome, respectively, that comprises at least one
target site of a given nuclease.
[0067] The term "target site," used herein interchangeably with the
term "nuclease target site," refers to a sequence within a nucleic
acid molecule that is bound and cleaved by a nuclease. A target
site may be single-stranded or double-stranded. In the context of
nucleases that dimerize, for example, nucleases comprising a FokI
DNA cleavage domain, a target sites typically comprises a left-half
site (bound by one monomer of the nuclease), a right-half site
(bound by the second monomer of the nuclease), and a spacer
sequence between the half sites in which the cut is made. This
structure ([left-half site]-[spacer sequence]-[right-half site]) is
referred to herein as an LSR structure. In some embodiments, the
left-half site and/or the right-half site is between 10-18
nucleotides long. In some embodiments, either or both half-sites
are shorter or longer. In some embodiments, the left and right half
sites comprise different nucleic acid sequences. In the context of
zinc finger nucleases, target sites may, in some embodiments
comprise two half-sites that are each 6-18 bp long flanking a
non-specified spacer region that is 4-8 bp long. In the context of
TALENs, target sites may, in some embodiments, comprise two
half-sites sites that are each 10-23 bp long flanking a
non-specified spacer region that is 10-30 bp long. In the context
of RNA-guided (e.g., RNA-programmable) nucleases, a target site
typically comprises a nucleotide sequence that is complementary to
the sgRNA of the RNA-programmable nuclease, and a protospacer
adjacent motif (PAM) at the 3' end adjacent to the
sgRNA-complementary sequence. For the RNA-guided nuclease Cas9, the
target site may be, in some embodiments, 20 base pairs plus a 3
base pair PAM (e.g., NNN, wherein N represents any nucleotide).
Typically, the first nucleotide of a PAM can be any nucleotide,
while the two downstream nucleotides are specified depending on the
specific RNA-guided nuclease. Exemplary target sites for RNA-guided
nucleases, such as Cas9, are known to those of skill in the art and
include, without limitation, NNG, NGN, NAG, and NGG, wherein N
represents any nucleotide. In addition, Cas9 nucleases from
different species (e.g., S. thermophilus instead of S. pyogenes)
recognizes a PAM that comprises the sequence NGGNG. Additional PAM
sequences are known, including, but not limited to NNAGAAW and NAAR
(see, e.g., Esvelt and Wang, Molecular Systems Biology, 9:641
(2013), the entire contents of which are incorporated herein by
reference). For example, the target site of an RNA-guided nuclease,
such as, e.g., Cas9, may comprise the structure [N.sub.Z]-[PAM],
where each N is, independently, any nucleotide, and .sub.Z is an
integer between 1 and 50. In some embodiments, .sub.Z is at least
2, at least 3, at least 4, at least 5, at least 6, at least 7, at
least 8, at least 9, at least 10, at least 11, at least 12, at
least 13, at least 14, at least 15, at least 16, at least 17, at
least 18, at least 19, at least 20, at least 25, at least 30, at
least 35, at least 40, at least 45, or at least 50. In some
embodiments, .sub.Z is 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16,
17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33,
34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48,49, or
50. In some embodiments, Z is 20.
[0068] The term "Transcriptional Activator-Like Effector," (TALE)
as used herein, refers to bacterial proteins comprising a DNA
binding domain, which contains a highly conserved 33-34 amino acid
sequence comprising a highly variable two-amino acid motif (Repeat
Variable Diresidue, RVD). The RVD motif determines binding
specificity to a nucleic acid sequence, and can be engineered
according to methods well known to those of skill in the art to
specifically bind a desired DNA sequence (see, e.g., Miller,
Jeffrey; et. al. (February 2011). "A TALE nuclease architecture for
efficient genome editing". Nature Biotechnology 29 (2): 143-8;
Zhang, Feng; et. al. (February 2011). "Efficient construction of
sequence-specific TAL effectors for modulating mammalian
transcription". Nature Biotechnology 29 (2): 149-53; Gei.beta.ler,
R.; Scholze, H.; Hahn, S.; Streubel, J.; Bonas, U.; Behrens, S. E.;
Boch, J. (2011), Shiu, Shin-Han. ed. "Transcriptional Activators of
Human Genes with Programmable DNA-Specificity". PLoS ONE 6 (5):
e19509; Boch, Jens (February 2011). "TALEs of genome targeting".
Nature Biotechnology 29 (2): 135-6; Boch, Jens; et. al. (December
2009). "Breaking the Code of DNA Binding Specificity of TAL-Type
III Effectors". Science 326 (5959): 1509-12; and Moscou, Matthew
J.; Adam J. Bogdanove (December 2009). "A Simple Cipher Governs DNA
Recognition by TAL Effectors". Science 326 (5959): 1501; the entire
contents of each of which are incorporated herein by reference).
The simple relationship between amino acid sequence and DNA
recognition has allowed for the engineering of specific DNA binding
domains by selecting a combination of repeat segments containing
the appropriate RVDs.
[0069] The term "Transcriptional Activator-Like Element Nuclease,"
(TALEN) as used herein, refers to an artificial nuclease comprising
a transcriptional activator like effector DNA binding domain to a
DNA cleavage domain, for example, a FokI domain. A number of
modular assembly schemes for generating engineered TALE constructs
have been reported (see e.g., Zhang, Feng; et. al. (February 2011).
"Efficient construction of sequence-specific TAL effectors for
modulating mammalian transcription". Nature Biotechnology 29 (2):
149-53; Gei.beta.ler, R.; Scholze, H.; Hahn, S.; Streubel, J.;
Bonas, U.; Behrens, S. E.; Boch, J. (2011), Shiu, Shin-Han. ed.
"Transcriptional Activators of Human Genes with Programmable
DNA-Specificity". PLoS ONE 6 (5): e19509; Cermak, T.; Doyle, E. L.;
Christian, M.; Wang, L.; Zhang, Y.; Schmidt, C.; Bailer, J. A.;
Somia, N. V. et al. (2011). "Efficient design and assembly of
custom TALEN and other TAL effector-based constructs for DNA
targeting". Nucleic Acids Research; Morbitzer, R.; Elsaesser, J.;
Hausner, J.; Lahaye, T. (2011). "Assembly of custom TALE-type DNA
binding domains by modular cloning". Nucleic Acids Research; Li,
T.; Huang, S.; Zhao, X.; Wright, D. A.; Carpenter, S.; Spalding, M.
H.; Weeks, D. P.; Yang, B. (2011). "Modularly assembled designer
TAL effector nucleases for targeted gene knockout and gene
replacement in eukaryotes". Nucleic Acids Research.; Weber, E.;
Gruetzner, R.; Werner, S.; Engler, C.; Marillonnet, S. (2011).
Bendahmane, Mohammed. ed. "Assembly of Designer TAL Effectors by
Golden Gate Cloning". PLoS ONE 6 (5): e19722; the entire contents
of each of which are incorporated herein by reference).
[0070] The terms "treatment," "treat," and "treating," refer to a
clinical intervention aimed to reverse, alleviate, delay the onset
of, or inhibit the progress of a disease or disorder, or one or
more symptoms thereof, as described herein. As used herein, the
terms "treatment," "treat," and "treating" refer to a clinical
intervention aimed to reverse, alleviate, delay the onset of, or
inhibit the progress of a disease or disorder, or one or more
symptoms thereof, as described herein. In some embodiments,
treatment may be administered after one or more symptoms have
developed and/or after a disease has been diagnosed. In other
embodiments, treatment may be administered in the absence of
symptoms, e.g., to prevent or delay onset of a symptom or inhibit
onset or progression of a disease. For example, treatment may be
administered to a susceptible individual prior to the onset of
symptoms (e.g., in light of a history of symptoms and/or in light
of genetic or other susceptibility factors). Treatment may also be
continued after symptoms have resolved, for example to prevent or
delay their recurrence.
[0071] The term "zinc finger," as used herein, refers to a small
nucleic acid-binding protein structural motif characterized by a
fold and the coordination of one or more zinc ions that stabilize
the fold. Zinc fingers encompass a wide variety of differing
protein structures (see, e.g., Klug A, Rhodes D (1987). "Zinc
fingers: a novel protein fold for nucleic acid recognition". Cold
Spring Harb. Symp. Quant. Biol. 52: 473-82, the entire contents of
which are incorporated herein by reference). Zinc fingers can be
designed to bind a specific sequence of nucleotides, and zinc
finger arrays comprising fusions of a series of zinc fingers, can
be designed to bind virtually any desired target sequence. Such
zinc finger arrays can form a binding domain of a protein, for
example, of a nuclease, e.g., if conjugated to a nucleic acid
cleavage domain. Different type of zinc finger motifs are known to
those of skill in the art, including, but not limited to,
Cys.sub.2His.sub.2, Gag knuckle, Treble clef, Zinc ribbon,
Zn.sub.2/Cys.sub.6, and TAZ2 domain-like motifs (see, e.g., Krishna
S S, Majumdar I, Grishin N V (January 2003). "Structural
classification of zinc fingers: survey and summary". Nucleic Acids
Res. 31 (2): 532-50). Typically, a single zinc finger motif binds 3
or 4 nucleotides of a nucleic acid molecule. Accordingly, a zinc
finger domain comprising 2 zinc finger motifs may bind 6-8
nucleotides, a zinc finger domain comprising 3 zinc finger motifs
may bind 9-12 nucleotides, a zinc finger domain comprising 4 zinc
finger motifs may bind 12-16 nucleotides, and so forth. Any
suitable protein engineering technique can be employed to alter the
DNA-binding specificity of zinc fingers and/or design novel zinc
finger fusions to bind virtually any desired target sequence from
3-30 nucleotides in length (see, e.g., Pabo C O, Peisach E, Grant R
A (2001). "Design and selection of novel cys2His2 Zinc finger
proteins". Annual Review of Biochemistry 70: 313-340; Jamieson A C,
Miller J C, Pabo C O (2003). "Drug discovery with engineered
zinc-finger proteins". Nature Reviews Drug Discovery 2 (5):
361-368; and Liu Q, Segal D J, Ghiara J B, Barbas C F (May 1997).
"Design of polydactyl zinc-finger proteins for unique addressing
within complex genomes". Proc. Natl. Acad. Sci. U.S.A. 94 (11); the
entire contents of each of which are incorporated herein by
reference). Fusions between engineered zinc finger arrays and
protein domains that cleave a nucleic acid can be used to generate
a "zinc finger nuclease." A zinc finger nuclease typically
comprises a zinc finger domain that binds a specific target site
within a nucleic acid molecule, and a nucleic acid cleavage domain
that cuts the nucleic acid molecule within or in proximity to the
target site bound by the binding domain. Typical engineered zinc
finger nucleases comprise a binding domain having between 3 and 6
individual zinc finger motifs and binding target sites ranging from
9 base pairs to 18 base pairs in length. Longer target sites are
particularly attractive in situations where it is desired to bind
and cleave a target site that is unique in a given genome.
[0072] The term "zinc finger nuclease," as used herein, refers to a
nuclease comprising a nucleic acid cleavage domain conjugated to a
binding domain that comprises a zinc finger array. In some
embodiments, the cleavage domain is the cleavage domain of the type
II restriction endonuclease FokI. Zinc finger nucleases can be
designed to target virtually any desired sequence in a given
nucleic acid molecule for cleavage, and the possibility to the
design zinc finger binding domains to bind unique sites in the
context of complex genomes allows for targeted cleavage of a single
genomic site in living cells, for example, to achieve a targeted
genomic alteration of therapeutic value. Targeting a double-strand
break to a desired genomic locus can be used to introduce
frame-shift mutations into the coding sequence of a gene due to the
error-prone nature of the non-homologous DNA repair pathway. Zinc
finger nucleases can be generated to target a site of interest by
methods well known to those of skill in the art. For example, zinc
finger binding domains with a desired specificity can be designed
by combining individual zinc finger motifs of known specificity.
The structure of the zinc finger protein Zif268 bound to DNA has
informed much of the work in this field and the concept of
obtaining zinc fingers for each of the 64 possible base pair
triplets and then mixing and matching these modular zinc fingers to
design proteins with any desired sequence specificity has been
described (Pavletich N P, Pabo C O (May 1991). "Zinc finger-DNA
recognition: crystal structure of a Zif268-DNA complex at 2.1 A".
Science 252 (5007): 809-17, the entire contents of which are
incorporated herein). In some embodiments, separate zinc fingers
that each recognize a 3 base pair DNA sequence are combined to
generate 3-, 4-, 5-, or 6-finger arrays that recognize target sites
ranging from 9 base pairs to 18 base pairs in length. In some
embodiments, longer arrays are contemplated. In other embodiments,
2-finger modules recognizing 6-8 nucleotides are combined to
generate 4-, 6-, or 8-zinc finger arrays. In some embodiments,
bacterial or phage display is employed to develop a zinc finger
domain that recognizes a desired nucleic acid sequence, for
example, a desired nuclease target site of 3-30 bp in length. Zinc
finger nucleases, in some embodiments, comprise a zinc finger
binding domain and a cleavage domain fused or otherwise conjugated
to each other via a linker, for example, a polypeptide linker. The
length of the linker determines the distance of the cut from the
nucleic acid sequence bound by the zinc finger domain. If a shorter
linker is used, the cleavage domain will cut the nucleic acid
closer to the bound nucleic acid sequence, while a longer linker
will result in a greater distance between the cut and the bound
nucleic acid sequence. In some embodiments, the cleavage domain of
a zinc finger nuclease has to dimerize in order to cut a bound
nucleic acid. In some such embodiments, the dimer is a heterodimer
of two monomers, each of which comprise a different zinc finger
binding domain. For example, in some embodiments, the dimer may
comprise one monomer comprising zinc finger domain A conjugated to
a FokI cleavage domain, and one monomer comprising zinc finger
domain B conjugated to a FokI cleavage domain. In this nonlimiting
example, zinc finger domain A binds a nucleic acid sequence on one
side of the target site, zinc finger domain B binds a nucleic acid
sequence on the other side of the target site, and the dimerize
FokI domain cuts the nucleic acid in between the zinc finger domain
binding sites.
DETAILED DESCRIPTION OF CERTAIN EMBODIMENTS OF THE INVENTION
Introduction
[0073] Site-specific nucleases are powerful tools for targeted
genome modification in vitro or in vivo. Some site specific
nucleases can theoretically achieve a level of specificity for a
target cleavage site that would allow one to target a single unique
site in a genome for cleavage without affecting any other genomic
site. It has been reported that nuclease cleavage in living cells
triggers a DNA repair mechanism that frequently results in a
modification of the cleaved, repaired genomic sequence, for
example, via homologous recombination. Accordingly, the targeted
cleavage of a specific unique sequence within a genome opens up new
avenues for gene targeting and gene modification in living cells,
including cells that are hard to manipulate with conventional gene
targeting methods, such as many human somatic or embryonic stem
cells. Nuclease-mediated modification of disease-related sequences,
e.g., the CCR-5 allele in HIV/AIDS patients, or of genes necessary
for tumor neovascularization, can be used in the clinical context,
and two site specific nucleases are currently in clinical
trials.
[0074] One important aspect in the field of site-specific
nuclease-mediated modification are off-target nuclease effects,
e.g., the cleavage of genomic sequences that differ from the
intended target sequence by one or more nucleotides. Undesired side
effects of off-target cleavage range from insertion into unwanted
loci during a gene targeting event to severe complications in a
clinical scenario. Off-target cleavage of sequences encoding
essential gene functions or tumor suppressor genes by an
endonuclease administered to a subject may result in disease or
even death of the subject. Accordingly, it is desirable to
characterize the cleavage preferences of a nuclease before using it
in the laboratory or the clinic in order to determine its efficacy
and safety. Further, the characterization of nuclease cleavage
properties allows for the selection of the nuclease best suited for
a specific task from a group of candidate nucleases, or for the
selection of evolution products obtained from a plurality of
nucleases. Such a characterization of nuclease cleavage properties
may also inform the de-novo design of nucleases with enhanced
properties, such as enhanced specificity or efficiency.
[0075] In many scenarios where a nuclease is employed for the
targeted manipulation of a nucleic acid, cleavage specificity is a
crucial feature. The imperfect specificity of some engineered
nuclease binding domains can lead to off-target cleavage and
undesired effects both in vitro and in vivo. Current methods of
evaluating site-specific nuclease specificity, including ELISA
assays, microarrays, one-hybrid systems, SELEX, and its variants,
and Rosetta-based computational predictions, are all premised on
the assumption that the binding specificity of the nuclease is
equivalent or proportionate to their cleavage specificity.
[0076] It was previously discovered that the prediction of nuclease
off-target binding effects constitute an imperfect approximation of
a nuclease's off-target cleavage effects that may result in
undesired biological effects (see PCT Application WO 2013/066438;
and Pattanayak, V., Ramirez, C. L., Joung, J. K. & Liu, D. R.
Revealing off-target cleavage specificities of zinc-finger
nucleases by in vitro selection. Nature methods 8, 765-770 (2011),
the entire contents of each of which are incorporated herein by
reference). This finding was consistent with the notion that the
reported toxicity of some site specific DNA nucleases results from
off-target DNA cleavage, rather than off-target binding alone.
[0077] The methods and reagents of the present disclosure
represent, in some aspects, an improvement over previous methods
and allow for an accurate evaluation of a given nuclease's target
site specificity and provide strategies for the selection of
suitable unique target sites and the design or selection of highly
specific nucleases for the targeted cleavage of a single site in
the context of a complex genome. For example, some previously
reported methods for determining nuclease target site specificity
profiles by screening libraries of nucleic acid molecules
comprising candidate target sites relied on a "two-cut" in vitro
selection method which requires indirect reconstruction of target
sites from sequences of two half-sites resulting from two adjacent
cuts of the nuclease of a library member nucleic acid (see e.g.,
Pattanayak, V. et al., Nature Methods 8, 765-770 (2011)). In
contrast to such "two-cut" strategies, the methods of the present
disclosure utilize a "one cut" screening strategy, which allows for
the identification of library members that have been cut at least
once by the nuclease. The "one-cut" selection strategies provided
herein are compatible with single end high-throughput sequencing
methods and do not require computational reconstruction of cleaved
target sites from cut half-sites because they feature, in some
embodiments, direct sequencing of an intact target nuclease
sequence in a cut library member nucleic acid.
[0078] Additionally, the presently disclosed "one-cut" screening
methods utilize concatemers of a candidate nuclease target site and
constant insert region that are about 10-fold shorter than
previously reported constructs used for two-cut strategies
(.about.50 bp repeat sequence length versus .about.500 bp repeat
sequence length in previous reports). This difference in repeat
sequence length in the concatemers of the library allows for the
generation of highly complex libraries of candidate nuclease target
sites, e.g., of libraries comprising 10.sup.12 different candidate
nuclease target sequences. As described herein, an exemplary
library of such complexity has been generated, templated on a known
Cas9 nuclease target site by varying the sequence of the known
target site. The exemplary library demonstrated that a greater than
10-fold coverage of all sequences with eight or fewer mutations of
the known target site can be achieved using the strategies provided
herein. The use of a shorter repeat sequence also allows the use of
single-end sequencing, since both a cut half-site and an adjacent
uncut site of the same library member are contained within a 100
nucleotide sequencing read.
[0079] The strategies, methods, libraries, and reagents provided
herein can be utilized to analyze the sequence preferences and
specificity of any site-specific nuclease, for example, to Zinc
Finger Nucleases (ZFNs), Transcription Activator-Like Effector
Nucleases (TALENs), homing endonucleases, organic compound
nucleases, and enediyne antibiotics (e.g., dynemicin,
neocarzinostatin, calicheamicin, esperamicin, bleomycin). Suitable
nucleases in addition to the ones described herein will be apparent
to those of skill in the art based on this disclosure.
[0080] Further, the methods, reagents, and strategies provided
herein allow those of skill in the art to identify, design, and/or
select nucleases with enhanced specificity and minimize the
off-target effects of any given nuclease (e.g., site-specific
nucleases such as ZFNs, and TALENS which produce cleavage products
with sticky ends, as well as RNA-programmable nucleases, for
example Cas9, which produce cleavage products having blunt ends).
While of particular relevance to DNA and DNA-cleaving nucleases,
the inventive concepts, methods, strategies, and reagents provided
herein are not limited in this respect, but can be applied to any
nucleic acid:nuclease pair.
Identifying Nuclease Target Sites Cleaved by a Site-Specific
Nuclease
[0081] Some aspects of this disclosure provide improved methods and
reagents to determine the nucleic acid target sites cleaved by any
site-specific nuclease. The methods provided herein can be used for
the evaluation of target site preferences and specificity of both
nucleases that create blunt ends and nucleases that create sticky
ends. In general, such methods comprise contacting a given nuclease
with a library of target sites under conditions suitable for the
nuclease to bind and cut a target site, and determining which
target sites the nuclease actually cuts. A determination of a
nuclease's target site profile based on actual cutting has the
advantage over methods that rely on binding in that it measures a
parameter more relevant for mediating undesired off-target effects
of site-specific nucleases. In general, the methods provided herein
comprise ligating an adapter of a known sequence to nucleic acid
molecules that have been cut by a nuclease of interest via
5'-phosphate-dependent ligation. Accordingly, the methods provided
herein are particularly useful for identifying target sites cut by
nucleases that leave a phosphate moiety at the 5'-end of the cut
nucleic acid strand when cleaving their target site. After ligating
an adapter to the 5'-end of a cut nucleic acid strand, the cut
strand can directly be sequenced using the adapter as a sequencing
linker, or a part of the cut library member concatemer comprising
an intact target site identical to the cut target site can be
amplified via PCR and the amplification product can then be
sequenced.
[0082] In some embodiments, the method comprises (a) providing a
nuclease that cuts a double-stranded nucleic acid target site,
wherein cutting of the target site results in cut nucleic acid
strands comprising a 5'-phosphate moiety; (b) contacting the
nuclease of (a) with a library of candidate nucleic acid molecules,
wherein each nucleic acid molecule comprises a concatemer of a
sequence comprising a candidate nuclease target site and a constant
insert sequence, under conditions suitable for the nuclease to cut
a candidate nucleic acid molecule comprising a target site of the
nuclease; and (c) identifying nuclease target sites cut by the
nuclease in (b) by determining the sequence of an uncut nuclease
target site on the nucleic acid strand that was cut by the nuclease
in step (b).
[0083] In some embodiments, the method comprises providing a
nuclease and contacting the nuclease with a library of candidate
nucleic acid molecules comprising candidate target sites. In some
embodiments, the candidate nucleic acid molecules are
double-stranded nucleic acid molecules. In some embodiments, the
candidate nucleic acid molecules are DNA molecules. In some
embodiments, each nucleic acid molecule in the library comprises a
concatemer of a sequence comprising a candidate nuclease target
site and a constant insert sequence. For example, in some
embodiments, the library comprises nucleic acid molecules that
comprise the structure R.sub.1-[(candidate nuclease target
site)-(constant insert sequence)].sub.n-R.sub.2, wherein R.sub.1
and R.sub.2 are, independently, nucleic acid sequences that may
comprise a fragment of the [(candidate nuclease target
site)-(constant insert sequence)] structure, and n is an integer
between 2 and y. In some embodiments, y is at least 10.sup.1, at
least 10.sup.2, at least 10.sup.3, at least 10.sup.4, at least
10.sup.5, at least 10.sup.6, at least 10.sup.7, at least 10.sup.8,
at least 10.sup.9, at least 10.sup.10, at least 10.sup.11, at least
10.sup.12, at least 10.sup.13, at least 10.sup.14, or at least
10.sup.15. In some embodiments, y is less than 10.sup.2, less than
10.sup.3, less than 10.sup.4, less than 10.sup.5, less than
10.sup.6, less than 10.sup.7, less than 10.sup.8, less than
10.sup.9, less than 10.sup.10, less than 10.sup.11, less than
10.sup.12, less than 10.sup.13, less than 10.sup.14, or less than
10.sup.15
[0084] For example, in some embodiments, the candidate nucleic acid
molecules of the library comprise a candidate nuclease target site
of the structure [(N.sub.Z)-(PAM)], and, thus, the nucleic acid
molecules of the library comprise the structure
R.sub.1-[(N.sub.Z)-(PAM)-(constant region)].sub.X-R.sub.2, wherein
R.sub.1 and R.sub.2 are, independently, nucleic acid sequences that
may comprise a fragment of the [(N.sub.Z)-(PAM)-(constant region)]
repeat unit; each N represents, independently, any nucleotide; Z is
an integer between 1 and 50; and X is an integer between 2 and y.
In some embodiments, y is at least 10.sup.1, at least 10.sup.2, at
least 10.sup.3, at least 10.sup.4, at least 10.sup.5, at least
10.sup.6, at least 10.sup.7, at least 10.sup.8, at least 10.sup.9,
at least 10.sup.10, at least 10.sup.11, at least 10.sup.12, at
least 10.sup.13, at least 10.sup.14, or at least 10.sup.15. In some
embodiments, y is less than 10.sup.2, less than 10.sup.3, less than
10.sup.4, less than 10.sup.5, less than 10.sup.6, less than
10.sup.7, less than 10.sup.8, less than 10.sup.9, less than
10.sup.10, less than 10.sup.11, less than 10.sup.12, less than
10.sup.13, less than 10.sup.14, or less than 10.sup.15. In some
embodiments, Z is at least 2, at least 3, at least 4, at least 5,
at least 6, at least 7, at least 8, at least 9, at least 10, at
least 11, at least 12, at least 13, at least 14, at least 15, at
least 16, at least 17, at least 18, at least 19, at least 20, at
least 25, at least 30, at least 35, at least 40, at least 45, or at
least 50. In some embodiments, Z is 20. Each N represents,
independently, any nucleotide. Accordingly, a sequence provided as
N.sub.Z with .sub.Z=2 would be NN, with each N, independently,
representing A, T, G, or C. Accordingly, N.sub.Z with .sub.Z=2 can
represent AA, AT, AG, AC, TA, TT, TG, TC, GA, GT, GG, GC, CA, CT,
CG, and CC.
[0085] In other embodiments, the candidate nucleic acid molecules
of the library comprise a candidate nuclease target site of the
structure [left-half site]-[spacer sequence]-[right-half site]
("LSR"), and, thus, the nucleic acid molecules of the library
comprise the structure R.sub.1-[(LSR)-(constant
region)].sub.X-R.sub.2, wherein R.sub.1 and R.sub.2 are,
independently, nucleic acid sequences that may comprise a fragment
of the [(LSR)-(constant region)] repeat unit, and X is an integer
between 2 and y. In some embodiments, y is at least 10.sup.1, at
least 10.sup.2, at least 10.sup.3, at least 10.sup.4, at least
10.sup.5, at least 10.sup.6, at least 10.sup.7, at least 10.sup.8,
at least 10.sup.9, at least 10.sup.10, at least 10.sup.11, at least
10.sup.12, at least 10.sup.13, at least 10.sup.14, or at least
10.sup.15. In some embodiments, y is less than 10.sup.2, less than
10.sup.3, less than 10.sup.4, less than 10.sup.5, less than
10.sup.6, less than 10.sup.7, less than 10.sup.8, less than
10.sup.9, less than 10.sup.10, less than 10.sup.11, less than
10.sup.12, less than 10.sup.13, less than 10.sup.14, or less than
10.sup.15. The constant region, in some embodiments, is of a length
that allows for efficient self-ligation of a single repeat unit.
Suitable lengths will be apparent to those of skill in the art. For
example, in some embodiments, the constant region is between 5 and
100 base pairs long, for example, about 5 base pairs, about 10 base
pairs, about 15 base pairs, about 20 base pairs, about 25 base
pairs, about 30 base pairs, about 35 base pairs, about 40 base
pairs, about 50 base pairs, about 60 base pairs, about 70 base
pairs, about 80 base pairs, about 90 base pairs, or about 100 base
pairs long. In some embodiments, the constant region is 16 base
pairs long. In some embodiments, the nuclease cuts a
double-stranded nucleic acid target site and creates blunt ends. In
other embodiments, the nuclease creates a 5'-overhang. In some such
embodiments, the target site comprises a [left-half site]-[spacer
sequence]-[right-half site] (LSR) structure, and the nuclease cuts
the target site within the spacer sequence.
[0086] In some embodiments, a nuclease cuts a double-stranded
target site and creates blunt ends. In some embodiments, a nuclease
cuts a double-stranded target site and creates an overhang, or
sticky end, for example, a 5'-overhang. In some such embodiments,
the method comprises filling in the 5'-overhangs of nucleic acid
molecules produced from a nucleic acid molecule that has been cut
once by the nuclease, wherein the nucleic acid molecules comprise a
constant insert sequence flanked by a left or right half-site and
cut spacer sequence on one side, and an uncut target site sequence
on the other side, thereby creating blunt ends.
[0087] In some embodiments, the determining of step (c) comprises
ligating a first nucleic acid adapter to the 5' end of a nucleic
acid strand that was cut by the nuclease in step (b) via
5'-phosphate-dependent ligation. In some embodiments, the nuclease
creates blunt ends. In such embodiments, an adapter can directly be
ligated to the blunt ends resulting from the nuclease cut of the
target site by contacting the cut library members with a
double-stranded, blunt-ended adapter lacking 5' phosphorylation. In
some embodiments, the nuclease creates an overhang (sticky end). In
some such embodiments, an adapter may be ligated to the cut site by
contacting the cut library member with an excess of adapter having
a compatible sticky end. If a nuclease is used that cuts within a
constant spacer sequence between variable half-sites, the sticky
end can be designed to match the 5' overhang created from the
spacer sequence. In embodiments, where the nuclease cuts within a
variable sequence, a population of adapters having a variable
overhang sequence and a constant annealed sequence (for use as a
sequencing linker or PCR primer) may be used, or the 5' overhangs
may be filled in to form blunt ends before adapter ligation.
[0088] In some embodiments, the determining of step (c) further
comprises amplifying a fragment of the concatemer cut by the
nuclease that comprises an uncut target site via PCR using a PCR
primer that hybridizes with the adapter and a PCR primer that
hybridizes with the constant insert sequence. Typically, the
amplification of concatemers via PCR will yield amplicons
comprising at least one intact candidate target site identical to
the cut target sites because the target sites in each concatemer
are identical. For single-direction sequencing, an enrichment of
amplicons that comprise one intact target site, no more than two
intact target sites, no more than three intact target sites, no
more than four intact target sites, or no more than five intact
target sites may be desirable. In embodiments where PCR is used for
amplification of cut nucleic acid molecules, the PCR parameters can
be optimized to favor the amplification of short sequences and
disfavor the amplification of longer sequences, e.g., by using a
short elongation time in the PCR cycle. Another possibility for
enrichment of short amplicons is size fractionation, e.g., via gel
electrophoresis or size exclusion chromatography. Size
fractionation can be performed before and/or after amplification.
Other suitable methods for enrichment of short amplicons will be
apparent to those of skill in the art and the disclosure is not
limited in this respect.
[0089] In some embodiments, the determining of step (c) comprises
sequencing the nucleic acid strand that was cut by the nuclease in
step (b), or a copy thereof obtained via amplification, e.g., by
PCR. Sequencing methods are well known to those of skill in the
art. The disclosure is not limited in this respect.
[0090] In some embodiments, the nuclease being profiled using the
inventive system is an RNA-programmable nuclease that forms a
complex with an RNA molecule, and wherein the nuclease:RNA complex
specifically binds a nucleic acid sequence complementary to the
sequence of the RNA molecule. In some embodiments, the RNA molecule
is a single-guide RNA (sgRNA). In some embodiments, the sgRNA
comprises 5-50 nucleotides, 10-30 nucleotides, 15-25 nucleotides,
18-22 nucleotides, 19-21 nucleotides, e.g., 10, 11, 12, 13, 14, 15,
16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30
nucleotides. In some embodiments, the sgRNA comprises 5-50
nucleotides, 10-30 nucleotides, 15-25 nucleotides, 18-22
nucleotides, 19-21 nucleotides, e.g., 10, 11, 12, 13, 14, 15, 16,
17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30
nucleotides that are complementary to a sequence of the nuclease
target site. In some embodiments, the sgRNA comprises 20
nucleotides that are complementary to the nuclease target site. In
some embodiments, the nuclease is a Cas9 nuclease. In some
embodiments, the nuclease target site comprises a
[sgRNA-complementary sequence]-[protospacer adjacent motif (PAM)]
structure, and the nuclease cuts the target site within the
sgRNA-complementary sequence. In some embodiments, the
sgRNA-complementary sequence comprises 5-50 nucleotides, 10-30
nucleotides, 15-25 nucleotides, 18-22 nucleotides, 19-21
nucleotides, e.g., 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21,
22, 23, 24, 25, 26, 27, 28, 29, or 30 nucleotides.
[0091] In some embodiments, the RNA-programmable nuclease is a Cas9
nuclease. The RNA-programmable Cas9 endonuclease cleaves
double-stranded DNA (dsDNA) at sites adjacent to a two-base-pair
PAM motif and complementary to a guide RNA sequence (sgRNA).
Typically, the sgRNA sequence that is complementary to the target
site sequence is about 20 nucleotides long, but shorter and longer
complementary sgRNA sequences can be used as well. For example, in
some embodiments, the sgRNA comprises 5-50 nucleotides, 10-30
nucleotides, 15-25 nucleotides, 18-22 nucleotides, 19-21
nucleotides, e.g., 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21,
22, 23, 24, 25, 26, 27, 28, 29, or 30 nucleotides. The Cas9 system
has been used to modify genomes in multiple cell types,
demonstrating its potential as a facile genome-engineering
tool.
[0092] In some embodiments, the nuclease comprises an unspecific
nucleic acid cleavage domain. In some embodiments, the nuclease
comprises a FokI cleavage domain. In some embodiments, the nuclease
comprises a nucleic acid cleavage domain that cleaves a target
sequence upon cleavage domain dimerization. In some embodiments,
the nuclease comprises a binding domain that specifically binds a
nucleic acid sequence. In some embodiments, the binding domain
comprises a zinc finger. In some embodiments, the binding domain
comprises at least 2, at least 3, at least 4, or at least 5 zinc
fingers. In some embodiments, the nuclease is a Zinc Finger
Nuclease. In some embodiments, the binding domain comprises a
Transcriptional Activator-Like Element. In some embodiments, the
nuclease is a Transcriptional Activator-Like Element Nuclease
(TALEN). In some embodiments, the nuclease is a homing
endonuclease. In some embodiments, the nuclease is an organic
compound. In some embodiments, the nuclease comprises an enediyne
functional group. In some embodiments, the nuclease is an
antibiotic. In some embodiments, the compound is dynemicin,
neocarzinostatin, calicheamicin, esperamicin, bleomycin, or a
derivative thereof.
[0093] Incubation of the nuclease with the library nucleic acids
will result in cleavage of those concatemers in the library that
comprise target sites that can be bound and cleaved by the
nuclease. If a given nuclease cleaves a specific target site with
high efficiency, a concatemer comprising target sites will be cut,
e.g., once or multiple times, resulting in the generation of
fragments comprising a cut target site adjacent to one or more
repeat units. Depending on the structure of the library members, an
exemplary cut nucleic acid molecule released from a library member
concatemer by a single nuclease cleavage may, for example, be of
the structure (cut target site)-(constant region)-[(target
site)-(constant region)].sub.X-R.sub.2. For example, in the context
of an RNA-guided nuclease, an exemplary cut nucleic acid molecule
released from a library member concatemer by a single nuclease
cleavage may, for example, be of the structure (PAM)-(constant
region)-[(N.sub.Z)-(PAM)-(constant region)].sub.X-R.sub.2. And in
the context of a nuclease cutting an LSR structure within the
spacer region, an exemplary cut nucleic acid molecule released from
a library member concatemer by a single nuclease cleavage may, for
example, be of the structure (cut spacer region)-(right half
site)-(constant region)-[(LSR)-(constant region)].sub.X-R.sub.2.
Such cut fragments released from library candidate molecules can
then be isolated and/or the sequence of the target site cleaved by
the nuclease identified by sequencing an intact target site (e.g.,
an intact (N.sub.Z)-(PAM) site of released repeat units. See, e.g.,
FIG. 1B for an illustration.
[0094] Suitable conditions for exposure of the library of nucleic
acid molecules will be apparent to those of skill in the art. In
some embodiments, suitable conditions do not result in denaturation
of the library nucleic acids or the nuclease and allow for the
nuclease to exhibit at least 50%, at least 60%, at least 70%, at
least 80%, at least 90%, at least 95%, or at least 98% of its
nuclease activity.
[0095] Additionally, if a given nuclease cleaves a specific target
site, some cleavage products will comprise a cut half site and an
intact, or uncut target site. As described herein, such products
can be isolated by routine methods, and because the insert
sequence, in some aspects, is less than 100 base pairs, such
isolated cleavage products may be sequenced in a single
read-through, allowing identification of the target site sequence
without reconstructing the sequence, e.g., from cut half sites.
[0096] Any method suitable for isolation and sequencing of the
repeat units can be employed to elucidate the LSR sequence cleaved
by the nuclease. For example, since the length of the constant
region is known, individual released repeat units can be separated
based on their size from the larger uncut library nucleic acid
molecules as well as from fragments of library nucleic acid
molecules that comprise multiple repeat units (indicating
non-efficient targeted cleavage by the nuclease). Suitable methods
for separating and/or isolating nucleic acid molecules based on
their size are well-known to those of skill in the art and include,
for example, size fractionation methods, such as gel
electrophoresis, density gradient centrifugation, and dialysis over
a semi-permeable membrane with a suitable molecular cutoff value.
The separated/isolated nucleic acid molecules can then be further
characterized, for example, by ligating PCR and/or sequencing
adapters to the cut ends and amplifying and/or sequencing the
respective nucleic acids. Further, if the length of the constant
region is selected to favor self-ligation of individual released
repeat units, such individual released repeat units may be enriched
by contacting the nuclease treated library molecules with a ligase
and subsequent amplification and/or sequencing based on the
circularized nature of the self-ligated individual repeat
units.
[0097] In some embodiments, where a nuclease is used that generates
5'-overhangs as a result of cutting a target nucleic acid, the
5'-overhangs of the cut nucleic acid molecules are filled in.
Methods for filling in 5'-overhangs are well known to those of
skill in the art and include, for example, methods using DNA
polymerase I Klenow fragment lacking exonuclease activity (Klenow
(3'.fwdarw.5' exo-)). Filling in 5'-overhangs results in the
overhang-templated extension of the recessed strand, which, in
turn, results in blunt ends. In the case of single repeat units
released from library concatemers, the resulting structure is a
blunt-ended S.sub.2'R-(constant region)-LS.sub.1', with S.sub.1'
and S.sub.2' comprising blunt ends. PCR and/or sequencing adapters
can then be added to the ends by blunt end ligation and the
respective repeat units (including S.sub.2'R and LS.sub.1' regions)
can be sequenced. From the sequence data, the original LSR region
can be deduced. Blunting of the overhangs created during the
nuclease cleavage process also allows for distinguishing between
target sites that were properly cut by the respective nuclease and
target sites that were non-specifically cut, e.g., based on
non-nuclease effects such as physical shearing. Correctly cleaved
nuclease target sites can be recognized by the existence of
complementary S.sub.2'R and LS.sub.1' regions, which comprise a
duplication of the overhang nucleotides as a result of the overhang
fill in while target sites that were not cleaved by the respective
nuclease are unlikely to comprise overhang nucleotide duplications.
In some embodiments, the method comprises identifying the nuclease
target site cut by the nuclease by determining the sequence of the
left-half site, the right-half-site, and/or the spacer sequence of
a released individual repeat unit. Any suitable method for
amplifying and/or sequencing can be used to identify the LSR
sequence of the target site cleaved by the respective nuclease.
Methods for amplifying and/or sequencing nucleic acids are well
known to those of skill in the art and the disclosure is not
limited in this respect. In the case of nucleic acids released from
library concatemers that comprise a cut half site and an uncut
target site (e.g., comprises at least about 1.5 repeat sequences),
filling in the 5'-overhangs also provides for assurance that the
nucleic acid was cleaved by the nuclease. Because the nucleic acid
also comprises an intact, or uncut target site, the sequence of
said site can be determined without having to reconstruct the
sequence from a left-half site, right-half site, and/or spacer
sequence.
[0098] Some of the methods and strategies provided herein allow for
the simultaneous assessment of a plurality of candidate target
sites as possible cleavage targets for any given nuclease.
Accordingly, the data obtained from such methods can be used to
compile a list of target sites cleaved by a given nuclease, which
is also referred to herein as a target site profile. If a
sequencing method is used that allows for the generation of
quantitative sequencing data, it is also possible to record the
relative abundance of any nuclease target site detected to be
cleaved by the respective nuclease. Target sites that are cleaved
more efficiently by the nuclease will be detected more frequently
in the sequencing step, while target sites that are not cleaved
efficiently will only rarely release an individual repeat unit from
a candidate concatemer, and thus, will only generate few, if any,
sequencing reads. Such quantitative sequencing data can be
integrated into a target site profile to generate a ranked list of
highly preferred and less preferred nuclease target sites.
[0099] The methods and strategies of nuclease target site profiling
provided herein can be applied to any site-specific nuclease,
including, for example, ZFNs, TALENs, homing endonucleases, and
RNA-programmable nucleases, such as Cas9 nucleases. As described in
more detail herein, nuclease specificity typically decreases with
increasing nuclease concentration, and the methods described herein
can be used to determine a concentration at which a given nuclease
efficiently cuts its intended target site, but does not efficiently
cut any off-target sequences. In some embodiments, a maximum
concentration of a therapeutic nuclease is determined at which the
therapeutic nuclease cuts its intended nuclease target site but
does not cut more than 10, more than 5, more than 4, more than 3,
more than 2, more than 1, or any additional sites. In some
embodiments, a therapeutic nuclease is administered to a subject in
an amount effective to generate a final concentration equal or
lower than the maximum concentration determined as described
above.
[0100] In some embodiments, the library of candidate nucleic acid
molecules used in the methods provided herein comprises at least
10.sup.8, at least 10.sup.9, at least 10.sup.10, at least
10.sup.11, or at least 10.sup.12 different candidate nuclease
target sites.
[0101] In some embodiments, the nuclease is a therapeutic nuclease
which cuts a specific nuclease target site in a gene associated
with a disease. In some embodiments, the method further comprises
determining a maximum concentration of the therapeutic nuclease at
which the therapeutic nuclease cuts the specific nuclease target
site and does not cut more than 10, more than 5, more than 4, more
than 3, more than 2, more than 1, or no additional sites. In some
embodiments, the method further comprises administering the
therapeutic nuclease to a subject in an amount effective to
generate a final concentration equal or lower than the maximum
concentration.
Nuclease Target Site Libraries
[0102] Some embodiments of this disclosure provide libraries of
nucleic acid molecules for nuclease target site profiling. In some
embodiments, the candidate nucleic acid molecules of the library
comprise the structure R.sub.1-[(N.sub.Z)-(PAM)-(constant
region)].sub.X-R.sub.2, wherein R.sub.1 and R.sub.2 are,
independently, nucleic acid sequences that may comprise a fragment
of the [(N.sub.Z)-(PAM)-(constant region)] repeat unit; each N
represents, independently, any nucleotide; Z is an integer between
1 and 50; and X is an integer between 2 and y. In some embodiments,
y is at least 10.sup.1, at least 10.sup.2, at least 10.sup.3, at
least 10.sup.4, at least 10.sup.5, at least 10.sup.6, at least
10.sup.7, at least 10.sup.8, at least 10.sup.9, at least 10.sup.10,
at least 10.sup.11, at least 10.sup.12, at least 10.sup.13, at
least 10.sup.14, or at least 10.sup.15. In some embodiments, y is
less than 10.sup.2, less than 10.sup.3, less than 10.sup.4, less
than 10.sup.5, less than 10.sup.6, less than 10.sup.7, less than
10.sup.8, less than 10.sup.9, less than 10.sup.10, less than
10.sup.11, less than 10.sup.12, less than 10.sup.13, less than
10.sup.14, or less than 10.sup.15. In some embodiments, Z is at
least 2, at least 3, at least 4, at least 5, at least 6, at least
7, at least 8, at least 9, at least 10, at least 11, at least 12,
at least 13, at least 14, at least 15, at least 16, at least 17, at
least 18, at least 19, at least 20, at least 25, at least 30, at
least 35, at least 40, at least 45, or at least 50. In some
embodiments, Z is 20. Each N represents, independently, any
nucleotide. Accordingly, a sequence provided as N.sub.Z with
.sub.Z=2 would be NN, with each N, independently, representing A,
T, G, or C. Accordingly, N.sub.Z with .sub.Z=2 can represent AA,
AT, AG, AC, TA, TT, TG, TC, GA, GT, GG, GC, CA, CT, CG, and CC.
[0103] In some embodiments, a library is provided comprising
candidate nucleic acid molecules that comprise target sites with a
partially randomized left-half site, a partially randomized
right-half site, and/or a partially randomized spacer sequence. In
some embodiments, the library is provided comprising candidate
nucleic acid molecules that comprise target sites with a partially
randomized left half site, a fully randomized spacer sequence, and
a partially randomized right half site. In some embodiments, a
library is provided comprising candidate nucleic acid molecules
that comprise target sites with a partially or fully randomized
sequence, wherein the target sites comprise the structure
[N.sub.Z-(PAM)], for example as described herein. In some
embodiments, partially randomized sites differ from the consensus
site by more than 5%, more than 10%, more than 15%, more than 20%,
more than 25%, or more than 30% on average, distributed
binomially.
[0104] In some embodiments such a library comprises a plurality of
nucleic acid molecules, each comprising a concatemer of a candidate
nuclease target site and a constant insert sequence, also referred
to herein as a constant region. For example, in some embodiments,
the candidate nucleic acid molecules of the library comprise the
structure R.sub.1-[(sgRNA-complementary sequence)-(PAM)-(constant
region)].sub.X-R.sub.2, or the structure R.sub.1-[(LSR)-(constant
region)].sub.X-R.sub.2, wherein the structure in square brackets
("[ . . . ]") is referred to as a repeat unit or repeat sequence;
R.sub.1 and R.sub.2 are, independently, nucleic acid sequences that
may comprise a fragment of the repeat unit, and X is an integer
between 2 and y. In some embodiments, y is at least 10.sup.1, at
least 10.sup.2, at least 10.sup.3, at least 10.sup.4, at least
10.sup.5, at least 10.sup.6, at least 10.sup.7, at least 10.sup.8,
at least 10.sup.9, at least 10.sup.10, at least 10.sup.11, at least
10.sup.12, at least 10.sup.13, at least 10.sup.14, or at least
10.sup.15. In some embodiments, y is less than 10.sup.2, less than
10.sup.3, less than 10.sup.4, less than 10.sup.5, less than
10.sup.6, less than 10.sup.7, less than 10.sup.8, less than
10.sup.9, less than 10.sup.10, less than 10.sup.11, less than
10.sup.12, less than 10.sup.13, less than 10.sup.14, or less than
10.sup.15. The constant region, in some embodiments, is of a length
that allows for efficient self-ligation of a single repeat unit. In
some embodiments, the constant region is of a length that allows
for efficient separation of single repeat units from fragments
comprising two or more repeat units. In some embodiments, the
constant region is of a length allows for efficient sequencing of a
complete repeat unit in one sequencing read. Suitable lengths will
be apparent to those of skill in the art. For example, in some
embodiments, the constant region is between 5 and 100 base pairs
long, for example, about 5 base pairs, about 10 base pairs, about
15 base pairs, about 20 base pairs, about 25 base pairs, about 30
base pairs, about 35 base pairs, about 40 base pairs, about 50 base
pairs, about 60 base pairs, about 70 base pairs, about 80 base
pairs, about 90 base pairs, or about 100 base pairs long. In some
embodiments, the constant region is 1, 2, 3, 4, 5, 6, 7, 8, 9, 0,
12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28,
29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45,
46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62,
63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79,
or 80 base pairs long.
[0105] An LSR site typically comprises a [left-half site]-[spacer
sequence]-[right-half site] structure. The lengths of the half-size
and the spacer sequence will depend on the specific nuclease to be
evaluated. In general, the half-sites will be 6-30 nucleotides
long, and preferably 10-18 nucleotides long. For example, each half
site individually may be 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16,
17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30
nucleotides long. In some embodiments, an LSR site may be longer
than 30 nucleotides. In some embodiments, the left half site and
the right half site of an LSR are of the same length. In some
embodiments, the left half site and the right half site of an LSR
are of different lengths. In some embodiments, the left half site
and the right half site of an LSR are of different sequences. In
some embodiments, a library is provided that comprises candidate
nucleic acids which comprise LSRs that can be cleaved by a FokI
cleavage domain, a Zinc Finger Nuclease (ZFN), a Transcription
Activator-Like Effector Nuclease (TALEN), a homing endonuclease, or
an organic compound (e.g., an enediyne antibiotic such as
dynemicin, neocarzinostatin, calicheamicin, and esperamicinl; and
bleomycin).
[0106] In some embodiments, a library of candidate nucleic acid
molecules is provided that comprises at least 10.sup.5, at least
10.sup.6, at least 10.sup.7, at least 10.sup.8, at least 10.sup.9,
at least 10.sup.10, at least 10.sup.11, at least 10.sup.12, at
least 10.sup.13, at least 10.sup.14, or at least 10.sup.15
different candidate nuclease target sites. In some embodiments, the
candidate nucleic acid molecules of the library are concatemers
produced from a secularized templates by rolling cycle
amplification. In some embodiments, the library comprises nucleic
acid molecules, e.g., concatemers, of a molecular weight of at
least 5 kDa, at least 6 kDa, at least 7 kDa, at least 8 kDa, at
least 9 kDa, at least 10 kDa, at least 12 kDa, or at least 15 kDa.
In some embodiments, the molecular weight of the nucleic acid
molecules within the library may be larger than 15 kDa. In some
embodiments, the library comprises nucleic acid molecules within a
specific size range, for example, within a range of 5-7 kDa, 5-10
kDa, 8-12 kDa, 10-15 kDa, or 12-15 kDa, or 5-10 kDa or any possible
subrange. While some methods suitable for generating nucleic acid
concatemers according to some aspects of this disclosure result in
the generation of nucleic acid molecules of greatly different
molecular weights, such mixtures of nucleic acid molecules may be
size fractionated to obtain a desired size distribution. Suitable
methods for enriching nucleic acid molecules of a desired size or
excluding nucleic acid molecules of a desired size are well known
to those of skill in the art and the disclosure is not limited in
this respect.
[0107] In some embodiments, partially randomized sites differ from
the consensus site by no more than 10%, no more than 15%, no more
than 20%, no more than 25%, nor more than 30%, no more than 40%, or
no more than 50% on average, distributed binomially. For example,
in some embodiments partially randomized sites differ from the
consensus site by more than 5%, but by no more than 10%; by more
than 10%, but by no more than 20%; by more than 20%, but by no more
than 25%; by more than 5%, but by no more than 20%, and so on.
Using partially randomized nuclease target sites in the library is
useful to increase the concentration of library members comprising
target sites that are closely related to the consensus site, for
example, that differ from the consensus sites in only one, only
two, only three, only four, or only five residues. The rationale
behind this is that a given nuclease, for example a given ZFN or
RNA-programmable nuclease, is likely to cut its intended target
site and any closely related target sites, but unlikely to cut a
target sites that is vastly different from or completely unrelated
to the intended target site. Accordingly, using a library
comprising partially randomized target sites can be more efficient
than using libraries comprising fully randomized target sites
without compromising the sensitivity in detecting any off-target
cleavage events for any given nuclease. Thus, the use of partially
randomized libraries significantly reduces the cost and effort
required to produce a library having a high likelihood of covering
virtually all off-target sites of a given nuclease. In some
embodiments however it may be desirable to use a fully randomized
library of target sites, for example, in embodiments, where the
specificity of a given nuclease is to be evaluated in the context
of any possible site in a given genome.
Selection and Design of Site-Specific Nucleases
[0108] Some aspects of this disclosure provide methods and
strategies for selecting and designing site-specific nucleases that
allow the targeted cleavage of a single, unique sites in the
context of a complex genome. In some embodiments, a method is
provided that comprises providing a plurality of candidate
nucleases that are designed or known to cut the same consensus
sequence; profiling the target sites actually cleaved by each
candidate nuclease, thus detecting any cleaved off-target sites
(target sites that differ from the consensus target site); and
selecting a candidate nuclease based on the off-target site(s) so
identified. In some embodiments, this method is used to select the
most specific nuclease from a group of candidate nucleases, for
example, the nuclease that cleaves the consensus target site with
the highest specificity, the nuclease that cleaves the lowest
number of off-target sites, the nuclease that cleaves the lowest
number of off-target sites in the context of a target genome, or a
nuclease that does not cleave any target site other than the
consensus target site. In some embodiments, this method is used to
select a nuclease that does not cleave any off-target site in the
context of the genome of a subject at concentration that is equal
to or higher than a therapeutically effective concentration of the
nuclease.
[0109] The methods and reagents provided herein can be used, for
example, to evaluate a plurality of different nucleases targeting
the same intended targets site, for example, a plurality of
variations of a given site-specific nuclease, for example a given
zinc finger nuclease. Accordingly, such methods may be used as the
selection step in evolving or designing a novel site-specific
nucleases with improved specificity.
Identifying Unique Nuclease Target Sites within a Genome
[0110] Some embodiments of this disclosure provide a method for
selecting a nuclease target site within a genome. As described in
more detail elsewhere herein, it was surprisingly discovered that
off target sites cleaved by a given nuclease are typically highly
similar to the consensus target site, e.g., differing from the
consensus target site in only one, only two, only three, only four,
or only five nucleotide residues. Based on this discovery, a
nuclease target sites within the genome can be selected to increase
the likelihood of a nuclease targeting this site not cleaving any
off target sites within the genome. For example, in some
embodiments, a method is provided that comprises identifying a
candidate nuclease target site; and comparing the candidate
nuclease target site to other sequences within the genome. Methods
for comparing candidate nuclease target sites to other sequences
within the genome are well known to those of skill in the art and
include for example sequence alignment methods, for example, using
a sequence alignment software or algorithm such as BLAST on a
general purpose computer. A suitable unique nuclease target site
can then be selected based on the results of the sequence
comparison. In some embodiments, if the candidate nuclease target
site differs from any other sequence within the genome by at least
3, at least 4, at least 5, at least 6, at least 7, at least 8, at
least 9, or at least 10 nucleotides, the nuclease target site is
selected as a unique site within the genome, whereas if the site
does not fulfill this criteria, the site may be discarded. In some
embodiments, once a site is selected based on the sequence
comparison, as outlined above, a site-specific nuclease targeting
the selected site is designed. For example, a zinc finger nuclease
may be designed to target any selected nuclease target site by
constructing a zinc finger array binding the target site, and
conjugating the zinc finger array to a DNA cleavage domain. In
embodiments where the DNA cleavage domain needs to dimerize in
order to cleave DNA, to zinc finger arrays will be designed, each
binding a half site of the nuclease target site, and each
conjugated to a cleavage domain. In some embodiments, nuclease
designing and/or generating is done by recombinant technology.
Suitable recombinant technologies are well known to those of skill
in the art, and the disclosure is not limited in this respect.
[0111] In some embodiments, a site-specific nuclease designed or
generated according to aspects of this disclosure is isolated
and/or purified. The methods and strategies for designing
site-specific nucleases according to aspects of this disclosure can
be applied to design or generate any site-specific nuclease,
including, but not limited to Zinc Finger Nucleases, Transcription
Activator-Like Effector Nucleases (TALENs), a homing endonuclease,
an organic compound nuclease, or an enediyne antibiotic (e.g.,
dynemicin, neocarzinostatin, calicheamicin, esperamicin,
bleomycin).
Isolated Nucleases
[0112] Some aspects of this disclosure provide isolated
site-specific nucleases with enhanced specificity that are designed
using the methods and strategies described herein. Some
embodiments, of this disclosure provide nucleic acids encoding such
nucleases. Some embodiments of this disclosure provide expression
constructs comprising such encoding nucleic acids. For example, in
some embodiments an isolated nuclease is provided that has been
engineered to cleave a desired target site within a genome, and has
been evaluated according to a method provided herein to cut less
than 1, less than 2, less than 3, less than 4, less than 5, less
than 6, less than 7, less than 8, less than 9 or less than 10
off-target sites at a concentration effective for the nuclease to
cut its intended target site. In some embodiments an isolated
nuclease is provided that has been engineered to cleave a desired
unique target site that has been selected to differ from any other
site within a genome by at least 3, at least 4, at least 5, at
least 6, at least 7, at least 8, at least 9, or at least 10
nucleotide residues. In some embodiments, the isolated nuclease is
an RNA-programmable nuclease, such as a Cas9 nuclease; a Zinc
Finger Nuclease (ZFN); or a Transcription Activator-Like Effector
Nuclease (TALEN), a homing endonuclease, an organic compound
nuclease, or an enediyne antibiotic (e.g., dynemicin,
neocarzinostatin, calicheamicin, esperamicin, bleomycin). In some
embodiments, the isolated nuclease cleaves a target site within an
allele that is associated with a disease or disorder. In some
embodiments, the isolated nuclease cleaves a target site the
cleavage of which results in treatment or prevention of a disease
or disorder. In some embodiments, the disease is HIV/AIDS, or a
proliferative disease. In some embodiments, the allele is a CCR5
(for treating HIV/AIDS) or a VEGFA allele (for treating a
proliferative disease).
[0113] In some embodiments, the isolated nuclease is provided as
part of a pharmaceutical composition. For example, some embodiments
provide pharmaceutical compositions comprising a nuclease as
provided herein, or a nucleic acid encoding such a nuclease, and a
pharmaceutically acceptable excipient. Pharmaceutical compositions
may optionally comprise one or more additional therapeutically
active substances.
[0114] In some embodiments, compositions provided herein are
administered to a subject, for example, to a human subject, in
order to effect a targeted genomic modification within the subject.
In some embodiments, cells are obtained from the subject and
contacted with a nuclease or a nuclease-encoding nucleic acid ex
vivo, and re-administered to the subject after the desired genomic
modification has been effected or detected in the cells. Although
the descriptions of pharmaceutical compositions provided herein are
principally directed to pharmaceutical compositions which are
suitable for administration to humans, it will be understood by the
skilled artisan that such compositions are generally suitable for
administration to animals of all sorts. Modification of
pharmaceutical compositions suitable for administration to humans
in order to render the compositions suitable for administration to
various animals is well understood, and the ordinarily skilled
veterinary pharmacologist can design and/or perform such
modification with merely ordinary, if any, experimentation.
Subjects to which administration of the pharmaceutical compositions
is contemplated include, but are not limited to, humans and/or
other primates; mammals, including commercially relevant mammals
such as cattle, pigs, horses, sheep, cats, dogs, mice, and/or rats;
and/or birds, including commercially relevant birds such as
chickens, ducks, geese, and/or turkeys.
[0115] Formulations of the pharmaceutical compositions described
herein may be prepared by any method known or hereafter developed
in the art of pharmacology. In general, such preparatory methods
include the step of bringing the active ingredient into association
with an excipient and/or one or more other accessory ingredients,
and then, if necessary and/or desirable, shaping and/or packaging
the product into a desired single- or multi-dose unit.
[0116] Pharmaceutical formulations may additionally comprise a
pharmaceutically acceptable excipient, which, as used herein,
includes any and all solvents, dispersion media, diluents, or other
liquid vehicles, dispersion or suspension aids, surface active
agents, isotonic agents, thickening or emulsifying agents,
preservatives, solid binders, lubricants and the like, as suited to
the particular dosage form desired. Remington's The Science and
Practice of Pharmacy, 21.sup.st Edition, A. R. Gennaro (Lippincott,
Williams & Wilkins, Baltimore, Md., 2006; incorporated in its
entirety herein by reference) discloses various excipients used in
formulating pharmaceutical compositions and known techniques for
the preparation thereof. See also PCT application
PCT/US2010/055131, incorporated in its entirety herein by
reference, for additional suitable methods, reagents, excipients
and solvents for producing pharmaceutical compositions comprising a
nuclease. Except insofar as any conventional excipient medium is
incompatible with a substance or its derivatives, such as by
producing any undesirable biological effect or otherwise
interacting in a deleterious manner with any other component(s) of
the pharmaceutical composition, its use is contemplated to be
within the scope of this disclosure.
[0117] The function and advantage of these and other embodiments of
the present invention will be more fully understood from the
Examples below. The following Examples are intended to illustrate
the benefits of the present invention and to describe particular
embodiments, but are not intended to exemplify the full scope of
the invention. Accordingly, it will be understood that the Examples
are not meant to limit the scope of the invention.
EXAMPLES
Materials and Methods
[0118] Oligonucleotides. All oligonucleotides used in this study
were purchased from Integrated DNA Technologies. Oligonucleotide
sequences are listed in Table 9.
[0119] Expression and Purification of S. pyogenes Cas9. E. coli
Rosetta (DE3) cells were transformed with plasmid pMJ806.sup.11,
encoding the S. pyogenes cas9 gene fused to an N-terminal
6.times.His-tag/maltose binding protein. The resulting expression
strain was inoculated in Luria-Bertani (LB) broth containing 100
.mu.g/mL of ampicillin and 30 .mu.g/mL of chloramphenicol at
37.degree. C. overnight. The cells were diluted 1:100 into the same
growth medium and grown at 37.degree. C. to OD.sub.600.about.0.6.
The culture was incubated at 18.degree. C. for 30 min, and
isopropyl .beta.-D-1-thiogalactopyranoside (IPTG) was added at 0.2
mM to induce Cas9 expression. After .about.17 h, the cells were
collected by centrifugation at 8,000 g and resuspended in lysis
buffer (20 mM tris(hydroxymethyl)-aminomethane (Tris)-HCl, pH 8.0,
1 M KCl, 20% glycerol, 1 mM tris (2-carboxyethyl)phosphine (TCEP)).
The cells were lysed by sonication (10 sec pulse-on and 30 sec
pulse-off for 10 min total at 6 W output) and the soluble lysate
was obtained by centrifugation at 20,000 g for 30 min. The cell
lysate was incubated with nickel-nitriloacetic acid (nickel-NTA)
resin (Qiagen) at 4.degree. C. for 20 min to capture His-tagged
Cas9. The resin was transferred to a 20-mL column and washed with
20 column volumes of lysis buffer. Cas9 was eluted in 20 mM
Tris-HCl (pH 8), 0.1 M KCl, 20% glycerol, 1 mM TCEP, and 250 mM
imidazole, and concentrated by Amicon ultra centrifugal filter
(Millipore, 30-kDa molecular weight cut-off) to .about.50 mg/mL.
The 6.times.His tag and maltose-binding protein were removed by TEV
protease treatment at 4.degree. C. for 20 h and captured by a
second Ni-affinity purification step. The eluent, containing Cas9,
was injected into a HiTrap SP FF column (GE Healthcare) in
purification buffer containing 20 mM Tris-HCl (pH 8), 0.1 M KCl,
20% glycerol, and 1 mM TCEP. Cas9 was eluted with purification
buffer containing a linear KCl gradient from 0.1 M to 1 M over five
column volumes. The eluted Cas9 was further purified by a HiLoad
Superdex 200 column in purification buffer, snap-frozen in liquid
nitrogen, and stored in aliquots at -80.degree. C.
[0120] In Vitro RNA Transcription. 100 pmol CLTA(#) v2.1 fwd and
v2.1 template rev were incubated at 95.degree. C. and cooled at
0.1.degree. C./s to 37.degree. C. in NEBuffer2 (50 mM sodium
chloride, 10 mM Tris-HCl, 10 mM magnesium chloride, 1 mM
dithiothreitol, pH 7.9) supplemented with 10 .mu.M dNTP mix
(Bio-Rad). 10 U of Klenow Fragment (3'.fwdarw.5' exo.sup.-) (NEB)
were added to the reaction mixture and a double-stranded CLTA(#)
v2.1 template was obtained by overlap extension for 1 h at
37.degree. C. 200 nM CLTA(#) v2.1 template alone or 100 nM CLTA(#)
template with 100 nM T7 promoter oligo was incubated overnight at
37.degree. C. with 0.16 U/.mu.L of T7 RNA Polymerase (NEB) in NEB
RNAPol Buffer (40 mM Tris-HCl, pH 7.9, 6 mM magnesium chloride, 10
mM dithiothreitol, 2 mM spermidine) supplemented with 1 mM rNTP mix
(1 mM rATP, 1 mM rCTP, 1 mM rGTP, 1 mM rUTP). In vitro transcribed
RNA was precipitated with ethanol and purified by gel
electrophoresis on a Criterion 10% polyacrylamide TBE-Urea gel
(Bio-Rad). Gel-purified sgRNA was precipitated with ethanol and
redissolved in water.
[0121] In Vitro Library Construction. 10 pmol of CLTA(#) lib
oligonucleotides were separately circularized by incubation with
100 units of CircLigase II ssDNA Ligase (Epicentre) in 1.times.
CircLigase II Reaction Buffer (33 mM Tris-acetate, 66 mM potassium
acetate, 0.5 mM dithiothreitol, pH 7.5) supplemented with 2.5 mM
manganese chloride in a total reaction volume of 20 .mu.L for 16
hours at 60.degree. C. The reaction mixture was incubated for 10
minutes at 85.degree. C. to inactivate the enzyme. 5 .mu.L (5 pmol)
of the crude circular single-stranded DNA were converted into the
concatemeric pre-selection libraries with the illustra TempliPhi
Amplification Kit (GE Healthcare) according to the manufacturer's
protocol. Concatemeric pre-selection libraries were quantified with
the Quant-it PicoGreen dsDNA Assay Kit (Invitrogen).
[0122] In Vitro Cleavage of On-Target and Off-Target Substrates.
Plasmid templates for PCR were constructed by ligation of annealed
oligonucleotides CLTA(#) site fwd/rev into HindIII/XbaI
double-digested pUC19 (NEB). On-target substrate DNAs were
generated by PCR with the plasmid templates and test fwd and test
rev primers, then purified with the QIAquick PCR Purification Kit
(Qiagen). Off-target substrate DNAs were generated by primer
extension. 100 pmol off-target (#) fwd and off-target (#) rev
primers were incubated at 95.degree. C. and cooled at 0.1.degree.
C./s to 37.degree. C. in NEBuffer2 (50 mM sodium chloride, 10 mM
Tris-HCl, 10 mM magnesium chloride, 1 mM dithiothreitol, pH 7.9)
supplemented with 10 .mu.M dNTP mix (Bio-Rad). 10 U of Klenow
Fragment (3'.fwdarw.5' exo-) (NEB) were added to the reaction
mixture and double-stranded off-target templates were obtained by
overlap extension for 1 h at 37.degree. C. followed by enzyme
inactivation for 20 min at 75.degree. C., then purified with the
QIAquick PCR Purification Kit (Qiagen). 200 nM substrate DNAs were
incubated with 100 nM Cas9 and 100 nM (v1.0 or v2.1) sgRNA or 1000
nM Cas9 and 1000 nM (v1.0 or v2.1) sgRNA in Cas9 cleavage buffer
(200 mM HEPES, pH 7.5, 1.5 M potassium chloride, 100 mM magnesium
chloride, 1 mM EDTA, 5 mM dithiothreitol) for 10 min at 37.degree.
C. On-target cleavage reactions were purified with the QIAquick PCR
Purification Kit (Qiagen), and off-target cleavage reactions were
purified with the QIAquick Nucleotide Removal Kit (Qiagen) before
electrophoresis in a Criterion 5% polyacrylamide TBE gel
(Bio-Rad).
[0123] In Vitro Selection. 200 nM concatemeric pre-selection
libraries were incubated with 100 nM Cas9 and 100 nM sgRNA or 1000
nM Cas9 and 1000 nM sgRNA in Cas9 cleavage buffer (200 mM HEPES, pH
7.5, 1.5 M potassium chloride, 100 mM magnesium chloride, 1 mM
EDTA, 5 mM dithiothreitol) for 10 min at 37.degree. C.
Pre-selection libraries were also separately incubated with 2 U of
BspMI restriction endonuclease (NEB) in NEBuffer 3 (100 mM NaCl, 50
mM Tris-HCl, 10 mM MgCl2, 1 mM dithiothreitol, pH 7.9) for 1 h at
37.degree. C. Blunt-ended post-selection library members or
sticky-ended pre-selection library members were purified with the
QIAQuick PCR Purification Kit (Qiagen) and ligated to 10 pmol
adapter1/2(AACA) (Cas9:v2.1 sgRNA, 100 nM), adapter1/2(TTCA)
(Cas9:v2.1 sgRNA, 1000 nM), adapter1/2 (Cas9:v2.1 sgRNA, 1000 nM),
or lib adapter1/CLTA(#) lib adapter 2 (pre-selection) with 1,000 U
of T4 DNA Ligase (NEB) in NEB T4 DNA Ligase Reaction Buffer (50 mM
Tris-HCl, pH 7.5, 10 mM magnesium chloride, 1 mM ATP, 10 mM
dithiothreitol) overnight (>10 h) at room temperature.
Adapter-ligated DNA was purified with the QIAquick PCR Purification
Kit and PCR-amplified for 10-13 cycles with Phusion Hot Start Flex
DNA Polymerase (NEB) in Buffer HF (NEB) and primers CLTA(#) sel
PCR/PE2 short (post-selection) or CLTA(#) lib seq PCR/lib fwd PCR
(pre-selection). Amplified DNAs were gel purified, quantified with
the KAPA Library Quantification Kit-Illumina (KAPA Biosystems), and
subjected to single-read sequencing on an Illumina MiSeq or Rapid
Run single-read sequencing on an Illumina HiSeq 2500 (Harvard
University FAS Center for Systems Biology Core facility, Cambridge,
Mass.).
[0124] Selection Analysis. Pre-selection and post-selection
sequencing data were analyzed as previously described.sup.21, with
modification (Algorithms) using scripts written in C++. Raw
sequence data is not shown; see Table 2 for a curated summary.
Specificity scores were calculated with the formulae: positive
specificity score=(frequency of base pair at
position[post-selection]-frequency of base pair at
position[pre-selection])/(1-frequency of base pair at
position[pre-selection]) and negative specificity score=(frequency
of base pair at position[post-selection]-frequency of base pair at
position[pre-selection])/(frequency of base pair at
position[pre-selection]). Normalization for sequence logos was
performed as previously described.sup.22.
[0125] Cellular Cleavage Assays. HEK293T cells were split at a
density of 0.8.times.10.sup.5 per well (6-well plate) before
transcription and maintained in Dulbecco's modified eagle medium
(DMEM) supplemented with 10% fetal bovine serum (FBS) in a
37.degree. C. humidified incubator with 5% CO.sub.2. After 1 day,
cells were transiently transfected using Lipofectamine 2000
(Invitrogen) following the manufacturer's protocols. HEK293T cells
were transfected at 70% confluency in each well of 6-well plate
with 1.0 .mu.g of the Cas9 expression plasmid
(Cas9-HA-2.times.NLS-GFP-NLS) and 2.5 .mu.g of the single-strand
RNA expression plasmid pSiliencer-CLTA (version 1.0 or 2.1). The
transfection efficiencies were estimated to be .about.70%, based on
the fraction of GFP-positive cells observed by fluorescence
microscopy. 48 h after transfection, cells were washed with
phosphate buffered saline (PBS), pelleted and frozen at -80.degree.
C. Genomic DNA was isolated from 200 .mu.L cell lysate using the
DNeasy Blood and Tissue Kit (Qiagen) according to the
manufacturer's protocol.
[0126] Off-Target Site Sequence Determination. 100 ng genomic DNA
isolated from cells treated with Cas9 expression plasmid and
single-strand RNA expression plasmid (treated cells) or Cas9
expression plasmid alone (control cells) were amplified by PCR with
10 s 72.degree. C. extension for 35 cycles with primers
CLTA(#)-(#)-(#) fwd and CLTA(#)-(#)-(#) rev and Phusion Hot Start
Flex DNA Polymerase (NEB) in Buffer GC (NEB), supplemented with 3%
DMSO. Relative amounts of crude PCR products were quantified by
gel, and Cas9-treated (control) and Cas9:sgRNA-treated PCRs were
separately pooled in equimolar concentrations before purification
with the QIAquick PCR Purification Kit (Qiagen). Purified DNA was
amplified by PCR with primers PE1-barcode# and PE2-barcode# for 7
cycles with Phusion Hot Start Flex DNA Polymerase (NEB) in Buffer
HF (NEB). Amplified control and treated DNA pools were purified
with the QIAquick PCR Purification Kit (Qiagen), followed by
purification with Agencourt AMPure XP (Beckman Coulter). Purified
control and treated DNAs were quantified with the KAPA Library
Quantification Kit-Illumina (KAPA Biosystems), pooled in a 1:1
ratio, and subjected to paired-end sequencing on an Illumina
MiSeq.
[0127] Statistical Analysis. Statistical analysis was performed as
previously described.sup.21. P-values in Table 1 and Table 6 were
calculated for a one-sided Fisher exact test.
Algorithms
[0128] All scripts were written in C++. Algorithms used in this
study are as previous reported (reference) with modification.
[0129] Sequence binning. 1) designate sequence pairs starting with
the barcode "AACA" or "TTCA" as post-selection library members. 2)
for post-selection library members (with illustrated example):
[0130] example read:
TABLE-US-00002 [0130] (SEQ ID NO: 42)
AACACATGGGTCGACACAAACACAACTCGGCAGGTACTTGCAGATGTAGT
CTTTCCACATGGGTCGACACAAACACAACTCGGCAGGTATCTCGTATGCC
[0131] i) search both paired reads for the positions, pos1 and
pos2, of the constant sequence
TABLE-US-00003 [0131] "CTCGGCAGGT". (SEQ ID NO: 43)
[0132] ii) keep only sequences that have identical sequences
between the barcode and pos1 and preceding pos2. iii) keep the
region between the two instances of the constant sequence (the
region between the barcode and pos1 contains a cut half-site; the
region that is between the two instances of the constant sequence
contains a full site) [0133] example:
TABLE-US-00004 [0133] (SEQ ID NO: 44)
ACTTGCAGATGTAGTCTTTCCACATGGGTCGACACAAACACAA
[0134] ii) search the sequence for a selection barcode
TABLE-US-00005 [0134] ("TGTGTTTGTGTT" (SEQ ID NO: 45) for CLTA1,
"AGAAGAAGAAGA" (SEQ ID NO: 46) for CLTA2, "TTCTCTTTCTCT" (SEQ ID
NO: 47) for CLTA3, "ACACAAACACAA" (SEQ ID NO: 48) for CLTA4)
[0135] example:
TABLE-US-00006 [0135] (SEQ ID NO: 49)
ACTTGCAGATGTAGTCTTTCCACATGGGTCGACACAAACACAA - CLTA4
[0136] iii) the sequence before the barcode is the full
post-selection library member (first four and last four nucleotides
are fully randomized flanking sequence) [0137] example:
TABLE-US-00007 [0137] (SEQ ID NO: 50) ACTT GCAGATGTAGTCTTTCCACATGG
GTCG
[0138] iv) parse the quality scores for the positions corresponding
to the 23 nucleotide post-selection library member [0139] example
read:
TABLE-US-00008 [0139] (SEQ ID NO: 51)
AACACATGGGTCGACACAAACACAACTCGGCAGGTACTTGCAGATGTAGT
CTTTCCACATGGGTCGACACAAACACAACTCGGCAGGTATCTCGTATGCC
CCCFFFFFHHHHHJJJJJJJJJJJJJJJJJJJJJGIJJJJIJIJJJIIIH
IIJJJHHHGHAEFCDDDDDDDDDDDDDDDDDDDDDDD?CDDEDD@DCCCD
[0140] v) keep sequences only if the corresponding quality score
string (underlined) FASTQ quality characters for the sequence are
`?` or higher in ASCII code (Phred quality score>=30)
[0141] NHEJ Sequence Calling [0142] example read:
TABLE-US-00009 [0142] (SEQ ID NO: 52)
CAATCTCCCGCATGCGCTCAGTCCTCATCTCCCTCAAGCAGGCCCCGCTG
GTGCACTGAAGAGCCACCCTGTGAAACACTACATCTGCAATATCTTAATC
CTACTCAGTGAAGCTCTTCACAGTCATTGGATTAATTATGTTGAGTTCTT TTGGACCAAACC
[0143] example quality scores:
TABLE-US-00010 [0143]
CCBCCFFFFCCCGGGGGGGGGGHHHHHHHHHHHHHHHHHHHHGGGGGGGG
GHHHHHHHHHHHHHHHHHGHHHHHHHHHHHHHHHHHHHHHGHHHHHHHHH
HHHHHHHHFHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH HHHGHFHHHHHF
[0144] 1) identify the 20 base pairs flanking both sides of 20 base
pair target site+three base pair PAM for each target site [0145]
example flanking sequences:
TABLE-US-00011 [0145] GCTGGTGCACTGAAGAGCCA (SEQ ID NO: 53)
AATATCTTAATCCTACTCAG (SEQ ID NO: 54)
[0146] 2) search all sequence reads for the flanking sequences to
identify the potential off-target site (the sequence between the
flanking sequences) [0147] example potential off-target site:
TABLE-US-00012 [0147] CCCTGTGAAACACTACATCTGC (SEQ ID NO: 55)
[0148] 3) if the potential off-target site contains indels (length
is less than 23), keep sequence as potential off-target site if all
corresponding FASTQ quality characters for the sequence are `?` or
higher in ASCII code (Phred quality score>=30) [0149] example
potential off-target site length=22 [0150] example corresponding
FASTQ quality characters: HHGHHHHHHHHHHHHHHHHHHH [0151] 4) bin and
manually inspect all sequences that pass steps 2 and 3 and keep
sequences as potential modified sequences if they have at least one
deletion involving position 16, 17, or 18 (of 20 counting from the
non-PAM end) of if they have an insertion between position 17 and
18, consistent with the most frequent modifications observed for
the intended target site (FIG. 3) [0152] example potential
off-target site (reverse complement, with positions labeled) with
reference sequence:
TABLE-US-00013 [0152] 11111111112222 non-PAM end
12345678901234567890123 PAM end GCAGATGTAGTGTTTC-ACAGGG (SEQ ID NO:
56) GCAGATGTAGTGTTTCCACAGGG (SEQ ID NO: 57)
[0153] 4) repeat steps 1-3 for read2 and keep only if the sequence
is the same [0154] 5) compare overall counts in Cas9+sgRNA treated
sample to Cas9 alone sample to identify modified sites
[0155] Filter Based on Cleavage Site (for Post-Selection
Sequences)
[0156] 1) tabulate the cleavage site locations across the
recognition site by identifying the first position in the full
sequenced recognition site (between the two constant sequences)
that is identical to the first position in the sequencing read
after the barcode (before the first constant sequence).
[0157] 2) after tabulation, repeat step 1, keeping only sequences
with cleavage site locations that are present in at least 5% of the
sequencing reads.
Results
Broad Off-Target DNA Cleavage Profiling Reveals RNA Programmed Cas9
Nuclease Specificity.
[0158] Sequence-specific endonucleases including zinc-finger
nucleases (ZFNs) and transcription activator-like effector
nucleases (TALENs) have become important tools to modify genes in
induced pluripotent stem cells (iPSCs),.sup.1-3 in multi-cellular
organisms,.sup.4-8 and in ex vivo gene therapy clinical
trials..sup.9, 10 Although ZFNs and TALENs have proved effective
for such genetic manipulation, a new ZFN or TALEN protein must be
generated for each DNA target site. In contrast, the RNA-guided
Cas9 endonuclease uses RNA:DNA hybridization to determine target
DNA cleavage sites, enabling a single monomeric protein to cleave,
in principle, any sequence specified by the guide RNA..sup.11
[0159] Previous studies.sup.12-17 demonstrated that Cas9 mediates
genome editing at sites complementary to a 20-nucleotide sequence
in a bound guide RNA. In addition, target sites must include a
protospacer adjacent motif (PAM) at the 3' end adjacent to the
20-nucleotide target site; for Streptococcus pyogenes Cas9, the PAM
sequence is NGG. Cas9-mediated DNA cleavage specificity both in
vitro and in cells has been inferred previously based on assays
against small collections of potential single-mutation off-target
sites. These studies suggested that perfect complementarity between
guide RNA and target DNA is required in the 7-12 base pairs
adjacent to the PAM end of the target site (3' end of the guide
RNA) and mismatches are tolerated at the non-PAM end (5' end of the
guide RNA)..sup.11, 12, 17-19
[0160] Although such a limited number of nucleotides specifying
Cas9:guide RNA target recognition would predict multiple sites of
DNA cleavage in genomes of moderate to large size
(>.about.10.sup.7 bp), Cas9:guide RNA complexes have been
successfully used to modify both cells.sup.12, 13, 15 and
organisms..sup.14 A study using Cas9:guide RNA complexes to modify
zebrafish embryos observed toxicity at a rate similar to that of
ZFNs and TALENs..sup.14 A recent, broad study of the specificity of
DNA binding (transcriptional repression) in E. coli of a
catalytically inactive Cas9 mutant using high-throughput sequencing
found no detectable off-target transcriptional repression in the
relatively small E. coli transcriptome..sup.20 While these studies
have substantially advanced our basic understanding of Cas9, a
systematic and comprehensive profile of Cas9:guide RNA-mediated DNA
cleavage specificity generated from measurements of Cas9 cleavage
on a large number of related mutant target sites has not been
described. Such a specificity profile is needed to understand and
improve the potential of Cas9:guide RNA complexes as research tools
and future therapeutic agents.
[0161] We modified our previously published in vitro
selection,.sup.21 adapted to process the blunt-ended cleavage
products produced by Cas9 compared to the overhang-containing
products of ZFN cleavage, to determine the off-target DNA cleavage
profiles of Cas9:single guide RNA (sgRNA).sup.11 complexes. Each
selection experiment used DNA substrate libraries containing
.about.10.sup.12 sequences, a size sufficiently large to include
ten-fold coverage of all sequences with eight or fewer mutations
relative to each 22-base pair target sequence (including the
two-base pair PAM) (FIG. 1). We used partially randomized
nucleotide mixtures at all 22 target-site base pairs to create a
binomially distributed library of mutant target sites with an
expected mean of 4.62 mutations per target site. In addition,
target site library members were flanked by four fully randomized
base pairs on each side to test for specificity patterns beyond
those imposed by the canonical 20-base pair target site and
PAM.
[0162] Pre-selection libraries of 10.sup.12 individual potential
off-target sites were generated for each of four different target
sequences in the human clathrin light chain A (CLTA) gene (FIG. 3).
Synthetic 5'-phosphorylated 53-base oligonucleotides were
self-ligated into circular single-stranded DNA in vitro, then
converted into concatemeric 53-base pair repeats through
rolling-circle amplification. The resulting pre-selection libraries
were incubated with their corresponding Cas9:sgRNA complexes.
Cleaved library members containing free 5' phosphates were
separated from intact library members through the 5'
phosphate-dependent ligation of non-phosphorylated double-stranded
sequencing adapters. The ligation-tagged post-selection libraries
were amplified by PCR. The PCR step generated a mixture of
post-selection DNA fragments containing 0.5, 1.5, or 2.5, etc.
repeats of library members cleaved by Cas9, resulting from
amplification of an adapter-ligated cut half-site with or without
one or more adjacent corresponding full sites (FIG. 1).
Post-selection library members with 1.5 target-sequence repeats
were isolated by gel purification and analyzed by high-throughput
sequencing. In a final computational selection step to minimize the
impact of errors during DNA amplification or sequencing, only
sequences with two identical copies of the repeated cut half-site
were analyzed.
[0163] Pre-selection libraries were incubated under enzyme-limiting
conditions (200 nM target site library, 100 nM Cas9:sgRNA v2.1) or
enzyme-saturating conditions (200 nM target site library, 1000 nM
Cas9:sgRNA v2.1) for each of the four guide RNAs targets tested
(CLTA1, CLTA2, CLTA3, and CLTA4) (FIGS. 3C and 3D). A second guide
RNA construct, sgRNA v1.0, which is less active than sgRNA v2.1,
was assayed under enzyme-saturating conditions alone for each of
the four guide RNA targets tested (200 nM target site library, 1000
nM Cas9:sgRNA v1.0). The two guide RNA constructs differ in their
length (FIG. 3) and in their DNA cleavage activity level under the
selection conditions, consistent with previous reports.sup.15 (FIG.
4). Both pre-selection and post-selection libraries were
characterized by high-throughput DNA sequencing and computational
analysis. As expected, library members with fewer mutations were
significantly enriched in post-selection libraries relative to
pre-selection libraries (FIG. 5).
[0164] Pre- and Post-Selection Library Composition. The
pre-selection libraries for CLTA1, CLTA2, CLTA3, and CLTA4 had
observed mean mutation rates of 4.82 (n=1,129,593), 5.06
(n=847,618), 4.66 (n=692,997), and 5.00 (n=951,503) mutations per
22-base pair target site, including the two-base pair PAM,
respectively. The post-selection libraries treated under
enzyme-limiting conditions with Cas9 plus CLTA1, CLTA2, CLTA3, or
CLTA4 v.2.1 sgRNAs contained means of 1.14 (n=1,206,268), 1.21
(n=668,312), 0.91 (n=1,138,568), and 1.82 (n=560,758) mutations per
22-base pair target site. Under enzyme-excess conditions, the mean
number of mutations among sequences surviving selection increased
to 1.61 (n=640,391), 1.86 (n=399,560), 1.46 (n=936,414), and 2.24
(n=506,179) mutations per 22-base pair target site, respectively,
for CLTA1, CLTA2, CLTA3, or CLTA4 v2.1 sgRNAs. These results reveal
that the selection significantly enriched library members with
fewer mutations for all Cas9:sgRNA complexes tested, and that
enzyme-excess conditions resulted in the putative cleavage of more
highly mutated library members compared with enzyme-limiting
conditions (FIG. 5).
[0165] We calculated specificity scores to quantify the enrichment
level of each base pair at each position in the post-selection
library relative to the pre-selection library, normalized to the
maximum possible enrichment of that base pair. Positive specificity
scores indicate base pairs that were enriched in the post-selection
library and negative specificity scores indicate base pairs that
were de-enriched in the post-selection library. For example, a
score of +0.5 indicates that a base pair is enriched to 50% of the
maximum enrichment value, while a score of -0.5 indicates that a
base pair is de-enriched to 50% of the maximum de-enrichment
value.
[0166] In addition to the two base pairs specified by the PAM, all
20 base pairs targeted by the guide RNA were enriched in the
sequences from the CLTA1 and CLTA2 selections (FIG. 2, FIGS. 6 and
9, and Table 2). For the CLTA3 and CLTA4 selections (FIGS. 7 and 8,
and Table 2), guide RNA-specified base pairs were enriched at all
positions except for the two most distal base pairs from the PAM
(5' end of the guide RNA), respectively. At these non-specified
positions farthest from the PAM, at least two of the three
alternate base pairs were nearly as enriched as the specified base
pair. Our finding that the entire 20 base-pair target site and two
base pair PAM can contribute to Cas9:sgRNA DNA cleavage specificity
contrasts with the results from previous single-substrate assays
suggesting that only 7-12 base pairs and two base pair PAM are
specified..sup.11, 12, 15
[0167] All single-mutant pre-selection (n.gtoreq.14,569) and
post-selection library members (n.gtoreq.103,660) were
computationally analyzed to provide a selection enrichment value
for every possible single-mutant sequence. The results of this
analysis (FIG. 2 and FIGS. 6 and 8) show that when only
single-mutant sequences are considered, the six to eight base pairs
closest to the PAM are generally highly specified and the non-PAM
end is poorly specified under enzyme-limiting conditions,
consistent with previous findings..sup.11, 12, 17-19 Under
enzyme-saturating conditions, however, single mutations even in the
six to eight base pairs most proximal to the PAM are tolerated,
suggesting that the high specificity at the PAM end of the DNA
target site can be compromised when enzyme concentrations are high
relative to substrate (FIG. 2). The observation of high specificity
against single mutations close to the PAM only applies to sequences
with a single mutation and the selection results do not support a
model in which any combination of mutations is tolerated in the
region of the target site farthest from the PAM (FIG. 10-15).
Analyses of pre- and post-selection library composition are
described elsewhere herein, position-dependent specificity patterns
are illustrated in FIGS. 18-20, PAM nucleotide specificity is
illustrated in FIGS. 21-24, and more detailed effects of Cas9:sgRNA
concentration on specificity are described in FIG. 2G and FIG.
25).
[0168] Specificity at the Non-PAM End of the Target Site. To assess
the ability of Cas9:v2.1 sgRNA under enzyme-excess conditions to
tolerate multiple mutations distal to the PAM, we calculated
maximum specificity scores at each position for sequences that
contained mutations only in the region of one to 12 base pairs at
the end of the target site most distal from the PAM (FIG.
10-17).
[0169] The results of this analysis show no selection (maximum
specificity score.about.0) against sequences with up to three
mutations, depending on the target site, at the end of the molecule
farthest from the PAM when the rest of the sequence contains no
mutations. For example, when only the three base pairs farthest
from the PAM are allowed to vary (indicated by dark bars in FIG.
11C) in the CLTA2 target site, the maximum specificity scores at
each of the three variable positions are close to zero, indicating
that there was no selection for any of the four possible base pairs
at each of the three variable positions. However, when the eight
base pairs farthest from the PAM are allowed to vary (FIG. 11H),
the maximum specificity scores at positions 4-8 are all greater
than +0.4, indicating that the Cas9:sgRNA has a sequence preference
at these positions even when the rest of the substrate contains
preferred, on-target base pairs.
[0170] We also calculated the distribution of mutations (FIG.
15-17), in both pre-selection and v2.1 sgRNA-treated post-selection
libraries under enzyme-excess conditions, when only the first 1-12
base pairs of the target site are allowed to vary. There is
significant overlap between the pre-selection and post-selection
libraries for only a subset of the data (FIG. 15-17, a-c),
demonstrating minimal to no selection in the post-selection library
for sequences with mutations only in the first three base pairs of
the target site. These results collectively show that Cas9:sgRNA
can tolerate a small number of mutations (.about.one to three) at
the end of the sequence farthest from the PAM when provided with
maximal sgRNA:DNA interactions in the rest of the target site.
[0171] Specificity at the PAM End of the Target Site. We plotted
positional specificity as the sum of the magnitudes of the
specificity scores for all four base pairs at each position of each
target site, normalized to the same sum for the most highly
specified position (FIG. 18-20). Under both enzyme-limiting and
enzyme-excess conditions, the PAM end of the target site is highly
specified. Under enzyme-limiting conditions, the PAM end of the
molecule is almost absolutely specified (specificity
score.gtoreq.+0.9 for guide RNA-specified base pairs) by CLTA1,
CTLA2, and CLTA3 guide RNAs (FIG. 2 and FIG. 6-9), and highly
specified by CLTA4 guide RNA (specificity score of +0.7 to +0.9).
Within this region of high specificity, specific single mutations,
consistent with wobble pairing between the guide RNA and target
DNA, that are tolerated. For example, under enzyme-limiting
conditions for single-mutant sequences, a dA:dT off-target base
pair and a guide RNA-specified dG:dC base pair are equally
tolerated at position 17 out of 20 (relative to the non-PAM end of
the target site) of the CLTA3 target site. At this position, an
rG:dT wobble RNA:DNA base pair may be formed, with minimal apparent
loss of cleavage activity.
[0172] Importantly, the selection results also reveal that the
choice of guide RNA hairpin affects specificity. The shorter,
less-active sgRNA v1.0 constructs are more specific than the
longer, more-active sgRNA v2.1 constructs when assayed under
identical, enzyme-saturating conditions that reflect an excess of
enzyme relative to substrate in a cellular context (FIG. 2 and
FIGS. 5-8). The higher specificity of sgRNA v1.0 over sgRNA v2.1 is
greater for CLTA1 and CLTA2 (.about.40-90% difference) than for
CLTA3 and CLTA4 (<40% difference). Interestingly, this
specificity difference is localized to different regions of the
target site for each target sequence (FIGS. 2H and 26).
Collectively, these results indicate that different guide RNA
architectures result in different DNA cleavage specificities, and
that guide RNA-dependent changes in specificity do not affect all
positions in the target site equally. Given the inverse
relationship between Cas9:sgRNA concentration and specificity
described above, we speculate that the differences in specificity
between guide RNA architectures arises from differences in their
overall level of DNA-cleavage activities.
[0173] Effects of Cas9:sgRNA Concentration on DNA Cleavage
Specificity. To assess the effect of enzyme concentration on
patterns of specificity for the four target sites tested, we
calculated the concentration-dependent difference in positional
specificity and compared it to the maximal possible change in
positional specificity (FIG. 25). In general, specificity was
higher under enzyme-limiting conditions than enzyme-excess
conditions. A change from enzyme-excess to enzyme-limiting
conditions generally increased the specificity at the PAM end of
the target by .gtoreq.80% of the maximum possible change in
specificity. Although a decrease in enzyme concentration generally
induces small (.about.30%) increases in specificity at the end of
the target sites farthest from the PAM, concentration decreases
induce much larger increases in specificity at the end of the
target site nearest the PAM. For CLTA4, a decrease in enzyme
concentration is accompanied by a small (.about.30%) decrease in
specificity at some base pairs near the end of the target site
farthest from the PAM.
[0174] Specificity of PAM Nucleotides. To assess the contribution
of the PAM to specificity, we calculated the abundance of all 16
possible PAM dinucleotides in the pre-selection and post-selection
libraries, considering all observed post-selection target site
sequences (FIG. 21) or considering only post-selection target site
sequences that contained no mutations in the 20 base pairs
specified by the guide RNA (FIG. 22). Considering all observed
post-selection target site sequences, under enzyme-limiting
conditions, GG dinucleotides represented 99.8%, 99.9%, 99.8%, and
98.5% of the post-selection PAM dinucleotides for selections with
CLTA1, CLTA2, CLTA3, and CLTA4 v2.1 sgRNAs, respectively. In
contrast, under enzyme-excess conditions, GG dinucleotides
represented 97.7%, 98.3%, 95.7%, and 87.0% of the post-selection
PAM dinucleotides for selections with CLTA1, CLTA2, CLTA3, and
CLTA4 v2.1 sgRNAs, respectively. These data demonstrate that an
increase in enzyme concentration leads to increased cleavage of
substrates containing non-canonical PAM dinucleotides.
[0175] To account for the pre-selection library distribution of PAM
dinucleotides, we calculated specificity scores for the PAM
dinucleotides (FIG. 23). When only on-target post-selection
sequences are considered under enzyme-excess conditions (FIG. 24),
non-canonical PAM dinucleotides with a single G rather than two Gs
are relatively tolerated. Under enzyme-excess conditions,
Cas9:CLTA4 sgRNA 2.1 exhibited the highest tolerance of
non-canonical PAM dinucleotides of all the Cas9:sgRNA combinations
tested. AG and GA dinucleotides were the most tolerated, followed
by GT, TG, and CG PAM dinucleotides. In selections with Cas9:CLTA1,
2, or 3 sgRNA 2.1 under enzyme-excess conditions, AG was the
predominate non-canonical PAM (FIGS. 23 and 24). Our results are
consistent with another recent study of PAM specificity, which
shows that Cas9:sgRNA can recognize AG PAM dinucleotides.sup.23. In
addition, our results show that under enzyme-limiting conditions,
GG PAM dinucleotides are highly specified, and under enzyme-excess
conditions, non-canonical PAM dinucleotides containing a single G
can be tolerated, depending on the guide RNA context.
[0176] To confirm that the in vitro selection results accurately
reflect the cleavage behavior of Cas9 in vitro, we performed
discrete cleavage assays of six CLTA4 off-target substrates
containing one to three mutations in the target site. We calculated
enrichment values for all sequences in the post-selection libraries
for the Cas9:CLTA4 v2.1 sgRNA under enzyme-saturating conditions by
dividing the abundance of each sequence in the post-selection
library by the calculated abundance in the pre-selection library.
Under enzyme-saturating conditions, the single one, two, and three
mutation sequences with the highest enrichment values (27.5, 43.9,
and 95.9) were cleaved to .gtoreq.71% completion (FIG. 27). A
two-mutation sequence with an enrichment value of 1.0 was cleaved
to 35%, and a two-mutation sequence with an enrichment value near
zero (0.064) was not cleaved. The three-mutation sequence, which
was cleaved to 77% by CLTA4 v2.1 sgRNA, was cleaved to a lower
efficiency of 53% by CLTA4 v1.0 sgRNA (FIG. 28). These results
indicate that the selection enrichment values of individual
sequences are predictive of in vitro cleavage efficiencies.
[0177] To determine if results of the in vitro selection and in
vitro cleavage assays pertain to Cas9:guide RNA activity in human
cells, we identified 51 off-target sites (19 for CLTA1 and 32 for
CLTA4) containing up to eight mutations that were both enriched in
the in vitro selection and present in the human genome (Tables
3-5). We expressed Cas9:CLTA1 sgRNA v1.0, Cas9:CLTA1 sgRNA v2.1,
Cas9:CLTA4 sgRNA v1.0, Cas9:CLTA4 sgRNA v2.1, or Cas9 without sgRNA
in HEK293T cells by transient transfection and used genomic PCR and
high-throughput DNA sequencing to look for evidence of Cas9:sgRNA
modification at 46 of the 51 off-target sites as well as at the
on-target loci; no specific amplified DNA was obtained for five of
the 51 predicted off-target sites (three for CLTA1 and two for
CLTA4).
[0178] Deep sequencing of genomic DNA isolated from HEK293T cells
treated with Cas9:CLTA1 sgRNA or Cas9:CLTA4 sgRNA identified
sequences evident of non-homologous end-joining (NHEJ) at the
on-target sites and at five of the 49 tested off-target sites
(CLTA1-1-1, CLTA1-2-2, CLTA4-3-1, CLTA4-3-3, and CLTA4-4-8) (Tables
1 and 6-8). The CLTA4 target site was modified by Cas9:CLTA4 v2.1
sgRNA at a frequency of 76%, while off-target sites, CLTA4-3-1
CLTA4-3-3, and CLTA4-4-8, were modified at frequencies of 24%,
0.47% and 0.73%, respectively. The CLTA1 target site was modified
by Cas9:CLTA1 v2.1 sgRNA at a frequency of 0.34%, while off-target
sites, CLTA1-1-1 and CLTA1-2-2, were modified at frequencies of
0.09% and 0.16%, respectively.
[0179] Under enzyme-saturating conditions with the v2.1 sgRNA, the
two verified CLTA1 off-target sites, CLTA1-1-1 and CLTA1-2-2, were
two of the three most highly enriched sequences identified in the
in vitro selection. CLTA4-3-1 and CLTA4-3-3 were the highest and
third-highest enriched sequences of the seven CLTA4 three-mutation
sequences enriched in the in vitro selection that are also present
in the genome. The in vitro selection enrichment values of the
four-mutation sequences were not calculated, since 12 out of the 14
CLTA4 sequences in the genome containing four mutations, including
CLTA4-4-8, were observed at a level of only one sequence count in
the post-selection library. Taken together, these results confirm
that several of the off-target substrates identified in the in
vitro selection that are present in the human genome are indeed
cleaved by Cas9:sgRNA complexes in human cells, and also suggest
that the most highly enriched genomic off-target sequences in the
selection are modified in cells to the greatest extent.
[0180] The off-target sites we identified in cells were among the
most-highly enriched in our in vitro selection and contain up to
four mutations relative to the intended target sites. While it is
possible that heterochromatin or covalent DNA modifications could
diminish the ability of a Cas9:guide RNA complex to access genomic
off-target sites in cells, the identification of five out of 49
tested cellular off-target sites in this study, rather than zero or
many, strongly suggests that Cas9-mediated DNA cleavage is not
limited to specific targeting of only a 7-12-base pair target
sequence, as suggested in recent studies..sup.11, 12, 19
[0181] The cellular genome modification data are also consistent
with the increase in specificity of sgRNA v1.0 compared to sgRNA
v2.1 sgRNAs observed in the in vitro selection data and discrete
assays. Although the CLTA1-2-2, CLTA 4-3-3, and CLTA 4-4-8 sites
were modified by the Cas9-sgRNA v2.1 complexes, no evidence of
modification at any of these three sites was detected in Cas9:sgRNA
v1.0-treated cells. The CLTA4-3-1 site, which was modified at 32%
of the frequency of on-target CLTA4 site modification in Cas9:v2.1
sgRNA-treated cells, was modified at only 0.5% of the on-target
modification frequency in v1.0 sgRNA-treated cells, representing a
62-fold change in selectivity. Taken together, these results
demonstrate that guide RNA architecture can have a significant
influence on Cas9 specificity in cells. Our specificity profiling
findings present an important caveat to recent and ongoing efforts
to improve the overall DNA modification activity of Cas9:guide RNA
complexes through guide RNA engineering..sup.11, 15
[0182] Overall, the off-target DNA cleavage profiling of Cas9 and
subsequent analyses show that (i) Cas9:guide RNA recognition
extends to 18-20 specified target site base pairs and a two-base
pair PAM for the four target sites tested; (ii) increasing
Cas9:guide RNA concentrations can decrease DNA-cleaving specificity
in vitro; (iii) using more active sgRNA architectures can increase
DNA-cleavage specificity both in vitro and in cells but impair
DNA-cleavage specificity both in vitro and in cells; and (iv) as
predicted by our in vitro results, Cas9:guide RNA can modify
off-target sites in cells with up to four mutations relative to the
on-target site. Our findings provide key insights to our
understanding of RNA-programmed Cas9 specificity, and reveal a
previously unknown role for sgRNA architecture in DNA-cleavage
specificity. The principles revealed in this study may also apply
to Cas9-based effectors engineered to mediate functions beyond DNA
cleavage.
Equivalents and Scope
[0183] Those skilled in the art will recognize, or be able to
ascertain using no more than routine experimentation, many
equivalents to the specific embodiments of the invention described
herein. The scope of the present invention is not intended to be
limited to the above description, but rather is as set forth in the
appended claims.
[0184] In the claims articles such as "a," "an," and "the" may mean
one or more than one unless indicated to the contrary or otherwise
evident from the context. Claims or descriptions that include "or"
between one or more members of a group are considered satisfied if
one, more than one, or all of the group members are present in,
employed in, or otherwise relevant to a given product or process
unless indicated to the contrary or otherwise evident from the
context. The invention includes embodiments in which exactly one
member of the group is present in, employed in, or otherwise
relevant to a given product or process. The invention also includes
embodiments in which more than one, or all of the group members are
present in, employed in, or otherwise relevant to a given product
or process.
[0185] Furthermore, it is to be understood that the invention
encompasses all variations, combinations, and permutations in which
one or more limitations, elements, clauses, descriptive terms,
etc., from one or more of the claims or from relevant portions of
the description is introduced into another claim. For example, any
claim that is dependent on another claim can be modified to include
one or more limitations found in any other claim that is dependent
on the same base claim. Furthermore, where the claims recite a
composition, it is to be understood that methods of using the
composition for any of the purposes disclosed herein are included,
and methods of making the composition according to any of the
methods of making disclosed herein or other methods known in the
art are included, unless otherwise indicated or unless it would be
evident to one of ordinary skill in the art that a contradiction or
inconsistency would arise.
[0186] Where elements are presented as lists, e.g., in Markush
group format, it is to be understood that each subgroup of the
elements is also disclosed, and any element(s) can be removed from
the group. It is also noted that the term "comprising" is intended
to be open and permits the inclusion of additional elements or
steps. It should be understood that, in general, where the
invention, or aspects of the invention, is/are referred to as
comprising particular elements, features, steps, etc., certain
embodiments of the invention or aspects of the invention consist,
or consist essentially of, such elements, features, steps, etc. For
purposes of simplicity those embodiments have not been specifically
set forth in haec verba herein. Thus for each embodiment of the
invention that comprises one or more elements, features, steps,
etc., the invention also provides embodiments that consist or
consist essentially of those elements, features, steps, etc.
[0187] Where ranges are given, endpoints are included. Furthermore,
it is to be understood that unless otherwise indicated or otherwise
evident from the context and/or the understanding of one of
ordinary skill in the art, values that are expressed as ranges can
assume any specific value within the stated ranges in different
embodiments of the invention, to the tenth of the unit of the lower
limit of the range, unless the context clearly dictates otherwise.
It is also to be understood that unless otherwise indicated or
otherwise evident from the context and/or the understanding of one
of ordinary skill in the art, values expressed as ranges can assume
any subrange within the given range, wherein the endpoints of the
subrange are expressed to the same degree of accuracy as the tenth
of the unit of the lower limit of the range.
[0188] In addition, it is to be understood that any particular
embodiment of the present invention may be explicitly excluded from
any one or more of the claims. Where ranges are given, any value
within the range may explicitly be excluded from any one or more of
the claims. Any embodiment, element, feature, application, or
aspect of the compositions and/or methods of the invention, can be
excluded from any one or more claims. For purposes of brevity, all
of the embodiments in which one or more elements, features,
purposes, or aspects is excluded are not set forth explicitly
herein.
Tables
[0189] Table 1. Cellular modification induced by Cas9:CLTA4 sgRNA.
33 human genomic DNA sequences were identified that were enriched
in the Cas9:CLTA4 v2.1 sgRNA in vitro selections under
enzyme-limiting or enzyme-saturating conditions. Sites shown with
underline contain insertions or deletions (indels) that are
consistent with significant Cas9:sgRNA-mediated modification in
HEK293T cells. In vitro enrichment values for selections with
Cas9:CLTA4 v1.0 sgRNA or Cas9:CLTA4 v2.1 sgRNA are shown for
sequences with three or fewer mutations. Enrichment values were not
calculated for sequences with four or more mutations due to low
numbers of in vitro selection sequence counts. Modification
frequencies (number of sequences with indels divided by total
number of sequences) in HEK293T cells treated with Cas9 without
sgRNA ("no sgRNA"), Cas9 with CLTA4 v1.0 sgRNA, or Cas9 with CLTA4
v2.1 sgRNA. P-values are listed for those sites that show
significant modification in v1.0 sgRNA- or v2.1 sgRNA-treated cells
compared to cells treated with Cas9 without sgRNA. "Not tested
(n.t.)" indicates that PCR of the genomic sequence failed to
provide specific amplification products.
[0190] Table 2: Raw selection sequence counts. Positions -4 to -1
are the four nucleotides preceding the 20-base pair target site.
PAM1, PAM2, and PAM3 are the PAM positions immediately following
the target site. Positions +4 to +7 are the four nucleotides
immediately following the PAM.
[0191] Table 3: CLTA1 genomic off-target sequences. 20 human
genomic DNA sequences were identified that were enriched in the
Cas9:CLTA1 v2.1 sgRNA in vitro selections under enzyme-limiting or
enzyme-excess conditions. "m" refers to number of mutations from
on-target sequence with mutations shown in lower case. Sites shown
with underline contain insertions or deletions (indels) that are
consistent with significant Cas9:sgRNA-mediated modification in
HEK293T cells. Human genome coordinates are shown for each site
(assembly GRCh37). CLTA1-0-1 is present at two loci, and sequence
counts were pooled from both loci. Sequence counts are shown for
amplified and sequenced DNA for each site from HEK293T cells
treated with Cas9 without sgRNA ("no sgRNA"), Cas9 with CLTA1 v1.0
sgRNA, or Cas9 with CLTA1 v2.1 sgRNA.
[0192] Table 4: CLTA4 genomic off-target sequences. 33 human
genomic DNA sequences were identified that were enriched in the
Cas9:CLTA4 v2.1 sgRNA in vitro selections under enzyme-limiting or
enzyme-excess conditions. "m" refers to number of mutations from
on-target sequence with mutations shown in lower case. Sites shown
with underline contain insertions or deletions (indels) that are
consistent with significant Cas9:sgRNA-mediated modification in
HEK293T cells. Human genome coordinates are shown for each site
(assembly GRCh37). Sequence counts are shown for amplified and
sequenced DNA for each site from HEK293T cells treated with Cas9
without sgRNA ("no sgRNA"), Cas9 with CLTA4 v1.0 sgRNA, or Cas9
with CLTA4 v2.1 sgRNA.
[0193] Table 5: Genomic coordinates of CLTA1 and CLTA4 off-target
sites. 54 human genomic DNA sequences were identified that were
enriched in the Cas9:CLTA1 v2.1 sgRNA and Cas9: CLTA4 v2.1 sgRNA in
vitro selections under enzyme-limiting or enzyme-excess conditions.
Human genome coordinates are shown for each site (assembly
GRCh37).
[0194] Table 6: Cellular modification induced by Cas9:CLTA1 sgRNA.
20 human genomic DNA sequences were identified that were enriched
in the Cas9:CLTA1 v2.1 sgRNA in vitro selections under
enzyme-limiting or enzyme-excess conditions. Sites shown with
underline contain insertions or deletions (indels) that are
consistent with significant Cas9:sgRNA-mediated modification in
HEK293T cells. In vitro enrichment values for selections with
Cas9:CLTA1 v1.0 sgRNA or Cas9:CLTA1 v2.1 sgRNA are shown for
sequences with three or fewer mutations. Enrichment values were not
calculated for sequences with four or more mutations due to low
numbers of in vitro selection sequence counts. Modification
frequencies (number of sequences with indels divided by total
number of sequences) in HEK293T cells treated with Cas9 without
sgRNA ("no sgRNA"), Cas9 with CLTA1 v1.0 sgRNA, or Cas9 with CLTA1
v2.1 sgRNA. P-values of sites that show significant modification in
v1.0 sgRNA- or v2.1 sgRNA-treated cells compared to cells treated
with Cas9 without sgRNA were 1.1E-05 (v1.0) and 6.9E-55 (v2.1) for
CLTA1-0-1, 2.6E-03 (v1.0) and 2.0E-10 (v2.1) for CLTA1-1-1, and
4.6E-08 (v2.1) for CLTA1-2-2. P-values were calculated using a
one-sided Fisher exact test. "Not tested (n.t.)" indicates that the
site was not tested or PCR of the genomic sequence failed to
provide specific amplification products.
[0195] Table 7: CLTA1 genomic off-target indel sequences. Insertion
and deletion-containing sequences from cells treated with amplified
and sequenced DNA for the on-target genomic sequence (CLTA1-0-1)
and each modified off-target site from HEK293T cells treated with
Cas9 without sgRNA ("no sgRNA"), Cas9 with CLTA1 v1.0 sgRNA, or
Cas9 with CLTA1 v2.1 sgRNA. "ref" refers to the human genome
reference sequence for each site, and the modified sites are listed
below. Mutations relative to the on-target genomic sequence are
shown in lowercase letters. Insertions and deletions are shown in
underlined bold letters or dashes, respectively. Modification
percentages are shown for those conditions (v1.0 sgRNA or v2.1
sgRNA) that show statistically significant enrichment of modified
sequences compared to the control (no sgRNA).
[0196] Table 8: CLTA4 genomic off-target indel sequences. Insertion
and deletion-containing sequences from cells treated with amplified
and sequenced DNA for the on-target genomic sequence (CLTA4-0-1)
and each modified off-target site from HEK293T cells treated with
Cas9 without sgRNA ("no sgRNA"), Cas9 with CLTA4 v1.0 sgRNA, or
Cas9 with CLTA4 v2.1 sgRNA. "ref" refers to the human genome
reference sequence for each site, and the modified sites are listed
below. Mutations relative to the on-target genomic sequence are
shown in lowercase letters. Insertions and deletions are shown in
underlined bold letters or dashes, respectively. Modification
percentages are shown for those conditions (v1.0 sgRNA or v2.1
sgRNA) that show statistically significant enrichment of modified
sequences compared to the control (no sgRNA).
[0197] Table 9: Oligonucleotides used in this study. All
oligonucleotides were purchased from Integrated DNA Technologies.
An asterisk (*) indicates that the preceding nucleotide was
incorporated as a hand mix of phosphoramidites consisting of 79 mol
% of the phosphoramidite corresponding to the preceding nucleotide
and 4 mol % of each of the other three canonical phosphoramidites.
"/5Phos/" denotes a 5' phosphate group installed during
synthesis.
TABLE-US-00014 TABLE 1 # of Mutations sequence SEQ ID NO. gene
CLTA4-0-1 0 GCAGATGTAGTGTTTCCACAGGG SEQ ID NO: 58 CLTA CLTA4-3-1 3
aCAtATGTAGTaTTTCCACAGGG SEQ ID NO: 59 CLTA4-3-2 3
GCAtATGTAGTGTTTCCAaATGt SEQ ID NO: 60 CLTA4-3-3 3
cCAGATGTAGTaTTcCCACAGGG SEQ ID NO: 61 CELF1 CLTA4-3-4 3
GCAGtTtTAGTGTTTtCACAGGG SEQ ID NO: 62 BC073807 CLTA4-3-5 3
GCAGAgtTAGTGTTTCCACACaG SEQ ID NO: 63 MPPED2 CLTA4-3-6 3
GCAGATGgAGgGTTTtCACAGGG SEQ ID NO: 64 DCHS2 CLTA4-3-7 3
GgAaATtTAGTGTTTCCACAGGG SEQ ID NO: 65 CLTA4-4-1 4
aaAGAaGTAGTaTTTCCACATGG SEQ ID NO: 66 CLTA4-4-2 4
aaAGATGTAGTcaTTCCACAAGG SEQ ID NO: 67 CLTA4-4-3 4
aaAtATGTAGTcTTTCCACAGGG SEQ ID NO: 68 CLTA4-4-4 4
atAGATGTAGTGTTTCCAaAGGa SEQ ID NO: 69 NR1H4 CLTA4-4-5 4
cCAGAgGTAGTGcTcCCACAGGG SEQ ID NO: 70 CLTA4-4-6 4
cCAGATGTgagGTTTCCACAAGG SEQ ID NO: 71 XKR6 CLTA4-4-7 4
ctAcATGTAGTGTTTCCAtATGG SEQ ID NO: 72 HKR1 CLTA4-4-8 4
ctAGATGaAGTGcTTCCACATGG SEQ ID NO: 73 CDK8 CLTA4-4-9 4
GaAaATGgAGTGTTTaCACATGG SEQ ID NO: 74 CLTA4-4-10 4
GCAaATGaAGTGTcaCCACAAGG SEQ ID NO: 75 CLTA4-4-11 4
GCAaATGTAtTaTTTCCACtAGG SEQ ID NO: 76 NOV CLTA4-4-12 4
GCAGATGTAGctTTTgtACATGG SEQ ID NO: 77 CLTA4-4-13 4
GCAGcTtaAGTGTTTtCACATGG SEQ ID NO: 78 GRHL2 CLTA4-4-14 4
ttAcATGTAGTGTTTaCACACGG SEQ ID NO: 79 LINC00535 CLTA4-5-1 5
GaAGAgGaAGTGTTTgCcCAGGG SEQ ID NO: 80 RNH1 CLTA4-5-2 5
GaAGATGTgGaGTTgaCACATGG SEQ ID NO: 81 FZD3 CLTA4-5-3 5
GCAGAaGTAcTGTTgttACAAGG SEQ ID NO: 82 CLTA4-5-4 5
GCAGATGTgGaaTTaCaACAGGG SEQ ID NO: 83 SLC9A2 CLTA4-5-5 5
GCAGtcaTAGTGTaTaCACATGG SEQ ID NO: 84 CLTA4-5-6 5
taAGATGTAGTaTTTCCAaAAGt SEQ ID NO: 85 CLTA4-6-1 6
GCAGcTGgcaTtTcTCCACACGG SEQ ID NO: 86 CLTA4-6-2 6
GgAGATcTgaTGgTTCtACAAGG SEQ ID NO: 87 CLTA4-6-3 6
taAaATGcAGTGTaTCCAtATGG SEQ ID NO: 88 SMA4 CLTA4-7-1 7
GCcagaaTAGTtTTTCaACAAGG SEQ ID NO: 89 SEPHS2 CLTA4-7-2 8
ttgtATtTAGaGaTTgCACAAGG SEQ ID NO: 90 RORB modification in vitro
frequency in enrichment HEK293T cells P-value v1.0 v2.1 no sgRNA
v1.0 v2.1 v1.0 v2.1 CLTA4-0-1 20 7.95 0.021% 11% 76% <1E-55
<1E-55 CLTA4-3-1 16.5 12.5 0.006% 0.055% 24% 6.0E-0 <1E-55
CLTA4-3-2 2.99 6.97 0.017% 0% 0.014% CLTA4-3-3 1.00 4.95 0% 0%
0.469% 2.5E-21 CLTA4-3-4 0.79 3.12 0% 0% 0% CLTA4-3-5 0 1.22 0.005%
0.015% 0.018% CLTA4-3-6 1.57 1.17 0.015% 0.023% 0.021% CLTA4-3-7
0.43 0.42 0.005% 0.012% 0.003% CLTA4-4-1 n.t. n.t. n.t. CLTA4-4-2
0.004% 0% 0.005% CLTA4-4-3 0.004% 0.009% 0% CLTA4-4-4 0.032% 0.006%
0.052% CLTA4-4-5 0.005% 0.006% 0.007% CLTA4-4-6 0.018% 0% 0.007%
CLTA4-4-7 0.006% 0% 0.008% CLTA4-4-8 0.009% 0.013% 0.730% 9.70E-21
CLTA4-4-9 0% 0% 0.004% CLTA4-4-10 0.004% 0% 0% CLTA4-4-11 0% 0.00%
0% CLTA4-4-12 0% 0.00% 0% CLTA4-4-13 0.020% 0.02% 0.030% CLTA4-4-14
n.t. n.t. n.t. CLTA4-5-1 0.004% 0.01% 0.006% CLTA4-5-2 0.004% 0.00%
0% CLTA4-5-3 0.002% 0.00% 0.003% CLTA4-5-4 0% 0.00% 0% CLTA4-5-5
0.004% 0.00% 0.005% CLTA4-5-6 0.007% 0.01% 0% CLTA4-6-1 n.t. n.t.
n.t. CLTA4-6-2 0.007% 0.00% 0.009% CLTA4-6-3 0.015% 0.00% 0%
CLTA4-7-1 0% 0.00% 0.007% CLTA4-7-2 0% 0.00% 0%
TABLE-US-00015 TABLE 2 position -4 -3 -2 -1 1 2 3 4 5 6 7 100 nM
Cas9:CLTA1 v2.1 sgRNA A 212906 240335 195549 240068 1.04E+06 72751
40206 62972 41734 17376 18710 C 285295 248395 263973 260202 37925
32496 24822 1.10E+06 1.12E+06 42444 1.16E+06 G 214213 219078 220275
189578 61062 1.04E+06 25785 11117 9125 5423 5745 T 493854 498460
526471 516420 64694 59173 1.12E+06 35336 34236 1.14E+06 20532 1000
nM Cas9:CLTA1 v1.0 sgRNA A 154613 184336 154288 177436 805105 66777
43354 56461 32941 15531 19465 C 227144 201856 215667 220894 30269
30133 24249 825333 865486 35164 889622 G 163868 174062 177891
148150 47940 784264 26342 17972 10299 6332 5785 T 389059 374430
386838 388204 51370 53510 840739 34918 25958 877657 19812 1000 nM
Cas9:CLTA1 v2.1 sgRNA A 104782 127116 103361 124521 554601 40232
29541 38710 23659 10435 11462 C 154144 136337 145670 146754 20057
19440 17922 569754 590426 25233 612203 G 113998 119668 120741
103026 32861 547445 18468 9314 6346 3908 4295 T 267467 257270
270619 266090 32872 33274 574460 22613 19960 600815 12431 CLTA1
pre-selection library A 241543 217144 209045 198284 943175 103452
76259 106919 124476 59762 108373 C 254366 269805 276090 322860
52984 65855 58943 834238 812029 52168 839963 G 230024 196574 210445
180859 60496 857631 66783 89366 85315 67098 77499 T 403590 446000
433943 427520 72868 102585 927538 99000 107703 950495 103688 100 nM
Cas9:CLTA2 v2.1 sgRNA A 109129 135587 94032 141748 5.74E+04 44902
48284 24464 11611 16668 6282 C 155710 138970 207735 220443 529643
24503 566049 6.27E+05 6.46E+05 19040 6.52E+05 G 136555 142038
118241 105620 39991 2.11E+04 26481 3756 3627 2889 2488 T 266918
251717 248304 200501 41277 577893 2.75E+04 13008 7318 6.30E+05 7487
1000 nM Cas9:CLTA2 v1.0 sgRNA A 94138 115828 85485 120876 52411
41438 46093 22399 9068 14310 5351 C 140895 125708 179224 191394
452192 21517 481298 538392 557549 16233 562576 G 113243 118054
101838 91048 35101 18969 22797 3440 2802 2960 2526 T 228367 217053
209898 173125 38739 494519 26255 12212 7026 542940 5990 1000 nM
Cas9:CLTA2 v2.1 sgRNA A 64249 81812 58977 65387 35172 29833 33434
19419 9272 13136 4907 C 96983 87918 124642 187760 316077 14548
327166 364874 380987 11360 387025 G 77913 80500 68612 64299 23522
15749 19664 3856 3035 2752 2062 T 160415 149330 147329 122114 94789
339431 19296 11411 6266 372312 5566 CLTA2 pre-selection library A
203147 173899 167999 170203 89970 73770 88239 88611 76114 78589
75016 C 181430 214835 246369 272618 632831 41977 641062 644565
670872 40877 649838 G 177090 153006 151178 140868 68664 49976 60827
56077 52341 49259 55484 T 285951 305878 282072 263929 66153 881895
57490 58365 48291 678892 67280 100 nM Cas9:CLTA3 v2.1 sgRNA A
212836 248582 202151 249368 9.13E+04 77392 19048 39738 1078580
1106930 46196 C 233270 241259 274819 305120 37894 35918 13930
5.61E+03 1.22E+04 3774 6.35E+03 G 211701 187534 185231 196614 66632
9.88E+05 26572 1074020 12936 9205 1066570 T 480761 461193 476317
387466 342707 37284 1.09E+05 19204 34885 1.87E+04 19450 1000 nM
Cas9:CLTA3 v1.0 sgRNA A 219823 263464 207913 264018 97886 78562
20562 29724 1126320 1151200 42366 C 240570 261247 311444 333414
39996 40484 13261 5323 11093 5475 10323 G 221683 206195 199246
215583 76580 1032080 24785 1126840 12654 12465 1114450 T 506611
457791 470094 375682 974235 37571 1129290 16811 28626 19580 20956
1000 nM Cas9:CLTA3 v2.1 sgRNA A 169775 206549 166197 201768 75243
67150 20443 36549 876154 838360 39901 C 197800 203445 243688 264177
32775 34540 14250 7885 14793 4378 7791 G 174766 158928 153884
168325 58121 801763 26558 356689 13343 12052 368394 T 394073 361492
367705 302144 770275 32956 875157 25291 32124 21124 20328 CLTA3
pre-selection library A 173122 135327 133244 142593 50365 69485
37040 56315 575295 566722 70243 C 143788 158534 162046 177240 25902
40142 28129 34669 38933 36129 61591 G 137601 132826 130592 128304
42860 534378 42217 531723 29873 34068 479149 T 238486 266310 261515
244854 573870 48391 595611 60291 48596 56079 82008 100 nM
Cas9:CLTA4 v2.1 sgRNA A 55030 78101 78867 81833 8.09E+04 58148
525585 29962 544918 19446 54151 C 168401 162082 139480 130495 22088
428628 4498 1.21E+04 5.14E+03 15601 7.10E+03 G 89302 75785 82959
133275 415632 4.70E+04 14868 504358 6156 9951 493432 T 248025
244790 259452 215155 42090 26956 1.58E+04 14300 4541 5.16E+05 6071
1000 nM Cas9:CLTA4 v1.0 sgRNA A 95188 141261 145156 141850 151224
116745 928773 50295 975924 29201 95476 C 305024 297215 260676
243819 34420 745345 8606 17266 7541 29948 10779 G 159888 139073
153474 225343 742232 85777 29776 907007 9285 13455 883325 T 438973
421524 439767 388061 71197 51206 31918 24505 6323 926469 9493 1000
nM Cas9:CLTA4 v2.1 sgRNA A 47674 70467 71535 72698 72554 54587
471218 27627 493315 16818 47470 C 154985 151636 133622 122579 18730
384037 4452 10916 4303 16232 5436 G 80869 69972 76726 118084 379024
42360 14989 453870 5084 6863 448784 T 222651 214104 224296 192818
35871 25195 15520 13766 3477 466266 4489 CLTA4 pre-selection
library A 106798 131577 131941 132368 127160 103294 820923 103844
840417 99163 133349 C 304597 297419 277233 283453 50833 722264
29748 65558 44890 59551 73916 G 146240 137027 134399 183111 695802
68240 51484 708098 30709 62837 673752 T 393868 385480 407930 352571
77708 57705 49348 74003 35487 729952 70486 position 8 9 10 11 12 13
14 15 16 17 100 nM Cas9:CLTA1 v2.1 sgRNA A 1.17E+06 24455 83195
46083 33528 8551 9668 4582 32237 1.19E+06 C 5339 22096 1.06E+06
48105 1.14E+06 1.14E+06 1.18E+06 4090 1.13E+06 4363 G 5121 8080
14905 8906 3732 3294 3867 3597 7260 3400 T 24018 1.15E+06 50488
1.10E+06 32417 57980 13065 1.19E+06 36826 8959 1000 nM Cas9:CLTA1
v1.0 sgRNA A 904223 19696 56566 35200 26674 7925 9269 4859 32891
910633 C 5488 17340 828521 36975 876790 880022 908816 4419 859691
5694 G 5938 9185 11560 10641 3020 2819 3185 2994 6763 3631 T 19035
888463 38037 851868 28200 43918 13414 922412 35339 14726 1000 nM
Cas9:CLTA1 v2.1 sgRNA A 618404 14608 41826 27762 19590 8961 19434
9549 35083 604115 C 3834 15297 561351 26392 592757 594469 616112
11645 553993 13212 G 3719 5851 10887 15360 5605 3378 3517 5896
22551 8658 T 14434 604635 26327 570877 22439 33583 1328 613301
28764 14406 CLTA1 pre-selection library A 937511 65477 110282 67774
96299 88029 109977 62686 119399 931093 C 54708 43285 831610 50109
861358 841819 817157 51676 797914 60106 G 59257 71824 89579 68090
66121 86080 96496 81367 104949 52143 T 78047 948937 98052 943550
105745 113595 105893 933794 107261 86181 100 nM Cas9:CLTA2 v2.1
sgRNA A 6.58E+05 655917 28909 24210 656617 59160 36601 2974 12980
3.27E+03 C 2951 2577 1.30E+04 617274 2.64E+03 1.48E+04 9.12E+03
660929 6.50E+05 660305 G 3025 3202 609865 8312 5889 581322 606454
1564 2134 1819 T 4920 6.62E+03 16554 1.85E+04 3165 13024 16134
2.85E+03 3253 2918 1000 nM Cas9:CLTA2 v1.0 sgRNA A 567337 565061
24132 23848 558483 49577 39401 5428 30774 6408 C 1973 2127 11807
525901 4892 13617 13316 563557 535780 560658 G 2895 2793 526655
9738 8100 495156 496382 1789 3325 1846 T 4238 6462 13849 16956 4868
18093 27344 5672 6564 7531 1000 nM Cas9:CLTA2 v2.1 sgRNA A 391675
389930 13852 16657 383605 32780 22855 9722 25181 12518 C 1694 1815
8124 363374 5168 9569 9710 374342 355544 373485 G 2398 2439 360755
7431 6019 344511 350245 1559 5882 1339 T 3793 5376 10829 12098 4768
12700 16750 13937 12953 12819 CLTA2 pre-selection library A 726091
712150 96111 90307 728931 91515 84764 79586 86205 87337 C 38931
44691 46591 628706 32296 49519 46571 641958 624548 637703 G 39801
38939 630670 55013 38368 627263 642878 59549 55292 53066 T 42795
51838 74246 73592 48023 79321 73405 66528 81573 69522 100 nM
Cas9:CLTA3 v2.1 sgRNA A 1.12E+06 64461 11912 30992 21158 6465
1130430 4037 5750 4.71E+04 C 4063 6018 1.11E+06 27501 4.68E+04
1.12E+06 1.96E+03 1123400 1.82E+03 3421 G 7418 1050360 3828 3949
2231 2504 2471 1726 2881 1081680 T 11145 1.77E+04 13689 1.08E+06
1068370 3829 3709 3.34E+03 1128120 6398 1000 nM Cas9:CLTA3 v1.0
sgRNA A 1156400 49443 18669 44652 44644 44771 1152540 16264 30980
71714 C 6501 8456 1126310 36792 56203 1086280 8427 1156840 8448
25120 G 12075 1112930 12078 19275 9014 7707 9466 2708 17195 1053760
T 13723 16864 31636 1087980 1078840 39940 16250 12883 1132070 38102
1000 nM Cas9:CLTA3 v2.1 sgRNA A 911344 44415 13218 37301 33080
26409 893670 6315 20807 52541 C 4636 7510 390531 28425 46269 870864
7991 310584 5931 19923 G 8637 667980 7923 14022 6553 3893 7912 1499
12906 836022 T 11597 16509 24682 856666 850512 35749 26841 16016
896770 27928 CLTA3 pre-selection library A 528947 72610 41265 61770
56547 75555 586476 61203 51740 70943 C 52201 46032 559715 32233
34830 519328 30904 540977 24982 45344 G 49753 501888 41949 43243
30118 38922 34282 34082 37275 515778 T 82036 72467 50068 555751
571502 59192 41335 56735 579000 60932 100 nM Cas9:CLTA4 v2.1 sgRNA
A 2.59E+04 550200 29521 34194 38891 26542 23991 15243 25122
5.36E+03 C 35217 2481 2.35E+04 16846 2.03E+04 3.69E+04 8.47E+03
5182 5.22E+05 547711 G 14899 4528 498832 27411 497382 6729 3344
3716 3926 3162 T 484788 3.55E+03 8877 4.82E+05 4222 490573 524958
5.37E+05 9437 4528 1000 nM Cas9:CLTA4 v1.0 sgRNA A 30383 980248
50181 65094 77253 42674 41050 32933 55244 39984 C 47831 5069 32501
30389 29610 61641 25910 21400 887446 900777 G 19640 8303 902733
44730 879985 16677 7879 8429 12432 17373 T 901219 5453 13658 858860
12225 878081 924234 936311 43951 40939 1000 nM Cas9:CLTA4 v2.1
sgRNA A 17728 498471 29769 40021 41618 24741 23050 16409 27974 2697
C 28594 1961 19017 19152 18001 35213 12845 13497 445302 480543 G
10260 3281 450120 23076 439828 7741 5091 5456 7558 7112 T 449597
2466 7273 423930 6732 438484 465193 470817 25345 15827 CLTA4
pre-selection library A 123366 824537 126564 115133 122618 108492
107761 96384 99908 76163 C 77470 45318 84973 73106 90384 78280
76978 66776 738550 776738 G 89897 49093 672860 88125 663922 67768
53472 58440 47550 41427 T 660770 32555 67106 675139 74579 696963
713292 729903 65495 57175 position 18 19 20 PAM1 PAM2 PAM3 +4 +5 +6
+7 100 nM Cas9:CLTA1 v2.1 sgRNA A 1.20E+06 2032 4237 261056 1386
574 235167 223887 222343 301356 C 628 969 1.19E+06 210095 167 152
211027 273777 264354 309690 G 2474 1.19E+06 1301 238989 1.20E+06
1.21E+06 205765 222282 240526 217260 T 3966 9354 8065 496128 475
211 554303 486322 479045 377362 1000 nM Cas9:CLTA1 v1.0 sgRNA A
925527 3595 5976 183479 1390 413 182704 171051 174062 221899 C 776
2120 920211 180463 120 88 180657 220438 211411 245967 G 2894 916417
1415 193418 932808 934044 172551 172071 176484 161703 T 5487 12552
7082 377324 366 139 398772 371124 372727 305115 1000 nM Cas9:CLTA1
v2.1 sgRNA A 607264 4665 16515 125225 10391 2519 125288 114575
120476 149847 C 4438 5146 590160 116022 329 138 123802 154249
146572 166531 G 12770 613580 3712 121392 628464 637588 118800
113560 118464 111278 T 15919 17000 30004 277752 1207 146 272501
258007 254879 212735 CLTA1 pre-selection library A 908362 64248
111479 190574 97896 104002 183367 178912 198049 219754 C 52998
42317 813253 239201 56843 59450 289074 295400 289007 284268 G 77389
918970 96000 192652 879150 870948 196672 202194 196499 202544 T
90774 103988 108791 507096 95634 95123 460410 453017 445968 422957
100 nM Cas9:CLTA2 v2.1 sgRNA A 1.09E+03 17686 689 193742 284 129
143150 165553 136708 146056 C 666122 1314 6.65E+05 42664 48 43
162563 111729 143442 177253 G 89 6.44E+05 505 137388 6.68E+05
6.68E+05 103305 146355 139972 124772 T 1016 4886 2608 294518 146 48
259294 244675 248190 220231 1000 nM Cas9:CLTA2 v1.0 sgRNA A 5055
36081 2573 148145 782 243 132801 126862 118528 122897 C 567693 4938
569653 46472 70 45 133402 123970 130555 148756 G 166 519782 520
125177 575395 576103 118877 108849 104210 103370 T 3529 15642 3697
256649 196 52 191363 216762 223150 201420 1000 nM Cas9:CLTA2 v2.1
sgRNA A 17950 28198 5471 100745 4933 834 89339 87351 82615 85108 C
370343 11652 378841 40532 238 34 93621 87320 91380 105625 G 391
331376 1034 74803 393760 398660 79776 75927 74068 70435 T 10876
28334 14214 183480 629 32 136824 148362 151497 138392 CLTA2
pre-selection library A 85547 92983 100316 177716 84144 88017
177831 180209 176904 174190 C 635473 51727 594349 136372 41282
41689 216880 206368 210039 235263 G 57979 616575 66553 158929
656315 654970 162242 160704 157741 138890 T 68619 86333 86400
274601 65877 62942 290665 300337 302934 299275 100 nM Cas9:CLTA3
v2.1 sgRNA A 1.14E+06 6151 2047 305062 1993 394 213566 240851
230230 252637 C 167 1451 6.66E+02 261609 103 82 313990 253055
261338 293644 G 876 1.13E+06 600 228865 1.14E+06 1.14E+06 142425
192720 220683 237840 T 1320 4480 1135260 343032 211 69 462587
451942 426317 364447 1000 nM Cas9:CLTA3 v1.0 sgRNA A 1156700 47106
27658 276285 26304 12701 219034 239515 244440 255260 C 4351 24685
9473 297135 1331 939 354289 298216 277740 292917 G 10278 1085310
10308 238545 1148550 1174510 171862 193096 217301 239319
T 17372 31596 1141260 376732 2514 560 443512 457870 449216 401101
1000 nM Cas9:CLTA3 v2.1 sgRNA A 903619 33690 20904 205940 26623
9880 172210 182986 187305 196429 C 4977 16171 6508 223797 1163 693
283240 240802 224453 236469 G 9011 859600 8302 190011 906628 925513
132620 153591 172169 167623 T 18807 24953 900700 310666 2000 323
346344 359035 352487 315893 CLTA3 pre-selection library A 563277
70484 50807 130402 57527 61702 110207 118993 126967 127707 C 35359
44014 35778 174938 42259 46083 201434 190347 184768 207347 G 36956
516177 45203 137307 539445 527404 113323 119846 118423 127230 T
51405 62322 561209 250350 53766 57808 268033 263811 262839 230713
100 nM Cas9:CLTA4 v2.1 sgRNA A 5.51E+05 1994 540029 47731 4642 1401
77633 56902 63224 54815 C 5715 546119 3.02E+03 152056 655 473
141123 164035 146401 190955 G 554 1.45E+03 4637 72296 5.55E+05
5.58E+05 84257 77627 75123 91454 T 3692 11194 13069 288675 911 495
257745 262194 276010 223534 1000 nM Cas9:CLTA4 v1.0 sgRNA A 942989
19900 887311 80159 28536 12390 142460 96664 110844 99920 C 34590
940504 23749 257985 2556 4791 252462 297152 258929 338099 G 4103
7346 20095 139488 964013 976818 154302 139784 136512 165750 T 17391
31323 67918 521441 3968 5074 449849 465473 492788 395304 1000 nM
Cas9:CLTA4 v2.1 sgRNA A 478335 12667 451298 36128 22041 16967 68943
49017 56451 51102 C 15631 469503 11832 122541 3529 8965 126313
153105 134293 171499 G 3083 5302 10184 87517 474540 471647 85849
72063 71600 85239 T 9130 18707 32865 259993 6069 8600 225074 231994
243835 198339 CLTA4 pre-selection library A 806675 75877 793806
87755 82113 83605 111015 103082 109315 101198 C 55522 754283 42188
278802 57603 55530 266156 281433 258029 295144 G 42574 54424 59162
151536 740525 732891 163824 158224 146268 151560 T 46732 66919
56347 433410 71265 79477 410508 408764 437891 403601
TABLE-US-00016 TABLE 3 no sgRNA v1.0 sgRNA v2.1 sgRNA modified
total modified total modified total m sequence sequences sequences
sequences sequences sequences sequences CLTA1-0- 0
AGTCCTCATCTCCCTCAAGCAGG 2 58889 18 42683 178 52845 (SEQ ID NO: 91)
CLTA1-1-1 1 AGTCCTCAaCTCCCTCAAGCAGG 1 39804 9 29000 37 40588 (SEQ
ID NO: 92) CLTA1-2-1 2 AGcCCTCATtTCCCTCAAGCAGG 0 16276 0 15032 0
18277 (SEQ ID NO: 93) CLTA1-2-2 2 AcTCCTCATCcCCCTCAAGCCGG 3 21267 1
20042 33 22579 (SEQ ID NO: 94) CLTA1-2-3 2 AGTCaTCATCTCCCTCAAGCAGa
0 0 0 0 0 0 (SEQ ID NO: 95) CLTA1-3-1 3 cGTCCTCcTCTCCCcCAAGCAGG 2
53901 0 42194 0 52205 (SEQ ID NO: 96) CLTA1-3-2 3
tGTCCTCtTCTCCCTCAAGCAGa 0 14890 0 14231 0 15937 (SEQ ID NO: 97)
CLTA1-4-1 4 AagCtTCATCTCtCTCAAGCTGG 0 49579 2 31413 0 41234 (SEQ ID
NO: 98) CLTA1-4-2 4 AGTaCTCtTtTCCCTCAgGCTGG 2 30013 1 23470 4 26999
(SEQ ID NO: 99) CLTA1-4-3 4 AGTCtTaAatTCCCTCAAGCAGG 2 63792 0 52321
1 73007 (SEQ ID NO: 100) CLTA1-4-4 4 AGTgCTCATCTaCCagAAGCTGG 1
12585 0 11339 0 12066 (SEQ ID NO: 101) CLTA1-4-5 4
ccTCCTCATCTCCCTgcAGCAGG 4 30568 1 23810 0 27870 (SEQ ID NO: 102)
CLTA1-4-6 4 ctaCaTCATCTCCCTCAAGCTGG 0 13200 1 12886 2 12843 (SEQ ID
NO: 103) CLTA1-4-7 4 gGTCCTCATCTCCCTaAAaCAGa 1 8697 3 8188 0 8783
(SEQ ID NO: 104) CLTA1-4-8 4 tGTCCTCATCggCCTCAgGCAGG 0 13169 0 8805
2 12830 (SEQ ID NO: 105) CLTA1-5-1 5 AGaCacCATCTCCCTtgAGCTGG 0
46109 1 32515 2 35567 (SEQ ID NO: 106) CLTA1-5-2 5
AGgCaTCATCTaCaTCAAGtTGG 0 41280 0 28896 0 35152 (SEQ ID NO: 107)
CLTA1-5-3 5 AGTaaTCActTCCaTCAAGCCGG 0 0 0 0 0 0 (SEQ ID NO: 108)
CLTA1-5-4 5 tccCCTCAcCTCCCTaAAGCAGG 2 24169 5 17512 1 23483 (SEQ ID
NO: 109) CLTA1-5-5 5 tGTCtTtATtTCCCTCtAGCTGG 0 11527 0 10481 1
11027 (SEQ ID NO: 110) CLTA1-6-1 6 AGTCCTCATCTCCCTCAAGCAGG 0 6537 0
5654 0 6741 (SEQ ID NO: 111)
TABLE-US-00017 TABLE 4 no sgRNA v1.0 sgRNA v2.1 sgRNA modified
total modified total modified m sequence sequences sequences
sequences sequences sequences total sequences CLTA4-0-1 0
GCAGATGTAGTGTTTCCACAGGG 6 29191 2005 18640 14970 19661 (SEQ ID NO:
112) CLTA4-3-1 3 aCAtATGTAGTaTTTCCACAGGG 2 34165 11 20018 3874
16082 (SEQ ID NO: 113) CLTA4-3-2 3 GCAtATGTAGTGTTTCCAaATGt 3 17923
0 11688 2 13880 (SEQ ID NO: 114) CLTA4-3-3 3
cCAGATGTAGTaTTcCCACAGGG 0 16559 0 12007 52 11082 (SEQ ID NO: 115)
CLTA4-3-4 3 GCAGtTtTAGTGTTTtCACAGGG 0 21722 0 12831 0 15726 (SEQ ID
NO: 116) CLTA4-3-5 3 GCAGAgtTAGTGTTTCCACACaG 1 21222 2 13555 3
16425 (SEQ ID NO: 117) CLTA4-3-6 3 GCAGATGgAGgGTTTtCACAGGG 3 20342
3 12804 3 14068 (SEQ ID NO: 118) CLTA4-3-7 3
GgAaATtTAGTGTTTCCACAGGG 2 38894 3 24017 1 29347 (SEQ ID NO: 119)
CLTA4-4-1 4 aaAGAaGTAGTaTTTCCACATGG 0 0 0 0 0 0 (SEQ ID NO: 120)
CLTA4-4-2 4 aaAGATGTAGTcaTTCCACAAGG 1 27326 0 17365 1 18941 (SEQ ID
NO: 121) CLTA4-4-3 4 aaAtATGTAGTcTTTCCACAGGG 2 46232 3 32264 0
32638 (SEQ ID NO: 122) CLTA4-4-4 4 atAGATGTAGTGTTTCCAaAGGa 9 27821
1 16223 8 15388 (SEQ ID NO: 123) CLTA4-4-5 4
cCAGAgGTAGTGcTcCCACAGGG 1 20979 1 15674 1 15086 (SEQ ID NO: 124)
CLTA4-4-6 4 cCAGATGTgagGTTTCCACAAGG 4 22021 0 15691 1 14253 (SEQ ID
NO: 125) CLTA4-4-7 4 ctAcATGTAGTGTTTCCAtATGG 2 35942 0 23076 1
11867 (SEQ ID NO: 126) CLTA4-4-8 4 ctAGATGaAGTGcTTCCACATGG 1 10692
1 7609 59 8077 (SEQ ID NO: 127) CLTA4-4-9 4 GaAaATGgAGTGTTTaCACATGG
0 34616 0 22302 1 24671 (SEQ ID NO: 128) CLTA4-4-10 4
GCAaATGaAGTGTcaCCACAAGG 1 25210 0 16187 0 16974 (SEQ ID NO: 129)
CLTA4-4-11 4 GCAaATGTAtTaTTTCCACtAGG 0 34144 1 24770 0 22547 (SEQ
ID NO: 130) CLTA4-4-12 4 GCAGATGTAGctTTTgtACATGG 0 14254 0 9616 0
9994 (SEQ ID NO: 131) CLTA4-4-13 4 GCAGcTtaAGTGTTTtCACATGG 8 39466
1 7609 5 16525 (SEQ ID NO: 132) CLTA4-4-14 4
ttAcATGTAGTGTTTaCACACGG 0 0 0 22302 0 0 (SEQ ID NO: 133) CLTA4-5-1
5 GaAGAgGaAGTGTTTgCcCAGGG 1 27616 1 16319 1 16140 (SEQ ID NO: 134)
CLTA4-5-2 5 GaAGATGTgGaGTTgaCACATGG 1 22533 0 14292 0 15013 (SEQ ID
NO: 135) CLTA4-5-3 5 GCAGAaGTAcTGTTgttACAAGG 1 44243 1 29391 1
29734 (SEQ ID NO: 136) CLTA4-5-4 5 GCAGATGTgGaaTTaCaACAGGG 0 27321
0 13640 0 14680 (SEQ ID NO: 137) CLTA4-5-5 5
GCAGtcaTAGTGTaTaCACATGG 1 26538 0 18449 1 20559 (SEQ ID NO: 138)
CLTA4-5-6 5 taAGATGTAGTaTTTCCAaAAGt 1 15145 1 8905 0 7911 (SEQ ID
NO: 139) CLTA4-6-1 6 GCAGcTGgcaTtTcTCCACACGG 0 2 0 0 0 0 (SEQ ID
NO: 140) CLTA4-6-2 6 GgAGATcTgaTGgTTCtACAAGG 2 27797 0 19450 2
21709 (SEQ ID NO: 141) CLTA4-6-3 6 taAaATGcAGTGTaTCCAtATGG 4 27551
0 18424 0 18783 (SEQ ID NO: 142) CLTA4-7-1 7
GCcagaaTAGTtTTTCaACAAGG 0 20942 0 13137 1 13792 (SEQ ID NO: 143)
CLTA4-7-2 8 ttgtATtTAGaGaTTgCACAAGG 0 28470 0 18104 0 20416 (SEQ ID
NO: 144)
TABLE-US-00018 TABLE 5 Off-target site Human genome coordinates
CLTA1-0-1 9(+): 36,211,732-36,211,754 12(+): 7,759,893-7,759,915
CLTA1-1-1 8(-): 15,546,437-15,546,459 CLTA1-2-1 3(-):
54,223,111-54,223,133 CLTA1-2-2 15(+): 89,388,670-89,388,692
CLTA1-2-3 5(+): 88716920-88,716,942 CLTA1-3-1 21(+):
27,972,462-27,972,484 CLTA1-3-2 4(-): 17,179,924-17,179,946
CLTA1-4-1 1(+): 147,288,742-147,288,764 CLTA1-4-2 10(+):
97,544,444-97,544,466 CLTA1-4-3 2(-): 161,873,870-161,873,892
CLTA1-4-4 1(+): 196,172,702-196,172,724 CLTA1-4-5 13(+):
56,574,636-56,574,658 CLTA1-4-6 2(+): 241,357,827-241,357,849
CLTA1-4-7 3(+): 121,248,627-121,248,649 CLTA1-4-8 12(+):
132,937,319-132,937,341 CLTA1-5-1 9(-): 80,930,919-80,930,941
CLTA1-5-2 2(+): 140,901,875-14,0901,897 CLTA1-5-3 3(+):
45,016,841-45,016,863 CLTA1-5-4 X(+): 40,775,684-40,775,706
CLTA1-5-5 2(-): 185,151,622-185,151,644 CLTA1-6-1 X(+):
150,655,097-150,655,119 CLTA4-0-1 9(-): 36,211,779-36,211,801
CLTA4-3-1 12(-): 50,679,419-50,679,441 CLTA4-3-2 X(-):
143,939,483-143,939,505 CLTA4-3-3 11(-): 47,492,611-47,492,633
CLTA4-3-4 3(-): 162,523,715-162,523,737 CLTA4-3-5 11(+):
30,592,975-30,592,997 CLTA4-3-6 4(-): 155,252,699-155,252,721
CLTA4-3-7 18(+): 39,209,441-39,209,463 CLTA4-4-1 17(-):
36,785,650-36,785,672 CLTA4-4-2 1(-): 241,537,119-241,537,141
CLTA4-4-3 8(-): 120,432,103-120,432,125 CLTA4-4-4 6(-):
106,204,600-106,204,622 CLTA4-4-5 8(+): 102,527,804-102,527,826
CLTA4-4-6 8(-): 94,685,538-94,685,560 CLTA4-4-7 2(+):
35,820,054-35,820,076 CLTA4-4-8 3(-): 36,590,352-36,590,374
CLTA4-4-9 12(+): 100,915,498-100,915,520 CLTA4-4-10 21(+):
33,557,705-33,557,727 CLTA4-4-11 8(+): 10,764,183-10,764,205
CLTA4-4-12 19(+): 37,811,645-37,811,667 CLTA4-4-13 13(-):
26,832,673-26,832,695 CLTA4-4-14 6(+): 19,349,572-19,349,594
CLTA4-5-1 11(-): 502,300-502,322 CLTA4-5-2 8(-):
28,389,683-28,389,705 CLTA4-5-3 2(-): 118,557,405-118,557,427
CLTA4-5-4 2(-): 103,248,360-103,248,382 CLTA4-5-5 21(-) :
42,929,085-42,929,107 CLTA4-5-6 13(-): 83,097,278-83,097,300
CLTA4-6-1 2(+): 43,078,423-43,078,445 CLTA4-6-2 7(-):
11,909,384-11,909,406 CLTA4-6-3 5(-): 69,775,482-69,775,504
CLTA4-7-1 16(+): 30,454,945-30,454,967 CLTA4-7-2 9(-):
77,211,328-77,211,350
TABLE-US-00019 TABLE 6 in vitro modification frequency number of
enrichment in HEK293T cells mutations sequence gene v1.0 v2.1 no
sgRNA v1.0 v2.1 CLTA1-0-1 0 AGTCCTCATCTCCCTCAAGCAGG CLTA 41.4 23.3
0.003% 0.042% 0.337% (SEQ ID NO: 145) CLTA1-1-1 1
AGTCCTCAaCTCCCTCAAGCAGG TUSC3 25.9 14 0.003% 0.031% 0.091% (SEQ ID
NO: 146) CLTA1-2-1 2 AGcCCTCATtTCCCTCAAGCAGG CACNA2D3 15.4 26.2 0%
0% 0% (SEQ ID NO: 147) CLTA1-2-2 2 AcTCCTCATCcCCCTCAAGCCGG ACAN
29.2 18.8 0.014% 0.005% 0.146% (SEQ ID NO: 148) CLTA1-2-3 2
AGTCaTCATCTCCCTCAAGCAGa 0.06 1.27 n.t. n.t. n.t. (SEQ ID NO: 149)
CLTA1-3-1 3 cGTCCTCcTCTCCCcCAAGCAGG 0 2.07 0.004% 0% 0% (SEQ ID NO:
150) CLTA1-3-2 3 tGTCCTCtTCTCCCTCAAGCAGa BC029598 0 1.47 0% 0% 0%
(SEQ ID NO: 151) CLTA1-4-1 4 AagCtTCATCTCtCTCAAGCTGG 0% 0.006% 0%
(SEQ ID NO: 152) CLTA1-4-2 4 AGTaCTCtTtTCCCTCAgGCTGG ENTPD1 0.007%
0.004% 0.015% (SEQ ID NO: 153) CLTA1-4-3 4 AGTCtTaAatTCCCTCAAGCAGG
0.003% 0% 0.001% (SEQ ID NO: 154) CLTA1-4-4 4
AGTgCTCATCTaCCagAAGCTGG 0.008% 0% 0% (SEQ ID NO: 155) CLTA1-4-5 4
ccTCCTCATCTCCCTgcAGCAGG 0.013% 0.004% 0% (SEQ ID NO: 156) CLTA1-4-6
4 ctaCaTCATCTCCCTCAAGCTGG 0% 0.008% 0.016% (SEQ ID NO: 157)
CLTA1-4-7 4 gGTCCTCATCTCCCTaAAaCAGa POLQ (coding) 0.011% 0.037% 0%
(SEQ ID NO: 158) CLTA1-4-8 4 tGTCCTCATCggCCTCAgGCAGG 0% 0% 0.016%
(SEQ ID NO: 159) CLTA1-5-1 5 AGaCacCATCTCCCTtgAGCTGG PSAT1 0%
0.003% 0.006% (SEQ ID NO: 160) CLTA1-5-2 5 AGgCaTCATCTaCaTCAAGtTGG
0% 0% 0% (SEQ ID NO: 161) CLTA1-5-3 5 AGTaaTCActTCCaTCAAGCCGG
ZDHHC3, n.t. n.t. n.t. (SEQ ID NO: 162) EXOSC7 CLTA1-5-4 5
tccCCTCAcCTCCCTaAAGCAGG 0.008% 0.029% 0.004% (SEQ ID NO: 163)
CLTA1-5-5 5 tGTCtTtATtTCCCTCtAGCTGG 0% 0% 0.009% (SEQ ID NO: 164)
CLTA1-6-1 6 AGTCCTCATCTCCCTCAAGCAGG 0% 0% 0% (SEQ ID NO: 165)
TABLE-US-00020 TABLE 7 # of sequences sequence no sgRNA v1.0 sgRNA
v2.1 sgRNA CLTA1-0-1 ref AGTCCTCATCTCCCTCAAGCAGG (SEQ ID 58,887
42,665 52,667 NO: 166) AGTCCTCATCTCCCTCAAAGCAGG (SEQ ID 0 0 66 NO:
167) AGTCCTCATCTCCCTC-AGCAGG (SEQ ID 0 2 28 NO: 168)
AGTCCTCAT-------------- 0 0 13 AGTCCTCATCTCCCTCATAGCAGG (SEQ ID 0 0
11 NO: 169) AGTCCTCAT--------AGCAGG (SEQ ID 0 0 9 NO: 170)
AGTCCTCATCT------AGCAGG (SEQ ID 0 0 8 NO: 171)
AGTCCTCA---------AGCAGG (SEQ ID 0 0 6 NO: 172)
AGTCCTCATCTCCCTCAAAGGCAGTGTTTGTT 0 0 4 ACTTGAGTTTGTCAGCAGG (SEQ ID
NO: 173) AGTCCTCATCTCCCTCATTAGCAGG (SEQ ID 0 0 4 NO: 174)
AGTCCTCATCTCCCTCAGGGCTTGTTTACAGC 0 0 3
TCACCTTTGAATTTGCACAAGCGTGCAAGCAG G (SEQ ID NO: 175)
AGTCCTCATCTCCCT-AGCAGG (SEQ ID 0 11 0 NO: 176)
AGTCCTCATCCCTC-AAGCAGG (SEQ ID 0 3 0 NO: 177)
AGTCCTCATCTCCCT-AAGCAGG (SEQ ID 1 2 0 NO: 178) other 1 0 26
modified total 2 18 178 (0.042%) (0.34%) CLTA1-1-1 ref
AGTCCTCATCTCCCTCAAGCAGG (SEQ ID 39,803 28,991 40,551 NO: 179)
AGTCCTCAaCTCCCTCAAAGCAGG (SEQ ID 0 4 13 NO: 180)
AGTCCTCAaCTCCCTCA------ (SEQ ID 0 0 12 NO: 181)
AGTCCTCAaCTCCCTC-AGCAGG (SEQ ID 0 2 4 NO: 182)
AGTCCTCAaCTCCCTCAAGAAAGGTGTTGAAAA 0 0 3 TCAGAAAGAGAGAAACAAGCAGG
(SEQ ID NO: 183) AGTCCTCAaCTCCCTCAATCTACGGTCCATTCC 0 0 2
CGTTTCCACTCACCTTGCGCCGCAGCAGG (SEQ ID NO: 184)
AGTCCTCAaCTCCCT-AAGCAGG (SEQ ID 0 3 1 NO: 185)
AGTCCTCAaCTCCCTCAACCAACTTTAACATCC 0 0 1
TGCTGGTTCTGTCATTAATAAGTTGAAAGCAGG (SEQ ID NO: 186)
AGTCCTCAaCTCCCTCACAGCAAATAAAAAAGT 0 0 1
TGTTTATGCATATTCAGATAAGCAAAGCAGG (SEQ ID NO: 187)
AGTCCTCAaCTCCC-AAGCAGG (SEQ ID 1 0 0 NO: 188) modified total 1 9 37
(0.031%) (0.091%) CLTA1-2-2 ref AcTCCTCATCcCCCTCAAGCCGG (SEQ ID
21,264 20,041 22,546 NO: 189) AcTCCTCATCcCCCTCAAAGCCGG (SEQ ID 0 0
8 NO: 190) AcTCCTCATCcCCCTCAGAGCCGG (SEQ ID 0 0 7 NO: 191)
AcTCCTC-----------AGCCGG (SEQ ID 0 0 5 NO: 192)
AcTCCTCATCcCCCTCAAAAGCCGG (SEQ ID 0 0 2 NO: 193)
AcTCCTCATCcCCCTCAGCAGCCGG (SEQ ID 0 0 2 NO: 194)
AcTCCTCATCcCCCTCATAGCCGG (SEQ ID 0 0 2 NO: 195)
AcTCCTCATCcCCCTCATCCCCGG (SEQ ID 0 0 2 NO: 196)
AcTCCTCATCcC-----AGCCGG (SEQ ID 0 0 2 NO: 197)
AcTCCTCATCcCCCTA-AGCCGG (SEQ ID 3 1 1 NO: 198)
AcTCCTCATCcCCCTCAATAGCCGG (SEQ ID 0 0 1 NO: 199)
AcTCCTCACCcCCCTCAGCAGCCGG (SEQ ID 0 0 1 NO: 200) modified total 3 1
33 (0.15%)
TABLE-US-00021 TABLE 8 # of sequences sequence control v1.0 sgRNA
v2.1 sgRNA CLTA4-0-1 ref GCAGATGTAGTGTTTCCACAGGG 29,185 16,635
17,555 (SEQ ID NO: 201) GCAGATGTAGTGTTTC-ACAGGG 1 891 5,937 (SEQ ID
NO: 202) GCAGATGTAGTGTTTCCCACAGGG 0 809 5,044 (SEQ ID NO: 203)
GCAGATGTAGTG----CACAGGG 0 14 400 (SEQ ID NO: 204)
GCAGATGTAGTGTTTCC-CAGGG 0 19 269 (SEQ ID NO: 205)
GCAGATGTAC-------ACAGGG 0 17 262 (SEQ ID NO: 206)
GCAGATGTAGTGTCA---CAGGG 2 6 254 (SEQ ID NO: 207)
GCAGATGTAGTGTTCA-CAGGG (SEQ 0 21 229 ID NO: 208)
GCAGATGTAGTGTTTC-CAGGG (SEQ 1 14 188 ID NO: 209)
GCAGATGTAGT-----CACAGGG 0 0 152 (SEQ ID NO: 210)
GCAGATGT-----------AGGG 0 6 129 (SEQ ID NO: 211) other 2 208 2,106
modified total 6 2,005 14,970 (11%) (76%) CLTA4-3-1 ref
aCAtATGTAGTaTTTCCACAGGG 34,163 20,007 12,208 (SEQ ID NO: 212)
aCAtATGTAGTaTTTCCCACAGGG 0 8 1779 (SEQ ID NO: 213)
aCAtATGTAGTaTTTCA-CAGGG 1 0 293 (SEQ ID NO: 214)
aCAtATGTAGTaTTTC-CAGGG (SEQ 1 0 227 ID NO: 215)
aCAtAT----------CACAGGG 0 0 117 (SEQ ID NO: 216)
a-----------------CAGGG 0 0 96 aCAt------------CACAGGG 0 0 78 (SEQ
ID NO: 217) aCAtATGTAGT-----CACAGGG 0 0 77 (SEQ ID NO: 218)
aCAtATGTAGTaTTTCC------ 0 0 76 (SEQ ID NO: 219)
aCAtATGT-----------AGGG 0 0 68 (SEQ ID NO: 220)
aCAtATGTAG------CACAGGG 0 0 64 (SEQ ID NO: 221) other 0 3 999
modified total 2 11 3874 (0.055%) (24%) CLTA4-3-3 ref
cCAGATGTAGTaTTcCCACAGGG 16,559 12,007 11,030 (SEQ ID NO: 222)
cCAGATGTAGTaTTcCCCACAGGG 0 0 35 (SEQ ID NO: 223)
cCAGATGTAGTaT----ACAGGG 0 0 5 (SEQ ID NO: 224)
cCAGATGTAGTaT---CACAGGG 0 0 3 (SEQ ID NO: 225)
cCAGATGTAGTaTTcCCAACACAGGG 0 0 2 (SEQ ID NO: 226)
cCAGATGTAGTaTT-CACAGGG (SEQ 0 0 2 ID NO: 227)
cCAGATGTAGTaTTcC-CAGGG (SEQ 0 0 2 ID NO: 228)
cCAGATGTA-------------- 0 0 2 cCAGATGTAGTaTTcC-ACAGGG 0 0 1 (SEQ ID
NO: 229) modified total 0 0 52 (0.47%) CLTA4-4-8 ref
ctAGATGaAGTGcTTCCACATGG 10,691 7,608 8,018 (SEQ ID NO: 230)
ctAGATGaAGTGcTTCCCACATGG 0 0 49 (SEQ ID NO: 231)
ctAGATGaAGTGcTTC-ACATGG 0 0 6 (SEQ ID NO: 232)
ctAGATGaAGTG----------- 0 0 2 (SEQ ID NO: 233)
ctAGATGaAGTGcTTCCACACATGG 0 0 1 (SEQ ID NO: 234)
ctAGATGaAGTGcTTC-CATGG (SEQ 1 0 0 ID NO: 235)
ctAGATGaAGTGcTTCC-CATGG 0 1 0 (SEQ ID NO: 236) modified total 1 1
59 (0.73%)
TABLE-US-00022 TABLE 9 oligonucleotide name oligonucleotide
sequence (5'->3') CLTA1 v2.1 template fwd TAA TAC GAC TCA CTA
TAG GAG TCC TCA TCT CCC TCA AGC GTT TTA GAG CTA TGC TG (SEQ ID NO:
237) CLTA2 v2.1 template fwd TAA TAC GAC TCA CTA TAG GCT CCC TCA
AGC AGG CCC CGC GTT TTA GAG CTA TGC TG (SEQ ID NO: 238) CLTA3 v2.1
template fwd TAA TAC GAC TCA CTA TAG GTG TGA AGA GCT TCA CTG AGT
GTT TTA GAG CTA TGC TG (SEQ ID NO: 239) CLTA4 v2.1 template fwd TAA
TAC GAC TCA CTA TAG GGC AGA TGT AGT GTT TCC ACA GTT TTA GAG CTA TGC
TG (SEQ ID NO: 240) v2.1 template rev GAT AAC GGA CTA GCC TTA TTT
TAA CTT GCT ATG CTT TTC AGC ATA GCT CTA AAA C (SEQ ID NO: 241)
CLTA1 v1.0 template CGG ACT AGC CTT ATT TTA ACT TGC TAT TTC TAG CTC
TAA AAC GCT TGA GGG AGA TGA GGA CTC CTA TAG TGA GTC GTA TTA (SEQ ID
NO: 242) CLTA2 v1.0 template CGG ACT AGC CTT ATT TTA ACT TGC TAT
TTC TAG CTC TAA AAC GCG GGG CCT GCT TGA GGG AGC CTA TAG TGA GTC GTA
TTA (SEQ ID NO: 243) CLTA3 v1.0 template CGG ACT AGC CTT ATT TTA
ACT TGC TAT TTC TAG CTC TAA AAC ACT CAG TGA AGC TCT TCA CAC CTA TAG
TGA GTC GTA TTA (SEQ ID NO: 244) CLTA4 v1.0 template CGG ACT AGC
CTT ATT TTA ACT TGC TAT TTC TAG CTC TAA AAC TGT GGA AAC ACT ACA TCT
GCC CTA TAG TGA GTC GTA TTA (SEQ ID NO: 245) T7 promoter oligo TAA
TAC GAC TCA CTA TAG G (SEQ ID NO: 246) CLTA1 lib /5Phos/AAC ACA NNN
NC*C* NG*C* T*T*G* A*G*G* G*A*G* A*T*G* A*G*G* A*C*T* NNN NAC CTG
CCG AGA ACA CA (SEQ ID NO: 247) CLTA2 lib /5Phos/TCT TCT NNN NC*C*
NG*C* G*G*G* G*C*C* T*G*C* T*T*G* A*G*G* G*A*G* NNN NAC CTG CCG AGT
CTT CT (SEQ ID NO: 248) CLTA3 lib /5Phos/AGA GAA NNN NC*C* NA*C*
T*C*A* G*T*G* A*A*G* C*T*C* T*T*C* A*C*A* NNN NAC CTG CCG AGA GAG
AA (SEQ ID NO: 249) CLTA4 lib /5Phos/TTG TGT NNN NC*C* NT*G* T*G*G*
A*A*A* C*A*C* T*A*C* A*T*C* T*G*C* NNN NAC CTG CCG AGT TGT GT (SEQ
ID NO: 250) CLTA1 site fwd CTA GCA GTC CTC ATC TCC CTC AAG CAG GC
(SEQ ID NO: 251) CLTA1 site rev AGC TGC CTG CTT GAG GGA GAT GAG GAC
TG (SEQ ID NO: 252) CLTA2 site fwd CTA GTC TCC CTC AAG CAG GCC CCG
CTG GT (SEQ ID NO: 253) CLTA2 site rev AGC TAC CAG CGG GGC CTG CTT
GAG GGA GA (SEQ ID NO: 254) CLTA3 site fwd CTA GCT GTG AAG AGC TTC
ACT GAG TAG GA (SEQ ID NO: 255) CLTA3 site rev AGC TTC CTA CTC AGT
GAA GCT CTT CAC AG (SEQ ID NO: 256) CLTA4 site fwd CTA GTG CAG ATG
TAG TGT TTC CAC AGG GT (SEQ ID NO: 257) CLTA4 site rev AGC TAC CCT
GTG GAA ACA CTA CAT CTG CA (SEQ ID NO: 258) test fwd GCG ACA CGG
AAA TGT TGA ATA CTC AT (SEQ ID NO: 259) test rev GGA GTC AGG CAA
CTA TGG ATG AAC G (SEQ ID NO: 260) off-target CLTA4-0 fwd ACT GTG
AAG AGC TTC ACT GAG TAG GAT TAA GAT ATT GCA GAT GTA GTG TTT CCA CAG
GGT (SEQ ID NO: 261) off-target CLTA4-1 fwd ACT GTG AAG AGC TTC ACT
GAG TAG GAT TAA GAT ATT GAA GAT GTA GTG TTT CCA CAG GGT (SEQ ID NO:
262) off-target CLTA4-2a fwd ACT GTG AAG AGC TTC ACT GAG TAG GAT
TAA GAT ATT GAA GAT GTA GTG TTT CCA CTG GGT (SEQ ID NO: 263)
off-target CLTA4-2b fwd ACT GTG AAG AGC TTC ACT GAG TAG GAT TAA GAT
ATT GCA GAT GGA GGG TTT CCA CAG GGT (SEQ ID NO: 264) off-target
CLTA4-2c fwd ACT GTG AAG AGC TTC ACT GAG TAG GAT TAA GAT ATT GCA
GAT GTA GTG TTA CCA GAG GGT (SEQ ID NO: 265) off-target CLTA4-3 fwd
ACT GTG AAG AGC TTC ACT GAG TAG GAT TAA GAT ATT GGG GAT GTA GTG TTT
CCA CTG GGT (SEQ ID NO: 266) off-target CLTA4-0 rev TCC CTC AAG CAG
GCC CCG CTG GTG CAC TGA AGA GCC ACC CTG TGG AAA CAC TAC ATC TGC
(SEQ ID NO: 267) off-target CLTA4-1 rev TCC CTC AAG CAG GCC CCG CTG
GTG CAC TGA AGA GCC ACC CTG TGG AAA CAC TAC ATC TTC (SEQ ID NO:
268) off-target CLTA4-2a rev TCC CTC AAG CAG GCC CCG CTG GTG CAC
TGA AGA GCC ACC CAG TGG AAA CAC TAC ATC TTC (SEQ ID NO: 269)
off-target CLTA4-2b rev TCC CTC AAG CAG GCC CCG CTG GTG CAC TGA AGA
GCC ACC CTG TGG AAA CCC TCC ATC TGC (SEQ ID NO: 270) off-target
CLTA4-2c rev TCC CTC AAG CAG GCC CCG CTG GTG CAC TGA AGA GCC ACC
CTC TGG TAA CAC TAC ATC TGC (SEQ ID NO: 271) off-target CLTA4-3 rev
TCC CTC AAG CAG GCC CCG CTG GTG CAC TGA AGA GCC ACC CAG TGG AAA CAC
TAC ATC CCC (SEQ ID NO: 272) adapter1(AACA) AAT GAT ACG GCG ACC ACC
GAG ATC TAC ACT CTT TCC CTA CAC GAC GCT CTT CCG ATC TAA CA (SEQ ID
NO: 273) adapter2(AACA) TGT TAG ATC GGA AGA GCG TCG TGT AGG GAA AGA
GTG TAG ATC TCG GTG G (SEQ ID NO: 274) adapter1(TTCA) AAT GAT ACG
GCG ACC ACC GAG ATC TAC ACT CTT TCC CTA CAC GAC GCT CTT CCG ATC TTT
CA (SEQ ID NO: 275) adapter2(TTCA) TGA AAG ATC GGA AGA GCG TCG TGT
AGG GAA AGA GTG TAG ATC TCG GTG G (SEQ ID NO: 276) adapter1 AAT GAT
ACG GCG ACC ACC GAG ATC TAC ACT CTT TCC CTA CAC GAC GCT CTT CCG ATC
T (SEQ ID NO: 277) adapter2 AGA TCG GAA GAG CGT CGT GTA GGG AAA GAG
TGT AGA TCT CGG TGG (SEQ ID NO: 278) lib adapter1 GAC GGC ATA CGA
GAT (SEQ ID NO: 279) CLTA1 lib adapter2 AAC AAT CTC GTA TGC CGT CTT
CTG CTT G (SEQ ID NO: 280) CLTA2 lib adapter2 TCT TAT CTC GTA TGC
CGT CTT CTG CTT G (SEQ ID NO: 281) CLTA3 lib adapter2 AGA GAT CTC
GTA TGC CGT CTT CTG CTT G (SEQ ID NO: 282) CLTA4 lib adapter2 TTG
TAT CTC GTA TGC CGT CTT CTG CTT G (SEQ ID NO: 283) CLTA1 sel PCR
CAA GCA GAA GAC GGC ATA CGA GAT TGT GTT CTC GGC AGG T (SEQ ID NO:
284) CLTA2 sel PCR CAA GCA GAA GAC GGC ATA CGA GAT AGA AGA CTC GGC
AGG T (SEQ ID NO: 285) CLTA3 sel PCR CAA GCA GAA GAC GGC ATA CGA
GAT TTC TCT CTC GGC AGG T (SEQ ID NO: 286) CLTA4 sel PCR CAA GCA
GAA GAC GGC ATA CGA GAT ACA CAA CTC GGC AGG T (SEQ ID NO: 287) PE2
short AAT GAT ACG GCG ACC ACC GA (SEQ ID NO: 288) CLTA1 lib seq PCR
AAT GAT ACG GCG ACC ACC GAG ATC TAC ACT CTT TCC CTA CAC GAC GCT CTT
CCG ATC TNN NNA CCT ACC TGC CGA GAA CAC A (SEQ ID NO: 289) CLTA2
lib seq PCR AAT GAT ACG GCG ACC ACC GAG ATC TAC ACT CTT TCC CTA CAC
GAC GCT CTT CCG ATC TNN NNA CCT ACC TGC CGA GTC TTC T (SEQ ID NO:
290) CLTA3 lib seq PCR AAT GAT ACG GCG ACC ACC GAG ATC TAC ACT CTT
TCC CTA CAC GAC GCT CTT CCG ATC TNN NNA CCT ACC TGC CGA GAG AGA A
(SEQ ID NO: 291) CLTA4 lib seq PCR AAT GAT ACG GCG ACC ACC GAG ATC
TAC ACT CTT TCC CTA CAC GAC GCT CTT CCG ATC TNN NNA CCT ACC TGC CGA
GTT GTG T (SEQ ID NO: 292) lib fwd PCR CAA GCA GAA GAC GGC ATA CGA
GAT (SEQ ID NO: 293) CLTA1-0-1 (Chr. 9) fwd ACA CTC TTT CCC TAC ACG
ACG CTC TTC CGA TCT CAA GTC TAG CAA GCA GGC CA (SEQ ID NO: 294)
CLTA1-0-1 (Chr. 12) fwd ACA CTC TTT CCC TAC ACG ACG CTC TTC CGA TCT
CAG GCA CTG AGT GGG AAA GT (SEQ ID NO: 295) CLTA1-1-1 fwd ACA CTC
TTT CCC TAC ACG ACG CTC TTC CGA TCT TAA CCC CAA GTC AGC AAG CA (SEQ
ID NO: 296) CLTA1-2-1 fwd ACA CTC TTT CCC TAC ACG ACG CTC TTC CGA
TCT TTG CTG GTC AAT ACC CTG GC (SEQ ID NO: 297) CLTA1-2-2 fwd ACA
CTC TTT CCC TAC ACG ACG CTC TTC CGA TCT TGA GTA CCC CTG AAA TGG GC
(SEQ ID NO: 298) CLTA1-3-1 fwd ACA CTC TTT CCC TAC ACG ACG CTC TTC
CGA TCT TCG CTA CCA ATC AGG GCT TT (SEQ ID NO: 299) CLTA1-3-2 fwd
ACA CTC TTT CCC TAC ACG ACG CTC TTC CGA TCT CCA TTG CCA CTT GTT TGC
AT (SEQ ID NO: 300) CLTA1-4-1 fwd ACA CTC TTT CCC TAC ACG ACG CTC
TTC CGA TCT CCT ACC CCC ACA ACT TTG CT (SEQ ID NO: 301) CLTA1-4-2
fwd ACA CTC TTT CCC TAC ACG ACG CTC TTC CGA TCT GTG TAC ATC CAG TGC
ACC CA (SEQ ID NO: 302) CLTA1-4-3 fwd ACA CTC TTT CCC TAC ACG ACG
CTC TTC CGA TCT TCG GAA AGG ACT TTG AAT ACT TGT (SEQ ID NO: 303)
CLTA1-4-4 fwd ACA CTC TTT CCC TAC ACG ACG CTC TTC CGA TCT CGG CCC
AAG ACC TCA TTC AC (SEQ ID NO: 304) CLTA1-4-5 fwd ACA CTC TTT CCC
TAC ACG ACG CTC TTC CGA TCT GTC CTC TCT GGG GCA GAA GT (SEQ ID NO:
305) CLTA1-4-6 fwd ACA CTC TTT CCC TAC ACG ACG CTC TTC CGA TCT AGC
TGA GTC ATG AGT TGT CTC C (SEQ ID NO: 306) CLTA1-4-7 fwd ACA CTC
TTT CCC TAC ACG ACG CTC TTC CGA TCT CTG CCA GCT TCT CAC ACC AT (SEQ
ID NO: 307) CLTA1-4-8 fwd ACA CTC TTT CCC TAC ACG ACG CTC TTC CGA
TCT CTG AAG GAC AAA GGC GGG AA (SEQ ID NO: 308) CLTA1-5-1 fwd ACA
CTC TTT CCC TAC ACG ACG CTC TTC CGA TCT AAG GTG CTA AAG GCT CCA CG
(SEQ ID NO: 309) CLTA1-5-2 fwd ACA CTC TTT CCC TAC ACG ACG CTC TTC
CGA TCT GAC CAT TGG TGA GCC CAG AG (SEQ ID NO: 310) CLTA1-5-3 fwd
ACA CTC TTT CCC TAC ACG ACG CTC TTC CGA TCT TTT TTC GGG CAA CTG CTC
AC (SEQ ID NO: 311) CLTA1-5-4 fwd ACA CTC TTT CCC TAC ACG ACG CTC
TTC CGA TCT GCA AGC CTT CTC TCC TCA GA (SEQ ID NO: 312) CLTA1-5-5
fwd ACA CTC TTT CCC TAC ACG ACG CTC TTC CGA TCT ACA CAA ACT TCC CTG
AGA CCC (SEQ ID NO: 313) CLTA1-6-1 fwd ACA CTC TTT CCC TAC ACG ACG
CTC TTC CGA TCT TGA GTT AGC CCT GCT GTT CA (SEQ ID NO: 314)
CLTA4-0-1 fwd ACA CTC TTT CCC TAC ACG ACG CTC TTC CGA TCT TGA AGA
GCT TCA CTG AGT AGG A (SEQ ID NO: 315) CLTA4-3-1 fwd ACA CTC TTT
CCC TAC ACG ACG CTC TTC CGA TCT TCC CCT TAC AGC CAA TTT CGT (SEQ ID
NO: 316) CLTA4-3-2 fwd ACA CTC TTT CCC TAC ACG ACG CTC TTC CGA TCT
TGC TGA TGA AAT GCA ATT AAG AGG T (SEQ ID NO: 317) CLTA4-3-3 fwd
ACA CTC TTT CCC TAC ACG ACG CTC TTC CGA TCT GGT CCC TGC AAG CCA GTA
TG (SEQ ID NO: 318) CLTA4-3-4 fwd ACA CTC TTT CCC TAC ACG ACG CTC
TTC CGA TCT ATC AAA GCC TTG TAT CAC AGT T (SEQ ID NO: 319)
CLTA4-3-5 fwd ACA CTC TTT CCC TAC ACG ACG CTC TTC CGA TCT CCC AAA
TAA TGC AGG AGC CAA (SEQ ID NO: 320) CLTA4-3-6 fwd ACA CTC TTT CCC
TAC ACG ACG CTC TTC CGA TCT CTG CCT TTA GTG GGA CAG ACT T (SEQ ID
NO: 321) CLTA4-3-7 fwd ACA CTC TTT CCC TAC ACG ACG CTC TTC CGA TCT
AGT AAC CCT AGT
AGC CCT CCA (SEQ ID NO: 322) CLTA4-4-1 fwd ACA CTC TTT CCC TAC ACG
ACG CTC TTC CGA TCT CAT TGC AGT GAG CCG AGA TTG (SEQ ID NO: 323)
CLTA4-4-2 fwd ACA CTC TTT CCC TAC ACG ACG CTC TTC CGA TCT TGG CAA
AGT TCA CTT CCA TGT (SEQ ID NO: 324) CLTA4-4-3 fwd ACA CTC TTT CCC
TAC ACG ACG CTC TTC CGA TCT TGC TCT GTG ATG TCT GCC AC (SEQ ID NO:
325) CLTA4-4-4 fwd ACA CTC TTT CCC TAC ACG ACG CTC TTC CGA TCT TGT
GTA GGA TTG TGA ACC AGC A (SEQ ID NO: 326) CLTA4-4-5 fwd ACA CTC
TTT CCC TAC ACG ACG CTC TTC CGA TCT TCC CAG CCC AGC ATT TTT CT (SEQ
ID NO: 327) CLTA4-4-6 fwd ACA CTC TTT CCC TAC ACG ACG CTC TTC CGA
TCT AGG TTG CTT TGT GCA CAG TC (SEQ ID NO: 328) CLTA4-4-7 fwd ACA
CTC TTT CCC TAC ACG ACG CTC TTC CGA TCT CCT GGC TTG GGA TGT TGG AA
(SEQ ID NO: 329) CLTA4-4-8 fwd ACA CTC TTT CCC TAC ACG ACG CTC TTC
CGA TCT TTG CCC AAG GTC ATA CTG CT (SEQ ID NO: 330) CLTA4-4-9 fwd
ACA CTC TTT CCC TAC ACG ACG CTC TTC CGA TCT ACC CAC TAG GTA GCC ATA
ATC CA (SEQ ID NO: 331) CLTA4-4-10 fwd ACA CTC TTT CCC TAC ACG ACG
CTC TTC CGA TCT CGG TCA TGT CGC TTG GAA GA (SEQ ID NO: 332)
CLTA4-4-11 fwd ACA CTC TTT CCC TAC ACG ACG CTC TTC CGA TCT TTG GCC
CAT ATT GCT TTA TGC TG (SEQ ID NO: 333) CLTA4-4-12 fwd ACA CTC TTT
CCC TAC ACG ACG CTC TTC CGA TCT ATT AGG GGT TGG CTG CAT GA (SEQ ID
NO: 334) CLTA4-4-13 fwd ACA CTC TTT CCC TAC ACG ACG CTC TTC CGA TCT
CCA AGA CGT GTT GCA TGC TG (SEQ ID NO: 335) CLTA4-4-14 fwd ACA CTC
TTT CCC TAC ACG ACG CTC TTC CGA TCT TGG GAG GTG ATA AAT TCC CTA AAT
(SEQ ID NO: 336) CLTA4-5-1 fwd ACA CTC TTT CCC TAC ACG ACG CTC TTC
CGA TCT CCA GAG ACA AAG GTG GGG AG (SEQ ID NO: 337) CLTA4-5-2 fwd
ACA CTC TTT CCC TAC ACG ACG CTC TTC CGA TCT TCA TAC AGA AGA GCA AAG
TAC CA (SEQ ID NO: 338) CLTA4-5-3 fwd ACA CTC TTT CCC TAC ACG ACG
CTC TTC CGA TCT CAA AGA GGG GTA TCG GGA GC (SEQ ID NO: 339)
CLTA4-5-4 fwd ACA CTC TTT CCC TAC ACG ACG CTC TTC CGA TCT AAA TGG
AAG AAC CAA GTA GAT GAA (SEQ ID NO: 340) CLTA4-5-5 fwd ACA CTC TTT
CCC TAC ACG ACG CTC TTC CGA TCT TTT TGG TTG ACA GAT GGC CAC A (SEQ
ID NO: 341) CLTA4-5-6 fwd ACA CTC TTT CCC TAC ACG ACG CTC TTC CGA
TCT TCT TAC TTG TGT GAT TTT AGA ACA A (SEQ ID NO: 342) CLTA4-6-1
fwd ACA CTC TTT CCC TAC ACG ACG CTC TTC CGA TCT GAT GGT TCA TGC AGA
GGG CT (SEQ ID NO: 343) CLTA4-6-2 fwd ACA CTC TTT CCC TAC ACG ACG
CTC TTC CGA TCT GCT GGT CTT TCC TGA GCT GT (SEQ ID NO: 344)
CLTA4-6-3 fwd ACA CTC TTT CCC TAC ACG ACG CTC TTC CGA TCT CTC CAT
CAG ATA CCT GTA CCC A (SEQ ID NO: 345) CLTA4-7-1 fwd ACA CTC TTT
CCC TAC ACG ACG CTC TTC CGA TCT GGG AAA ACA CTC TCT CTC TGC T (SEQ
ID NO: 346) CLTA4-7-2 fwd ACA CTC TTT CCC TAC ACG ACG CTC TTC CGA
TCT GGA GGC CAC GAC ACA CAA TA (SEQ ID NO: 347) CLTA1-0-1 (Chr. 9)
rev GTG ACT GGA GTT CAG ACG TGT GCT CTT CCG ATCT CAC AGG GTG GCT
CTT CAG TG (SEQ ID NO: 348) CLTA1-0-1 (Chr. 12) rev GTG ACT GGA GTT
CAG ACG TGT GCT CTT CCG ATCT TGC ACA TGT TTC CAC AGG GT (SEQ ID NO:
349) CLTA1-1-1 rev GTG ACT GGA GTT CAG ACG TGT GCT CTT CCG ATCT AGT
GTT TCC AGG AGC GGT TT (SEQ ID NO: 350) CLTA1-2-1 rev GTG ACT GGA
GTT CAG ACG TGT GCT CTT CCG ATCT AAG CCT CAG GCA CAA CTC TG (SEQ ID
NO: 351) CLTA1-2-2 rev GTG ACT GGA GTT CAG ACG TGT GCT CTT CCG ATCT
TAG GGG AGG GGC AAA GAC A (SEQ ID NO: 352) CLTA1-3-1 rev GTG ACT
GGA GTT CAG ACG TGT GCT CTT CCG ATCT GGG AAC AGT GGT ATG CTG GT
(SEQ ID NO: 353) CLTA1-3-2 rev GTG ACT GGA GTT CAG ACG TGT GCT CTT
CCG ATCT AGT GTG GAC ACT GAC AAG GAA (SEQ ID NO: 354) CLTA1-4-1 rev
GTG ACT GGA GTT CAG ACG TGT GCT CTT CCG ATCT TCA CTG CCT GGG TGC
TTT AG (SEQ ID NO: 355) CLTA1-4-2 rev GTG ACT GGA GTT CAG ACG TGT
GCT CTT CCG ATCT TAC CCC AGC CTC CAG CTT TA (SEQ ID NO: 356)
CLTA1-4-3 rev GTG ACT GGA GTT CAG ACG TGT GCT CTT CCG ATCT TGA CTA
CTG GGG AGC GAT GA (SEQ ID NO: 357) CLTA1-4-4 rev GTG ACT GGA GTT
CAG ACG TGT GCT CTT CCG ATCT AGG CTG TTA TGC AGG AAA GGA A (SEQ ID
NO: 358) CLTA1-4-5 rev GTG ACT GGA GTT CAG ACG TGT GCT CTT CCG ATCT
GCG GTT GAG GTG GAT GGA AG (SEQ ID NO: 359) CLTA1-4-6 rev GTG ACT
GGA GTT CAG ACG TGT GCT CTT CCG ATCT GGC AGC ATC CCT TAC ATC CT
(SEQ ID NO: 360) CLTA1-4-7 rev GTG ACT GGA GTT CAG ACG TGT GCT CTT
CCG ATCT AGA AAA AGC TTC CCC AGA AAG GA (SEQ ID NO: 361) CLTA1-4-8
rev GTG ACT GGA GTT CAG ACG TGT GCT CTT CCG ATCT CTG CAC CAA CCT
CTA CGT CC (SEQ ID NO: 362) CLTA1-5-1 rev GTG ACT GGA GTT CAG ACG
TGT GCT CTT CCG ATCT CTG GAG AGG GCA TAG TTG GC (SEQ ID NO: 363)
CLTA1-5-2 rev GTG ACT GGA GTT CAG ACG TGT GCT CTT CCG ATCT TGG AAG
GCT CTT TGT GGG TT (SEQ ID NO: 364) CLTA1-5-3 rev GTG ACT GGA GTT
CAG ACG TGT GCT CTT CCG ATCT TTC CTA GCG GGA ACT GGA AA (SEQ ID NO:
365) CLTA1-5-4 rev GTG ACT GGA GTT CAG ACG TGT GCT CTT CCG ATCT AGG
CTA ATG GGG TAG GGG AT (SEQ ID NO: 366) CLTA1-5-5 rev GTG ACT GGA
GTT CAG ACG TGT GCT CTT CCG ATCT TGT CCA TGT TGG CTG AGG TG (SEQ ID
NO: 367) CLTA1-6-1 rev GTG ACT GGA GTT CAG ACG TGT GCT CTT CCG ATCT
CAG GCC AAC CTT GAC AAC TT (SEQ ID NO: 368) CLTA4-0-1 rev GTG ACT
GGA GTT CAG ACG TGT GCT CTT CCG ATCT AGC AGG CCA AAG ATG TCT CC
(SEQ ID NO: 369) CLTA4-3-1 rev GTG ACT GGA GTT CAG ACG TGT GCT CTT
CCG ATCT TCT GCT CTT GAG GTT ATT TGT CC (SEQ ID NO: 370) CLTA4-3-2
rev GTG ACT GGA GTT CAG ACG TGT GCT CTT CCG ATCT GGG ACC AAT TTG
CTA CTC ATG G (SEQ ID NO: 371) CLTA4-3-3 rev GTG ACT GGA GTT CAG
ACG TGT GCT CTT CCG ATCT TGG AGG CTG TAA ACG TCC TG (SEQ ID NO:
372) CLTA4-3-4 rev GTG ACT GGA GTT CAG ACG TGT GCT CTT CCG ATCT TGC
TAT GAT TTG CTG AAT TAC TCC T (SEQ ID NO: 373) CLTA4-3-5 rev GTG
ACT GGA GTT CAG ACG TGT GCT CTT CCG ATCT GCA ATT TTG CAG ACC ACC
ATC (SEQ ID NO: 374) CLTA4-3-6 rev GTG ACT GGA GTT CAG ACG TGT GCT
CTT CCG ATCT GGC AGC TTG CAA CCT TCT TG (SEQ ID NO: 375) CLTA4-3-7
rev GTG ACT GGA GTT CAG ACG TGT GCT CTT CCG ATCT TCA TGA GAG TTT
CCC CAA CA (SEQ ID NO: 376) CLTA4-4-1 rev GTG ACT GGA GTT CAG ACG
TGT GCT CTT CCG ATCT ACT TGA GGG GGA AAA AGT TTC TTA (SEQ ID NO:
377) CLTA4-4-2 rev GTG ACT GGA GTT CAG ACG TGT GCT CTT CCG ATCT TGG
TCC CTG TCT GTC ATT GG (SEQ ID NO: 378) CLTA4-4-3 rev GTG ACT GGA
GTT CAG ACG TGT GCT CTT CCG ATCT AAG CGA GTG ACT GTC TGG GA (SEQ ID
NO: 379) CLTA4-4-4 rev GTG ACT GGA GTT CAG ACG TGT GCT CTT CCG ATCT
CAT GGG TGG GAC ACG TAG TT (SEQ ID NO: 380) CLTA4-4-5 rev GTG ACT
GGA GTT CAG ACG TGT GCT CTT CCG ATCT GGC TTT CCT GGA CAC CCT ATC
(SEQ ID NO: 381) CLTA4-4-6 rev GTG ACT GGA GTT CAG ACG TGT GCT CTT
CCG ATCT AGA GCG AGG GAG CGA TGT A (SEQ ID NO: 382) CLTA4-4-7 rev
GTG ACT GGA GTT CAG ACG TGT GCT CTT CCG ATCT TTG TGG ACC ACT GCT
TAG TGC (SEQ ID NO: 383) CLTA4-4-8 rev GTG ACT GGA GTT CAG ACG TGT
GCT CTT CCG ATCT CAA CTA CCC TGA GGC CAC C (SEQ ID NO: 384)
CLTA4-4-9 rev GTG ACT GGA GTT CAG ACG TGT GCT CTT CCG ATCT GGT CAG
CAC TCC TCA GCT TT (SEQ ID NO: 385) CLTA4-4-10 rev GTG ACT GGA GTT
CAG ACG TGT GCT CTT CCG ATCT TGG AGG ATG CAT GCC ACA TT (SEQ ID NO:
386) CLTA4-4-11 rev GTG ACT GGA GTT CAG ACG TGT GCT CTT CCG ATCT
CCC AGC CTC TTT GAC CCT TC (SEQ ID NO: 387) CLTA4-4-12 rev GTG ACT
GGA GTT CAG ACG TGT GCT CTT CCG ATCT CCC ACA CCA GGC TGT AAG G (SEQ
ID NO: 388) CLTA4-4-13 rev GTG ACT GGA GTT CAG ACG TGT GCT CTT CCG
ATCT TAG ATA TAT GGG TGT GTC TGT ACG (SEQ ID NO: 389) CLTA4-4-14
rev GTG ACT GGA GTT CAG ACG TGT GCT CTT CCG ATCT TTC CAA AGT GGC
TGA ACC AT (SEQ ID NO: 390) CLTA4-5-1 rev GTG ACT GGA GTT CAG ACG
TGT GCT CTT CCG ATCT CCC ACA GGG CTG ATG TTT CA (SEQ ID NO: 391)
CLTA4-5-2 rev GTG ACT GGA GTT CAG ACG TGT GCT CTT CCG ATCT TTG TAA
TGC AAC CTC TGT CAT GC (SEQ ID NO: 392) CLTA4-5-3 rev GTG ACT GGA
GTT CAG ACG TGT GCT CTT CCG ATCT CCA GCT CCA GCA ATC CAT GA (SEQ ID
NO: 393) CLTA4-5-4 rev GTG ACT GGA GTT CAG ACG TGT GCT CTT CCG ATCT
TTT GGG AAA GAT AGC CCT GGA (SEQ ID NO: 394) CLTA4-5-5 rev GTG ACT
GGA GTT CAG ACG TGT GCT CTT CCG ATCT CAA TGA AAC AGC GGG GAG GT
(SEQ ID NO: 395) CLTA4-5-6 rev GTG ACT GGA GTT CAG ACG TGT GCT CTT
CCG ATCT ACA ATC ACG TGT CCT TCA CT (SEQ ID NO: 396) CLTA4-6-1 rev
GTG ACT GGA GTT CAG ACG TGT GCT CTT CCG ATCT CAG ATC CCT CCT GGG
CAA TG (SEQ ID NO: 397) CLTA4-6-2 rev GTG ACT GGA GTT CAG ACG TGT
GCT CTT CCG ATCT GTC AGG AGG CAA GGA GGA AC (SEQ ID NO: 398)
CLTA4-6-3 rev GTG ACT GGA GTT CAG ACG TGT GCT CTT CCG ATCT ACT TCC
TTC CTT TTG AGA CCA AGT (SEQ ID NO: 399) CLTA4-7-1 rev GTG ACT GGA
GTT CAG ACG TGT GCT CTT CCG ATCT GCG GCA GAT TCC TGG TGA TT (SEQ ID
NO: 400) CLTA4-7-2 rev GTG ACT GGA GTT CAG ACG TGT GCT CTT CCG ATCT
GGT CAC CAT CAG CAC AGT CA (SEQ ID NO: 401) PE1-barcode1 CAA GCA
GAA GAC GGC ATA CGA GAT ATA TCA GTG TGA CTG GAG TTC AGA CGT GTG CT
(SEQ ID NO: 402) PE1-barcode2 CAA GCA GAA GAC GGC ATA CGA GAT TTT
CAC CGG TGA CTG GAG TTC AGA CGT GTG CT (SEQ ID NO: 403)
PE1-barcode3 CAA GCA GAA GAC GGC ATA CGA GAT CCA CTC ATG TGA CTG
GAG TTC AGA CGT GTG CT (SEQ ID NO: 404) PE1-barcode4 CAA GCA GAA
GAC GGC ATA CGA GAT TAC GTA CGG TGA CTG GAG TTC AGA CGT GTG CT (SEQ
ID NO: 405)
PE1-barcode5 CAA GCA GAA GAC GGC ATA CGA GAT CGA AAC TCG TGA CTG
GAG TTC AGA CGT GTG CT (SEQ ID NO: 406) PE1-barcode6 CAA GCA GAA
GAC GGC ATA CGA GAT ATC AGT ATG TGA CTG GAG TTC AGA CGT GTG CT (SEQ
ID NO: 407) PE2-barcode1 AAT GAT ACG GCG ACC ACC GAG ATC TAC ACA
TTA CTC GAC ACT CTT TCC CTA CAC GAC (SEQ ID NO: 408) PE2-barcode2
AAT GAT ACG GCG ACC ACC GAG ATC TAC ACT CCG GAG AAC ACT CTT TCC CTA
CAC GAC (SEQ ID NO: 409) PE2-barcode3 AAT GAT ACG GCG ACC ACC GAG
ATC TAC ACC GCT CAT TAC ACT CTT TCC CTA CAC GAC (SEQ ID NO:
410)
REFERENCES
[0198] 1. Hockemeyer, D. et al. Genetic engineering of human
pluripotent cells using TALE nucleases. Nature biotechnology 29,
731-734 (2011). [0199] 2. Zou, J. et al. Gene targeting of a
disease-related gene in human induced pluripotent stem and
embryonic stem cells. Cell stem cell 5, 97-110 (2009). [0200] 3.
Hockemeyer, D. et al. Efficient targeting of expressed and silent
genes in human ESCs and iPSCs using zinc-finger nucleases. Nature
biotechnology 27, 851-857 (2009). [0201] 4. Doyon, Y. et al.
Heritable targeted gene disruption in zebrafish using designed
zinc-finger nucleases. Nature biotechnology 26, 702-708 (2008).
[0202] 5. Meng, X., Noyes, M. B., Zhu, L. J., Lawson, N. D. &
Wolfe, S. A. Targeted gene inactivation in zebrafish using
engineered zinc-finger nucleases. Nature biotechnology 26, 695-701
(2008). [0203] 6. Sander, J. D. et al. Targeted gene disruption in
somatic zebrafish cells using engineered TALENs. Nature
biotechnology 29, 697-698 (2011). [0204] 7. Tesson, L. et al.
Knockout rats generated by embryo microinjection of TALENs. Nature
biotechnology 29, 695-696 (2011). [0205] 8. Cui, X. et al. Targeted
integration in rat and mouse embryos with zinc-finger nucleases.
Nature biotechnology 29, 64-67 (2011). [0206] 9. Perez, E. E. et
al. Establishment of HIV-1 resistance in CD4+ T cells by genome
editing using zinc-finger nucleases. Nature biotechnology 26,
808-816 (2008). [0207] 10. NCT00842634, NCT01044654, NCT01252641,
NCT01082926. [0208] 11. Jinek, M. et al. A programmable
dual-RNA-guided DNA endonuclease in adaptive bacterial immunity.
Science 337, 816-821 (2012). [0209] 12. Cong, L. et al. Multiplex
genome engineering using CRISPR/Cas systems. Science 339, 819-823
(2013). [0210] 13. Mali, P. et al. RNA-guided human genome
engineering via Cas9. Science 339, 823-826 (2013). [0211] 14.
Hwang, W. Y. et al. Efficient genome editing in zebrafish using a
CRISPR-Cas system. Nature biotechnology 31, 227-229 (2013). [0212]
15. Jinek, M. et al. RNA-programmed genome editing in human cells.
eLife 2, e00471 (2013). [0213] 16. Dicarlo, J. E. et al. Genome
engineering in Saccharomyces cerevisiae using CRISPR-Cas systems.
Nucleic acids research (2013). [0214] 17. Jiang, W., Bikard, D.,
Cox, D., Zhang, F. & Marraffini, L. A. RNA-guided editing of
bacterial genomes using CRISPR-Cas systems. Nature biotechnology
31, 233-239 (2013). [0215] 18. Sapranauskas, R. et al. The
Streptococcus thermophilus CRISPR/Cas system provides immunity in
Escherichia coli. Nucleic acids research 39, 9275-9282 (2011).
[0216] 19. Semenova, E. et al. Interference by clustered regularly
interspaced short palindromic repeat (CRISPR) RNA is governed by a
seed sequence. Proceedings of the National Academy of Sciences of
the United States of America 108, 10098-10103 (2011). [0217] 20.
Qi, L. S. et al. Repurposing CRISPR as an RNA-Guided Platform for
Sequence-Specific Control of Gene Expression. Cell 152, 1173-1183
(2013). [0218] 21. Pattanayak, V., Ramirez, C. L., Joung, J. K.
& Liu, D. R. Revealing off-target cleavage specificities of
zinc-finger nucleases by in vitro selection. Nature methods 8,
765-770 (2011). [0219] 22. Doyon, J. B., Pattanayak, V., Meyer, C.
B. & Liu, D. R. Directed evolution and substrate specificity
profile of homing endonuclease I-SceI. Journal of the American
Chemical Society 128, 2477-2484 (2006). [0220] 23. Jiang, W.,
Bikard, D., Cox, D., Zhang, F. & Marraffini, L. A. RNA-guided
editing of bacterial genomes using CRISPR-Cas systems. Nature
biotechnology 31, 233-239 (2013). [0221] 24. Pattanayak, V.,
Ramirez, C. L., Joung, J. K. & Liu, D. R. Revealing off-target
cleavage specificities of zinc-finger nucleases by in vitro
selection. Nature methods 8, 765-770 (2011). [0222] 25. Schneider,
T. D. & Stephens, R. M. Sequence logos: a new way to display
consensus sequences. Nucleic acids research 18, 6097-6100
(1990).
[0223] All publications, patents and sequence database entries
mentioned herein, including those items listed above, are hereby
incorporated by reference in their entirety as if each individual
publication or patent was specifically and individually indicated
to be incorporated by reference. In case of conflict, the present
application, including any definitions herein, will control.
Sequence CWU 1
1
410123DNAArtificial SequenceSynthetic Polynucleotide 1agtcctcatc
tccctcaagc ngg 23248DNAArtificial SequenceSynthetic Oligonucleotide
2atgtctcccg catgcgctca gtcctcatct ccctcaagca ggccccgc
48348DNAArtificial SequenceSynthetic Oligonucleotide 3gcggggcctg
cttgagggag atgaggactg agcgcatgcg ggagacat 48448DNAArtificial
SequenceSynthetic Oligonucleotide 4tggtgcactg aagagccacc ctgtggaaac
actacatctg caatatct 48548DNAArtificial SequenceSynthetic
Oligonucleotide 5agatattgca gatgtagtgt ttccacaggg tggctcttca
gtgcacca 48648DNAArtificial SequenceSynthetic Oligonucleotide
6taatcctact cagtgaagct cttcacagtc attggattaa ttatgttg
48748DNAArtificial SequenceSynthetic Oligonucleotide 7caacataatt
aatccaatga ctgtgaagag cttcactgag taggatta 48823DNAArtificial
SequenceSynthetic Oligonucleotide 8agtcctcatc tccctcaagc agg
23923DNAArtificial SequenceSynthetic Oligonucleotide 9cctgcttgag
ggagatgagg act 231060RNAArtificial SequenceSynthetic
Oligonucleotide 10gaguccucau cucccucaag cguuuuagag cuagaaauag
cuuaaaauaa ggcuaguccg 601123DNAArtificial SequenceSynthetic
Oligonucleotide 11ctccctcaag caggccccgc tgg 231223DNAArtificial
SequenceSynthetic Oligonucleotide 12ccagcggggc ctgcttgagg gag
231360RNAArtificial SequenceSynthetic Oligonucleotide 13gcucccucaa
gcaggccccg cguuuuagag cuagaaauag cuuaaaauaa ggcuaguccg
601423DNAArtificial SequenceSynthetic Oligonucleotide 14tgtgaagagc
ttcactgagt agg 231523DNAArtificial SequenceSynthetic
Oligonucleotide 15cctactcagt gaagctcttc aca 231660RNAArtificial
SequenceSynthetic Oligonucleotide 16gugugaagag cuucacugag
uguuuuagag cuagaaauag cuuaaaauaa ggcuaguccg 601723DNAArtificial
SequenceSynthetic Oligonucleotide 17gcagatgtag tgtttccaca ggg
231823DNAArtificial SequenceSynthetic Oligonucleotide 18ccctgtggaa
acactacatc tgc 231960RNAArtificial SequenceSynthetic
Oligonucleotide 19ggcagaugua guguuuccac aguuuuagag cuagaaauag
cuuaaaauaa ggcuaguccg 602023DNAArtificial SequenceSynthetic
Oligonucleotide 20agtcctcatc tccctcaagc agg 232123DNAArtificial
SequenceSynthetic Oligonucleotide 21cctgcttgag ggagatgagg act
232273RNAArtificial SequenceSynthetic Oligonucleotide 22gaguccucau
cucccucaag cguuuuagag cuaugcugaa aagcauagcu uaaaauaagg 60cuaguccguu
auc 732323DNAArtificial SequenceSynthetic Oligonucleotide
23ctccctcaag caggccccgc tgg 232423DNAArtificial SequenceSynthetic
Oligonucleotide 24ccagcggggc ctgcttgagg gag 232573RNAArtificial
SequenceSynthetic Oligonucleotide 25gcucccucaa gcaggccccg
cguuuuagag cuaugcugaa aagcauagcu uaaaauaagg 60cuaguccguu auc
732623DNAArtificial SequenceSynthetic Oligonucleotide 26tgtgaagagc
ttcactgagt agg 232723DNAArtificial SequenceSynthetic
Oligonucleotide 27cctactcagt gaagctcttc aca 232873RNAArtificial
SequenceSynthetic Oligonucleotide 28gugugaagag cuucacugag
uguuuuagag cuaugcugaa aagcauagcu uaaaauaagg 60cuaguccguu auc
732923DNAArtificial SequenceSynthetic Oligonucleotide 29gcagatgtag
tgtttccaca ggg 233023DNAArtificial SequenceSynthetic
Oligonucleotide 30ccctgtggaa acactacatc tgc 233173RNAArtificial
SequenceSynthetic Oligonucleotide 31ggcagaugua guguuuccac
aguuuuagag cuaugcugaa aagcauagcu uaaaauaagg 60cuaguccguu auc
733223DNAArtificial SequenceSynthetic Oligonucleotide 32ctccctcaag
caggccccgc ngg 233323DNAArtificial SequenceSynthetic
Oligonucleotide 33gcagatgtag tgtttccaca ngg 233423DNAArtificial
SequenceSynthetic Oligonucleotide 34gcagatgtag tgtttccaca ggg
233523DNAArtificial SequenceSynthetic Oligonucleotide 35gaagatgtag
tgtttccaca ggg 233623DNAArtificial SequenceSynthetic
Oligonucleotide 36gaagatgtag tgtttccact ggg 233723DNAArtificial
SequenceSynthetic Oligonucleotide 37gcagatggag ggtttccaca ggg
233823DNAArtificial SequenceSynthetic Oligonucleotide 38gcagatgtag
tgttaccaga ggg 233923DNAArtificial SequenceSynthetic
Oligonucleotide 39ggggatgtag tgtttccact ggg 23404104DNAArtificial
SequenceSynthetic Oligonucleotide 40atggataaga aatactcaat
aggcttagat atcggcacaa atagcgtcgg atgggcggtg 60atcactgatg attataaggt
tccgtctaaa aagttcaagg ttctgggaaa tacagaccgc 120cacagtatca
aaaaaaatct tataggggct cttttatttg gcagtggaga gacagcggaa
180gcgactcgtc tcaaacggac agctcgtaga aggtatacac gtcggaagaa
tcgtatttgt 240tatctacagg agattttttc aaatgagatg gcgaaagtag
atgatagttt ctttcatcga 300cttgaagagt cttttttggt ggaagaagac
aagaagcatg aacgtcatcc tatttttgga 360aatatagtag atgaagttgc
ttatcatgag aaatatccaa ctatctatca tctgcgaaaa 420aaattggcag
attctactga taaagcggat ttgcgcttaa tctatttggc cttagcgcat
480atgattaagt ttcgtggtca ttttttgatt gagggagatt taaatcctga
taatagtgat 540gtggacaaac tatttatcca gttggtacaa atctacaatc
aattatttga agaaaaccct 600attaacgcaa gtagagtaga tgctaaagcg
attctttctg cacgattgag taaatcaaga 660cgattagaaa atctcattgc
tcagctcccc ggtgagaaga gaaatggctt gtttgggaat 720ctcattgctt
tgtcattggg attgacccct aattttaaat caaattttga tttggcagaa
780gatgctaaat tacagctttc aaaagatact tacgatgatg atttagataa
tttattggcg 840caaattggag atcaatatgc tgatttgttt ttggcagcta
agaatttatc agatgctatt 900ttactttcag atatcctaag agtaaatagt
gaaataacta aggctcccct atcagcttca 960atgattaagc gctacgatga
acatcatcaa gacttgactc ttttaaaagc tttagttcga 1020caacaacttc
cagaaaagta taaagaaatc ttttttgatc aatcaaaaaa cggatatgca
1080ggttatattg atgggggagc tagccaagaa gaattttata aatttatcaa
accaatttta 1140gaaaaaatgg atggtactga ggaattattg gtgaaactaa
atcgtgaaga tttgctgcgc 1200aagcaacgga cctttgacaa cggctctatt
ccccatcaaa ttcacttggg tgagctgcat 1260gctattttga gaagacaaga
agacttttat ccatttttaa aagacaatcg tgagaagatt 1320gaaaaaatct
tgacttttcg aattccttat tatgttggtc cattggcgcg tggcaatagt
1380cgttttgcat ggatgactcg gaagtctgaa gaaacaatta ccccatggaa
ttttgaagaa 1440gttgtcgata aaggtgcttc agctcaatca tttattgaac
gcatgacaaa ctttgataaa 1500aatcttccaa atgaaaaagt actaccaaaa
catagtttgc tttatgagta ttttacggtt 1560tataacgaat tgacaaaggt
caaatatgtt actgagggaa tgcgaaaacc agcatttctt 1620tcaggtgaac
agaagaaagc cattgttgat ttactcttca aaacaaatcg aaaagtaacc
1680gttaagcaat taaaagaaga ttatttcaaa aaaatagaat gttttgatag
tgttgaaatt 1740tcaggagttg aagatagatt taatgcttca ttaggcgcct
accatgattt gctaaaaatt 1800attaaagata aagatttttt ggataatgaa
gaaaatgaag atatcttaga ggatattgtt 1860ttaacattga ccttatttga
agataggggg atgattgagg aaagacttaa aacatatgct 1920cacctctttg
atgataaggt gatgaaacag cttaaacgtc gccgttatac tggttgggga
1980cgtttgtctc gaaaattgat taatggtatt agggataagc aatctggcaa
aacaatatta 2040gattttttga aatcagatgg ttttgccaat cgcaatttta
tgcagctgat ccatgatgat 2100agtttgacat ttaaagaaga tattcaaaaa
gcacaggtgt ctggacaagg ccatagttta 2160catgaacaga ttgctaactt
agctggcagt cctgctatta aaaaaggtat tttacagact 2220gtaaaaattg
ttgatgaact ggtcaaagta atggggcata agccagaaaa tatcgttatt
2280gaaatggcac gtgaaaatca gacaactcaa aagggccaga aaaattcgcg
agagcgtatg 2340aaacgaatcg aagaaggtat caaagaatta ggaagtcaga
ttcttaaaga gcatcctgtt 2400gaaaatactc aattgcaaaa tgaaaagctc
tatctctatt atctacaaaa tggaagagac 2460atgtatgtgg accaagaatt
agatattaat cgtttaagtg attatgatgt cgatcacatt 2520gttccacaaa
gtttcattaa agacgattca atagacaata aggtactaac gcgttctgat
2580aaaaatcgtg gtaaatcgga taacgttcca agtgaagaag tagtcaaaaa
gatgaaaaac 2640tattggagac aacttctaaa cgccaagtta atcactcaac
gtaagtttga taatttaacg 2700aaagctgaac gtggaggttt gagtgaactt
gataaagctg gttttatcaa acgccaattg 2760gttgaaactc gccaaatcac
taagcatgtg gcacaaattt tggatagtcg catgaatact 2820aaatacgatg
aaaatgataa acttattcga gaggttaaag tgattacctt aaaatctaaa
2880ttagtttctg acttccgaaa agatttccaa ttctataaag tacgtgagat
taacaattac 2940catcatgccc atgatgcgta tctaaatgcc gtcgttggaa
ctgctttgat taagaaatat 3000ccaaaacttg aatcggagtt tgtctatggt
gattataaag tttatgatgt tcgtaaaatg 3060attgctaagt ctgagcaaga
aataggcaaa gcaaccgcaa aatatttctt ttactctaat 3120atcatgaact
tcttcaaaac agaaattaca cttgcaaatg gagagattcg caaacgccct
3180ctaatcgaaa ctaatgggga aactggagaa attgtctggg ataaagggcg
agattttgcc 3240acagtgcgca aagtattgtc catgccccaa gtcaatattg
tcaagaaaac agaagtacag 3300acaggcggat tctccaagga gtcaatttta
ccaaaaagaa attcggacaa gcttattgct 3360cgtaaaaaag actgggatcc
aaaaaaatat ggtggttttg atagtccaac ggtagcttat 3420tcagtcctag
tggttgctaa ggtggaaaaa gggaaatcga agaagttaaa atccgttaaa
3480gagttactag ggatcacaat tatggaaaga agttcctttg aaaaaaatcc
gattgacttt 3540ttagaagcta aaggatataa ggaagttaaa aaagacttaa
tcattaaact acctaaatat 3600agtctttttg agttagaaaa cggtcgtaaa
cggatgctgg ctagtgccgg agaattacaa 3660aaaggaaatg agctggctct
gccaagcaaa tatgtgaatt ttttatattt agctagtcat 3720tatgaaaagt
tgaagggtag tccagaagat aacgaacaaa aacaattgtt tgtggagcag
3780cataagcatt atttagatga gattattgag caaatcagtg aattttctaa
gcgtgttatt 3840ttagcagatg ccaatttaga taaagttctt agtgcatata
acaaacatag agacaaacca 3900atacgtgaac aagcagaaaa tattattcat
ttatttacgt tgacgaatct tggagctccc 3960gctgctttta aatattttga
tacaacaatt gatcgtaaac gatatacgtc tacaaaagaa 4020gttttagatg
ccactcttat ccatcaatcc atcactggtc tttatgaaac acgcattgat
4080ttgagtcagc taggaggtga ctga 4104411367PRTArtificial
SequenceSynthetic Polypeptide 41Met Asp Lys Lys Tyr Ser Ile Gly Leu
Asp Ile Gly Thr Asn Ser Val 1 5 10 15 Gly Trp Ala Val Ile Thr Asp
Asp Tyr Lys Val Pro Ser Lys Lys Phe 20 25 30 Lys Val Leu Gly Asn
Thr Asp Arg His Ser Ile Lys Lys Asn Leu Ile 35 40 45 Gly Ala Leu
Leu Phe Gly Ser Gly Glu Thr Ala Glu Ala Thr Arg Leu 50 55 60 Lys
Arg Thr Ala Arg Arg Arg Tyr Thr Arg Arg Lys Asn Arg Ile Cys 65 70
75 80 Tyr Leu Gln Glu Ile Phe Ser Asn Glu Met Ala Lys Val Asp Asp
Ser 85 90 95 Phe Phe His Arg Leu Glu Glu Ser Phe Leu Val Glu Glu
Asp Lys Lys 100 105 110 His Glu Arg His Pro Ile Phe Gly Asn Ile Val
Asp Glu Val Ala Tyr 115 120 125 His Glu Lys Tyr Pro Thr Ile Tyr His
Leu Arg Lys Lys Leu Ala Asp 130 135 140 Ser Thr Asp Lys Ala Asp Leu
Arg Leu Ile Tyr Leu Ala Leu Ala His 145 150 155 160 Met Ile Lys Phe
Arg Gly His Phe Leu Ile Glu Gly Asp Leu Asn Pro 165 170 175 Asp Asn
Ser Asp Val Asp Lys Leu Phe Ile Gln Leu Val Gln Ile Tyr 180 185 190
Asn Gln Leu Phe Glu Glu Asn Pro Ile Asn Ala Ser Arg Val Asp Ala 195
200 205 Lys Ala Ile Leu Ser Ala Arg Leu Ser Lys Ser Arg Arg Leu Glu
Asn 210 215 220 Leu Ile Ala Gln Leu Pro Gly Glu Lys Arg Asn Gly Leu
Phe Gly Asn 225 230 235 240 Leu Ile Ala Leu Ser Leu Gly Leu Thr Pro
Asn Phe Lys Ser Asn Phe 245 250 255 Asp Leu Ala Glu Asp Ala Lys Leu
Gln Leu Ser Lys Asp Thr Tyr Asp 260 265 270 Asp Asp Leu Asp Asn Leu
Leu Ala Gln Ile Gly Asp Gln Tyr Ala Asp 275 280 285 Leu Phe Leu Ala
Ala Lys Asn Leu Ser Asp Ala Ile Leu Leu Ser Asp 290 295 300 Ile Leu
Arg Val Asn Ser Glu Ile Thr Lys Ala Pro Leu Ser Ala Ser 305 310 315
320 Met Ile Lys Arg Tyr Asp Glu His His Gln Asp Leu Thr Leu Leu Lys
325 330 335 Ala Leu Val Arg Gln Gln Leu Pro Glu Lys Tyr Lys Glu Ile
Phe Phe 340 345 350 Asp Gln Ser Lys Asn Gly Tyr Ala Gly Tyr Ile Asp
Gly Gly Ala Ser 355 360 365 Gln Glu Glu Phe Tyr Lys Phe Ile Lys Pro
Ile Leu Glu Lys Met Asp 370 375 380 Gly Thr Glu Glu Leu Leu Val Lys
Leu Asn Arg Glu Asp Leu Leu Arg 385 390 395 400 Lys Gln Arg Thr Phe
Asp Asn Gly Ser Ile Pro His Gln Ile His Leu 405 410 415 Gly Glu Leu
His Ala Ile Leu Arg Arg Gln Glu Asp Phe Tyr Pro Phe 420 425 430 Leu
Lys Asp Asn Arg Glu Lys Ile Glu Lys Ile Leu Thr Phe Arg Ile 435 440
445 Pro Tyr Tyr Val Gly Pro Leu Ala Arg Gly Asn Ser Arg Phe Ala Trp
450 455 460 Met Thr Arg Lys Ser Glu Glu Thr Ile Thr Pro Trp Asn Phe
Glu Glu 465 470 475 480 Val Val Asp Lys Gly Ala Ser Ala Gln Ser Phe
Ile Glu Arg Met Thr 485 490 495 Asn Phe Asp Lys Asn Leu Pro Asn Glu
Lys Val Leu Pro Lys His Ser 500 505 510 Leu Leu Tyr Glu Tyr Phe Thr
Val Tyr Asn Glu Leu Thr Lys Val Lys 515 520 525 Tyr Val Thr Glu Gly
Met Arg Lys Pro Ala Phe Leu Ser Gly Glu Gln 530 535 540 Lys Lys Ala
Ile Val Asp Leu Leu Phe Lys Thr Asn Arg Lys Val Thr 545 550 555 560
Val Lys Gln Leu Lys Glu Asp Tyr Phe Lys Lys Ile Glu Cys Phe Asp 565
570 575 Ser Val Glu Ile Ser Gly Val Glu Asp Arg Phe Asn Ala Ser Leu
Gly 580 585 590 Ala Tyr His Asp Leu Leu Lys Ile Ile Lys Asp Lys Asp
Phe Leu Asp 595 600 605 Asn Glu Glu Asn Glu Asp Ile Leu Glu Asp Ile
Val Leu Thr Leu Thr 610 615 620 Leu Phe Glu Asp Arg Gly Met Ile Glu
Glu Arg Leu Lys Thr Tyr Ala 625 630 635 640 His Leu Phe Asp Asp Lys
Val Met Lys Gln Leu Lys Arg Arg Arg Tyr 645 650 655 Thr Gly Trp Gly
Arg Leu Ser Arg Lys Leu Ile Asn Gly Ile Arg Asp 660 665 670 Lys Gln
Ser Gly Lys Thr Ile Leu Asp Phe Leu Lys Ser Asp Gly Phe 675 680 685
Ala Asn Arg Asn Phe Met Gln Leu Ile His Asp Asp Ser Leu Thr Phe 690
695 700 Lys Glu Asp Ile Gln Lys Ala Gln Val Ser Gly Gln Gly His Ser
Leu 705 710 715 720 His Glu Gln Ile Ala Asn Leu Ala Gly Ser Pro Ala
Ile Lys Lys Gly 725 730 735 Ile Leu Gln Thr Val Lys Ile Val Asp Glu
Leu Val Lys Val Met Gly 740 745 750 His Lys Pro Glu Asn Ile Val Ile
Glu Met Ala Arg Glu Asn Gln Thr 755 760 765 Thr Gln Lys Gly Gln Lys
Asn Ser Arg Glu Arg Met Lys Arg Ile Glu 770 775 780 Glu Gly Ile Lys
Glu Leu Gly Ser Gln Ile Leu Lys Glu His Pro Val 785 790 795 800 Glu
Asn Thr Gln Leu Gln Asn Glu Lys Leu Tyr Leu Tyr Tyr Leu Gln 805 810
815 Asn Gly Arg Asp Met Tyr Val Asp Gln Glu Leu Asp Ile Asn Arg Leu
820 825 830 Ser Asp Tyr Asp Val Asp His Ile Val Pro Gln Ser Phe Ile
Lys Asp 835 840 845 Asp Ser Ile Asp Asn Lys Val Leu Thr Arg Ser Asp
Lys Asn Arg Gly 850 855 860 Lys Ser Asp Asn Val Pro Ser Glu Glu Val
Val Lys Lys Met Lys Asn 865 870 875 880 Tyr Trp Arg Gln Leu Leu Asn
Ala Lys Leu Ile Thr Gln Arg Lys Phe 885 890 895 Asp Asn Leu Thr Lys
Ala Glu Arg Gly Gly Leu Ser Glu Leu Asp
Lys 900 905 910 Ala Gly Phe Ile Lys Arg Gln Leu Val Glu Thr Arg Gln
Ile Thr Lys 915 920 925 His Val Ala Gln Ile Leu Asp Ser Arg Met Asn
Thr Lys Tyr Asp Glu 930 935 940 Asn Asp Lys Leu Ile Arg Glu Val Lys
Val Ile Thr Leu Lys Ser Lys 945 950 955 960 Leu Val Ser Asp Phe Arg
Lys Asp Phe Gln Phe Tyr Lys Val Arg Glu 965 970 975 Ile Asn Asn Tyr
His His Ala His Asp Ala Tyr Leu Asn Ala Val Val 980 985 990 Gly Thr
Ala Leu Ile Lys Lys Tyr Pro Lys Leu Glu Ser Glu Phe Val 995 1000
1005 Tyr Gly Asp Tyr Lys Val Tyr Asp Val Arg Lys Met Ile Ala Lys
1010 1015 1020 Ser Glu Gln Glu Ile Gly Lys Ala Thr Ala Lys Tyr Phe
Phe Tyr 1025 1030 1035 Ser Asn Ile Met Asn Phe Phe Lys Thr Glu Ile
Thr Leu Ala Asn 1040 1045 1050 Gly Glu Ile Arg Lys Arg Pro Leu Ile
Glu Thr Asn Gly Glu Thr 1055 1060 1065 Gly Glu Ile Val Trp Asp Lys
Gly Arg Asp Phe Ala Thr Val Arg 1070 1075 1080 Lys Val Leu Ser Met
Pro Gln Val Asn Ile Val Lys Lys Thr Glu 1085 1090 1095 Val Gln Thr
Gly Gly Phe Ser Lys Glu Ser Ile Leu Pro Lys Arg 1100 1105 1110 Asn
Ser Asp Lys Leu Ile Ala Arg Lys Lys Asp Trp Asp Pro Lys 1115 1120
1125 Lys Tyr Gly Gly Phe Asp Ser Pro Thr Val Ala Tyr Ser Val Leu
1130 1135 1140 Val Val Ala Lys Val Glu Lys Gly Lys Ser Lys Lys Leu
Lys Ser 1145 1150 1155 Val Lys Glu Leu Leu Gly Ile Thr Ile Met Glu
Arg Ser Ser Phe 1160 1165 1170 Glu Lys Asn Pro Ile Asp Phe Leu Glu
Ala Lys Gly Tyr Lys Glu 1175 1180 1185 Val Lys Lys Asp Leu Ile Ile
Lys Leu Pro Lys Tyr Ser Leu Phe 1190 1195 1200 Glu Leu Glu Asn Gly
Arg Lys Arg Met Leu Ala Ser Ala Gly Glu 1205 1210 1215 Leu Gln Lys
Gly Asn Glu Leu Ala Leu Pro Ser Lys Tyr Val Asn 1220 1225 1230 Phe
Leu Tyr Leu Ala Ser His Tyr Glu Lys Leu Lys Gly Ser Pro 1235 1240
1245 Glu Asp Asn Glu Gln Lys Gln Leu Phe Val Glu Gln His Lys His
1250 1255 1260 Tyr Leu Asp Glu Ile Ile Glu Gln Ile Ser Glu Phe Ser
Lys Arg 1265 1270 1275 Val Ile Leu Ala Asp Ala Asn Leu Asp Lys Val
Leu Ser Ala Tyr 1280 1285 1290 Asn Lys His Arg Asp Lys Pro Ile Arg
Glu Gln Ala Glu Asn Ile 1295 1300 1305 Ile His Leu Phe Thr Leu Thr
Asn Leu Gly Ala Pro Ala Ala Phe 1310 1315 1320 Lys Tyr Phe Asp Thr
Thr Ile Asp Arg Lys Arg Tyr Thr Ser Thr 1325 1330 1335 Lys Glu Val
Leu Asp Ala Thr Leu Ile His Gln Ser Ile Thr Gly 1340 1345 1350 Leu
Tyr Glu Thr Arg Ile Asp Leu Ser Gln Leu Gly Gly Asp 1355 1360 1365
42100DNAArtificial SequenceSynthetic Oligonucleotide 42aacacatggg
tcgacacaaa cacaactcgg caggtacttg cagatgtagt ctttccacat 60gggtcgacac
aaacacaact cggcaggtat ctcgtatgcc 1004310DNAArtificial
SequenceSynthetic Oligonucleotide 43ctcggcaggt 104443DNAArtificial
SequenceSynthetic Oligonucleotide 44acttgcagat gtagtctttc
cacatgggtc gacacaaaca caa 434512DNAArtificial SequenceSynthetic
Oligonucleotide 45tgtgtttgtg tt 124612DNAArtificial
SequenceSynthetic Oligonucleotide 46agaagaagaa ga
124712DNAArtificial SequenceSynthetic Oligonucleotide 47ttctctttct
ct 124812DNAArtificial SequenceSynthetic Oligonucleotide
48acacaaacac aa 124943DNAArtificial SequenceSynthetic
Oligonucleotide 49acttgcagat gtagtctttc cacatgggtc gacacaaaca caa
435031DNAArtificial SequenceSynthetic Oligonucleotide 50acttgcagat
gtagtctttc cacatgggtc g 3151100DNAArtificial SequenceSynthetic
Oligonucleotide 51aacacatggg tcgacacaaa cacaactcgg caggtacttg
cagatgtagt ctttccacat 60gggtcgacac aaacacaact cggcaggtat ctcgtatgcc
10052162DNAArtificial SequenceSynthetic Oligonucleotide
52caatctcccg catgcgctca gtcctcatct ccctcaagca ggccccgctg gtgcactgaa
60gagccaccct gtgaaacact acatctgcaa tatcttaatc ctactcagtg aagctcttca
120cagtcattgg attaattatg ttgagttctt ttggaccaaa cc
1625320DNAArtificial SequenceSynthetic Oligonucleotide 53gctggtgcac
tgaagagcca 205420DNAArtificial SequenceSynthetic Oligonucleotide
54aatatcttaa tcctactcag 205522DNAArtificial SequenceSynthetic
Oligonucleotide 55ccctgtgaaa cactacatct gc 225622DNAArtificial
SequenceSynthetic Oligonucleotide 56gcagatgtag tgtttcacag gg
225723DNAArtificial SequenceSynthetic Oligonucleotide 57gcagatgtag
tgtttccaca ggg 235823DNAArtificial SequenceSynthetic
Oligonucleotide 58gcagatgtag tgtttccaca ggg 235923DNAArtificial
SequenceSynthetic Oligonucleotide 59acatatgtag tatttccaca ggg
236023DNAArtificial SequenceSynthetic Oligonucleotide 60gcatatgtag
tgtttccaaa tgt 236123DNAArtificial SequenceSynthetic
Oligonucleotide 61ccagatgtag tattcccaca ggg 236223DNAArtificial
SequenceSynthetic Oligonucleotide 62gcagttttag tgttttcaca ggg
236323DNAArtificial SequenceSynthetic Oligonucleotide 63gcagagttag
tgtttccaca cag 236423DNAArtificial SequenceSynthetic
Oligonucleotide 64gcagatggag ggttttcaca ggg 236523DNAArtificial
SequenceSynthetic Oligonucleotide 65ggaaatttag tgtttccaca ggg
236623DNAArtificial SequenceSynthetic Oligonucleotide 66aaagaagtag
tatttccaca tgg 236723DNAArtificial SequenceSynthetic
Oligonucleotide 67aaagatgtag tcattccaca agg 236823DNAArtificial
SequenceSynthetic Oligonucleotide 68aaatatgtag tctttccaca ggg
236923DNAArtificial SequenceSynthetic Oligonucleotide 69atagatgtag
tgtttccaaa gga 237023DNAArtificial SequenceSynthetic
Oligonucleotide 70ccagaggtag tgctcccaca ggg 237123DNAArtificial
SequenceSynthetic Oligonucleotide 71ccagatgtga ggtttccaca agg
237223DNAArtificial SequenceSynthetic Oligonucleotide 72ctacatgtag
tgtttccata tgg 237322DNAArtificial SequenceSynthetic
Oligonucleotide 73tagatgaagt gcttccacat gg 227423DNAArtificial
SequenceSynthetic Oligonucleotide 74gaaaatggag tgtttacaca tgg
237523DNAArtificial SequenceSynthetic Oligonucleotide 75gcaaatgaag
tgtcaccaca agg 237623DNAArtificial SequenceSynthetic
Oligonucleotide 76gcaaatgtat tatttccact agg 237723DNAArtificial
SequenceSynthetic Oligonucleotide 77gcagatgtag cttttgtaca tgg
237823DNAArtificial SequenceSynthetic Oligonucleotide 78gcagcttaag
tgttttcaca tgg 237923DNAArtificial SequenceSynthetic
Oligonucleotide 79ttacatgtag tgtttacaca cgg 238023DNAArtificial
SequenceSynthetic Oligonucleotide 80gaagaggaag tgtttgccca ggg
238123DNAArtificial SequenceSynthetic Oligonucleotide 81gaagatgtgg
agttgacaca tgg 238223DNAArtificial SequenceSynthetic
Oligonucleotide 82gcagaagtac tgttgttaca agg 238323DNAArtificial
SequenceSynthetic Oligonucleotide 83gcagatgtgg aattacaaca ggg
238423DNAArtificial SequenceSynthetic Oligonucleotide 84gcagtcatag
tgtatacaca tgg 238523DNAArtificial SequenceSynthetic
Oligonucleotide 85taagatgtag tatttccaaa agt 238623DNAArtificial
SequenceSynthetic Oligonucleotide 86gcagctggca tttctccaca cgg
238723DNAArtificial SequenceSynthetic Oligonucleotide 87ggagatctga
tggttctaca agg 238823DNAArtificial SequenceSynthetic
Oligonucleotide 88taaaatgcag tgtatccata tgg 238923DNAArtificial
SequenceSynthetic Oligonucleotide 89gccagaatag tttttcaaca agg
239023DNAArtificial SequenceSynthetic Oligonucleotide 90ttgtatttag
agattgcaca agg 239123DNAArtificial SequenceSynthetic
Oligonucleotide 91agtcctcatc tccctcaagc agg 239223DNAArtificial
SequenceSynthetic Oligonucleotide 92agtcctcaac tccctcaagc agg
239323DNAArtificial SequenceSynthetic Oligonucleotide 93agccctcatt
tccctcaagc agg 239423DNAArtificial SequenceSynthetic
Oligonucleotide 94actcctcatc cccctcaagc cgg 239523DNAArtificial
SequenceSynthetic Oligonucleotide 95agtcatcatc tccctcaagc aga
239623DNAArtificial SequenceSynthetic Oligonucleotide 96cgtcctcctc
tcccccaagc agg 239723DNAArtificial SequenceSynthetic
Oligonucleotide 97tgtcctcttc tccctcaagc aga 239823DNAArtificial
SequenceSynthetic Oligonucleotide 98aagcttcatc tctctcaagc tgg
239923DNAArtificial SequenceSynthetic Oligonucleotide 99agtactcttt
tccctcaggc tgg 2310023DNAArtificial SequenceSynthetic
Oligonucleotide 100agtcttaaat tccctcaagc agg 2310123DNAArtificial
SequenceSynthetic Oligonucleotide 101agtgctcatc taccagaagc tgg
2310223DNAArtificial SequenceSynthetic Oligonucleotide
102cctcctcatc tccctgcagc agg 2310323DNAArtificial SequenceSynthetic
Oligonucleotide 103ctacatcatc tccctcaagc tgg 2310423DNAArtificial
SequenceSynthetic Oligonucleotide 104ggtcctcatc tccctaaaac aga
2310523DNAArtificial SequenceSynthetic Oligonucleotide
105tgtcctcatc ggcctcaggc agg 2310623DNAArtificial SequenceSynthetic
Oligonucleotide 106agacaccatc tcccttgagc tgg 2310723DNAArtificial
SequenceSynthetic Oligonucleotide 107aggcatcatc tacatcaagt tgg
2310823DNAArtificial SequenceSynthetic Oligonucleotide
108agtaatcact tccatcaagc cgg 2310923DNAArtificial SequenceSynthetic
Oligonucleotide 109tcccctcacc tccctaaagc agg 2311023DNAArtificial
SequenceSynthetic Oligonucleotide 110tgtctttatt tccctctagc tgg
2311123DNAArtificial SequenceSynthetic Oligonucleotide
111agtcctcatc tccctcaagc agg 2311223DNAArtificial SequenceSynthetic
Oligonucleotide 112gcagatgtag tgtttccaca ggg 2311323DNAArtificial
SequenceSynthetic Oligonucleotide 113acatatgtag tatttccaca ggg
2311423DNAArtificial SequenceSynthetic Oligonucleotide
114gcatatgtag tgtttccaaa tgt 2311523DNAArtificial SequenceSynthetic
Oligonucleotide 115ccagatgtag tattcccaca ggg 2311623DNAArtificial
SequenceSynthetic Oligonucleotide 116gcagttttag tgttttcaca ggg
2311723DNAArtificial SequenceSynthetic Oligonucleotide
117gcagagttag tgtttccaca cag 2311823DNAArtificial SequenceSynthetic
Oligonucleotide 118gcagatggag ggttttcaca ggg 2311923DNAArtificial
SequenceSynthetic Oligonucleotide 119ggaaatttag tgtttccaca ggg
2312023DNAArtificial SequenceSynthetic Oligonucleotide
120aaagaagtag tatttccaca tgg 2312123DNAArtificial SequenceSynthetic
Oligonucleotide 121aaagatgtag tcattccaca agg 2312223DNAArtificial
SequenceSynthetic Oligonucleotide 122aaatatgtag tctttccaca ggg
2312323DNAArtificial SequenceSynthetic Oligonucleotide
123atagatgtag tgtttccaaa gga 2312423DNAArtificial SequenceSynthetic
Oligonucleotide 124ccagaggtag tgctcccaca ggg 2312523DNAArtificial
SequenceSynthetic Oligonucleotide 125ccagatgtga ggtttccaca agg
2312623DNAArtificial SequenceSynthetic Oligonucleotide
126ctacatgtag tgtttccata tgg 2312723DNAArtificial SequenceSynthetic
Oligonucleotide 127ctagatgaag tgcttccaca tgg 2312823DNAArtificial
SequenceSynthetic Oligonucleotide 128gaaaatggag tgtttacaca tgg
2312923DNAArtificial SequenceSynthetic Oligonucleotide
129gcaaatgaag tgtcaccaca agg 2313023DNAArtificial SequenceSynthetic
Oligonucleotide 130gcaaatgtat tatttccact agg 2313123DNAArtificial
SequenceSynthetic Oligonucleotide 131gcagatgtag cttttgtaca tgg
2313223DNAArtificial SequenceSynthetic Oligonucleotide
132gcagcttaag tgttttcaca tgg 2313323DNAArtificial SequenceSynthetic
Oligonucleotide 133ttacatgtag tgtttacaca cgg 2313423DNAArtificial
SequenceSynthetic Oligonucleotide 134gaagaggaag tgtttgccca ggg
2313523DNAArtificial SequenceSynthetic Oligonucleotide
135gaagatgtgg agttgacaca tgg 2313623DNAArtificial SequenceSynthetic
Oligonucleotide 136gcagaagtac tgttgttaca agg 2313723DNAArtificial
SequenceSynthetic Oligonucleotide 137gcagatgtgg aattacaaca ggg
2313823DNAArtificial SequenceSynthetic Oligonucleotide
138gcagtcatag tgtatacaca tgg 2313923DNAArtificial SequenceSynthetic
Oligonucleotide 139taagatgtag tatttccaaa agt
2314023DNAArtificial SequenceSynthetic Oligonucleotide
140gcagctggca tttctccaca cgg 2314123DNAArtificial SequenceSynthetic
Oligonucleotide 141ggagatctga tggttctaca agg 2314223DNAArtificial
SequenceSynthetic Oligonucleotide 142taaaatgcag tgtatccata tgg
2314323DNAArtificial SequenceSynthetic Oligonucleotide
143gccagaatag tttttcaaca agg 2314423DNAArtificial SequenceSynthetic
Oligonucleotide 144ttgtatttag agattgcaca agg 2314523DNAArtificial
SequenceSynthetic Oligonucleotide 145agtcctcatc tccctcaagc agg
2314623DNAArtificial SequenceSynthetic Oligonucleotide
146agtcctcaac tccctcaagc agg 2314723DNAArtificial SequenceSynthetic
Oligonucleotide 147agccctcatt tccctcaagc agg 2314823DNAArtificial
SequenceSynthetic Oligonucleotide 148actcctcatc cccctcaagc cgg
2314923DNAArtificial SequenceSynthetic Oligonucleotide
149agtcatcatc tccctcaagc aga 2315023DNAArtificial SequenceSynthetic
Oligonucleotide 150cgtcctcctc tcccccaagc agg 2315123DNAArtificial
SequenceSynthetic Oligonucleotide 151tgtcctcttc tccctcaagc aga
2315223DNAArtificial SequenceSynthetic Oligonucleotide
152aagcttcatc tctctcaagc tgg 2315323DNAArtificial SequenceSynthetic
Oligonucleotide 153agtactcttt tccctcaggc tgg 2315423DNAArtificial
SequenceSynthetic Oligonucleotide 154agtcttaaat tccctcaagc agg
2315523DNAArtificial SequenceSynthetic Oligonucleotide
155agtgctcatc taccagaagc tgg 2315623DNAArtificial SequenceSynthetic
Oligonucleotide 156cctcctcatc tccctgcagc agg 2315723DNAArtificial
SequenceSynthetic Oligonucleotide 157ctacatcatc tccctcaagc tgg
2315823DNAArtificial SequenceSynthetic Oligonucleotide
158ggtcctcatc tccctaaaac aga 2315923DNAArtificial SequenceSynthetic
Oligonucleotide 159tgtcctcatc ggcctcaggc agg 2316023DNAArtificial
SequenceSynthetic Oligonucleotide 160agacaccatc tcccttgagc tgg
2316123DNAArtificial SequenceSynthetic Oligonucleotide
161aggcatcatc tacatcaagt tgg 2316223DNAArtificial SequenceSynthetic
Oligonucleotide 162agtaatcact tccatcaagc cgg 2316323DNAArtificial
SequenceSynthetic Oligonucleotide 163tcccctcacc tccctaaagc agg
2316423DNAArtificial SequenceSynthetic Oligonucleotide
164tgtctttatt tccctctagc tgg 2316523DNAArtificial SequenceSynthetic
Oligonucleotide 165agtcctcatc tccctcaagc agg 2316623DNAArtificial
SequenceSynthetic Oligonucleotide 166agtcctcatc tccctcaagc agg
2316724DNAArtificial SequenceSynthetic Oligonucleotide
167agtcctcatc tccctcaaag cagg 2416822DNAArtificial
SequenceSynthetic Oligonucleotide 168agtcctcatc tccctcagca gg
2216924DNAArtificial SequenceSynthetic Oligonucleotide
169agtcctcatc tccctcatag cagg 2417015DNAArtificial
SequenceSynthetic Oligonucleotide 170agtcctcata gcagg
1517117DNAArtificial SequenceSynthetic Oligonucleotide
171agtcctcatc tagcagg 1717214DNAArtificial SequenceSynthetic
Oligonucleotide 172agtcctcaag cagg 1417351DNAArtificial
SequenceSynthetic Oligonucleotide 173agtcctcatc tccctcaaag
gcagtgtttg ttacttgagt ttgtcagcag g 5117425DNAArtificial
SequenceSynthetic Oligonucleotide 174agtcctcatc tccctcatta gcagg
2517565DNAArtificial SequenceSynthetic Oligonucleotide
175agtcctcatc tccctcaggg cttgtttaca gctcaccttt gaatttgcac
aagcgtgcaa 60gcagg 6517621DNAArtificial SequenceSynthetic
Oligonucleotide 176agtcctcatc tccctagcag g 2117721DNAArtificial
SequenceSynthetic Oligonucleotide 177agtcctcatc cctcaagcag g
2117822DNAArtificial SequenceSynthetic Oligonucleotide
178agtcctcatc tccctaagca gg 2217923DNAArtificial SequenceSynthetic
Oligonucleotide 179agtcctcaac tccctcaagc agg 2318024DNAArtificial
SequenceSynthetic Oligonucleotide 180agtcctcaac tccctcaaag cagg
2418117DNAArtificial SequenceSynthetic Oligonucleotide
181agtcctcaac tccctca 1718222DNAArtificial SequenceSynthetic
Oligonucleotide 182agtcctcaac tccctcagca gg 2218356DNAArtificial
SequenceSynthetic Oligonucleotide 183agtcctcaac tccctcaaga
aaggtgttga aaatcagaaa gagagaaaca agcagg 5618462DNAArtificial
SequenceSynthetic Oligonucleotide 184agtcctcaac tccctcaatc
tacggtccat tcccgtttcc actcaccttg cgccgcagca 60gg
6218522DNAArtificial SequenceSynthetic Oligonucleotide
185agtcctcaac tccctaagca gg 2218666DNAArtificial SequenceSynthetic
Oligonucleotide 186agtcctcaac tccctcaacc aactttaaca tcctgctggt
tctgtcatta ataagttgaa 60agcagg 6618764DNAArtificial
SequenceSynthetic Oligonucleotide 187agtcctcaac tccctcacag
caaataaaaa agttgtttat gcatattcag ataagcaaag 60cagg
6418821DNAArtificial SequenceSynthetic Oligonucleotide
188agtcctcaac tcccaagcag g 2118923DNAArtificial SequenceSynthetic
Oligonucleotide 189actcctcatc cccctcaagc cgg 2319024DNAArtificial
SequenceSynthetic Oligonucleotide 190actcctcatc cccctcaaag ccgg
2419124DNAArtificial SequenceSynthetic Oligonucleotide
191actcctcatc cccctcagag ccgg 2419213DNAArtificial
SequenceSynthetic Oligonucleotide 192actcctcagc cgg
1319325DNAArtificial SequenceSynthetic Oligonucleotide
193actcctcatc cccctcaaaa gccgg 2519425DNAArtificial
SequenceSynthetic Oligonucleotide 194actcctcatc cccctcagca gccgg
2519524DNAArtificial SequenceSynthetic Oligonucleotide
195actcctcatc cccctcatag ccgg 2419624DNAArtificial
SequenceSynthetic Oligonucleotide 196actcctcatc cccctcatcc ccgg
2419718DNAArtificial SequenceSynthetic Oligonucleotide
197actcctcatc ccagccgg 1819822DNAArtificial SequenceSynthetic
Oligonucleotide 198actcctcatc cccctaagcc gg 2219925DNAArtificial
SequenceSynthetic Oligonucleotide 199actcctcatc cccctcaata gccgg
2520025DNAArtificial SequenceSynthetic Oligonucleotide
200actcctcacc cccctcagca gccgg 2520123DNAArtificial
SequenceSynthetic Oligonucleotide 201gcagatgtag tgtttccaca ggg
2320222DNAArtificial SequenceSynthetic Oligonucleotide
202gcagatgtag tgtttcacag gg 2220324DNAArtificial SequenceSynthetic
Oligonucleotide 203gcagatgtag tgtttcccac aggg 2420419DNAArtificial
SequenceSynthetic Oligonucleotide 204gcagatgtag tgcacaggg
1920522DNAArtificial SequenceSynthetic Oligonucleotide
205gcagatgtag tgtttcccag gg 2220616DNAArtificial SequenceSynthetic
Oligonucleotide 206gcagatgtac acaggg 1620720DNAArtificial
SequenceSynthetic Oligonucleotide 207gcagatgtag tgtcacaggg
2020821DNAArtificial SequenceSynthetic Oligonucleotide
208gcagatgtag tgttcacagg g 2120921DNAArtificial SequenceSynthetic
Oligonucleotide 209gcagatgtag tgtttccagg g 2121018DNAArtificial
SequenceSynthetic Oligonucleotide 210gcagatgtag tcacaggg
1821112DNAArtificial SequenceSynthetic Oligonucleotide
211gcagatgtag gg 1221223DNAArtificial SequenceSynthetic
Oligonucleotide 212acatatgtag tatttccaca ggg 2321324DNAArtificial
SequenceSynthetic Oligonucleotide 213acatatgtag tatttcccac aggg
2421422DNAArtificial SequenceSynthetic Oligonucleotide
214acatatgtag tatttcacag gg 2221521DNAArtificial SequenceSynthetic
Oligonucleotide 215acatatgtag tatttccagg g 2121613DNAArtificial
SequenceSynthetic Oligonucleotide 216acatatcaca ggg
1321711DNAArtificial SequenceSynthetic Oligonucleotide
217acatcacagg g 1121818DNAArtificial SequenceSynthetic
Oligonucleotide 218acatatgtag tcacaggg 1821917DNAArtificial
SequenceSynthetic Oligonucleotide 219acatatgtag tatttcc
1722012DNAArtificial SequenceSynthetic Oligonucleotide
220acatatgtag gg 1222117DNAArtificial SequenceSynthetic
Oligonucleotide 221acatatgtag cacaggg 1722223DNAArtificial
SequenceSynthetic Oligonucleotide 222ccagatgtag tattcccaca ggg
2322324DNAArtificial SequenceSynthetic Oligonucleotide
223ccagatgtag tattccccac aggg 2422419DNAArtificial
SequenceSynthetic Oligonucleotide 224ccagatgtag tatacaggg
1922520DNAArtificial SequenceSynthetic Oligonucleotide
225ccagatgtag tatcacaggg 2022626DNAArtificial SequenceSynthetic
Oligonucleotide 226ccagatgtag tattcccaac acaggg
2622721DNAArtificial SequenceSynthetic Oligonucleotide
227ccagatgtag tattcacagg g 2122821DNAArtificial SequenceSynthetic
Oligonucleotide 228ccagatgtag tattcccagg g 2122922DNAArtificial
SequenceSynthetic Oligonucleotide 229ccagatgtag tattccacag gg
2223023DNAArtificial SequenceSynthetic Oligonucleotide
230ctagatgaag tgcttccaca tgg 2323124DNAArtificial SequenceSynthetic
Oligonucleotide 231ctagatgaag tgcttcccac atgg 2423222DNAArtificial
SequenceSynthetic Oligonucleotide 232ctagatgaag tgcttcacat gg
2223312DNAArtificial SequenceSynthetic Oligonucleotide
233ctagatgaag tg 1223425DNAArtificial SequenceSynthetic
Oligonucleotide 234ctagatgaag tgcttccaca catgg 2523521DNAArtificial
SequenceSynthetic Oligonucleotide 235ctagatgaag tgcttccatg g
2123622DNAArtificial SequenceSynthetic Oligonucleotide
236ctagatgaag tgcttcccat gg 2223756DNAArtificial SequenceSynthetic
Oligonucleotide 237taatacgact cactatagga gtcctcatct ccctcaagcg
ttttagagct atgctg 5623856DNAArtificial SequenceSynthetic
Oligonucleotide 238taatacgact cactataggc tccctcaagc aggccccgcg
ttttagagct atgctg 5623956DNAArtificial SequenceSynthetic
Oligonucleotide 239taatacgact cactataggt gtgaagagct tcactgagtg
ttttagagct atgctg 5624056DNAArtificial SequenceSynthetic
Oligonucleotide 240taatacgact cactataggg cagatgtagt gtttccacag
ttttagagct atgctg 5624155DNAArtificial SequenceSynthetic
Oligonucleotide 241gataacggac tagccttatt ttaacttgct atgcttttca
gcatagctct aaaac 5524281DNAArtificial SequenceSynthetic
Oligonucleotide 242cggactagcc ttattttaac ttgctatttc tagctctaaa
acgcttgagg gagatgagga 60ctcctatagt gagtcgtatt a
8124381DNAArtificial SequenceSynthetic Oligonucleotide
243cggactagcc ttattttaac ttgctatttc tagctctaaa acgcggggcc
tgcttgaggg 60agcctatagt gagtcgtatt a 8124481DNAArtificial
SequenceSynthetic Oligonucleotide 244cggactagcc ttattttaac
ttgctatttc tagctctaaa acactcagtg aagctcttca 60cacctatagt gagtcgtatt
a 8124581DNAArtificial SequenceSynthetic Oligonucleotide
245cggactagcc ttattttaac ttgctatttc tagctctaaa actgtggaaa
cactacatct 60gccctatagt gagtcgtatt a 8124619DNAArtificial
SequenceSynthetic Oligonucleotide 246taatacgact cactatagg
1924753DNAArtificial SequenceSynthetic Oligonucleotide
247aacacannnn ccngcttgag ggagatgagg actnnnnacc tgccgagaac aca
5324853DNAArtificial SequenceSynthetic Oligonucleotide
248tcttctnnnn ccngcggggc ctgcttgagg gagnnnnacc tgccgagtct tct
5324953DNAArtificial SequenceSynthetic Oligonucleotide
249agagaannnn ccnactcagt gaagctcttc acannnnacc tgccgagaga gaa
5325053DNAArtificial SequenceSynthetic Oligonucleotide
250ttgtgtnnnn ccntgtggaa acactacatc tgcnnnnacc tgccgagttg tgt
5325129DNAArtificial SequenceSynthetic Oligonucleotide
251ctagcagtcc tcatctccct caagcaggc 2925229DNAArtificial
SequenceSynthetic Oligonucleotide 252agctgcctgc ttgagggaga
tgaggactg 2925329DNAArtificial SequenceSynthetic Oligonucleotide
253ctagtctccc tcaagcaggc cccgctggt 2925429DNAArtificial
SequenceSynthetic Oligonucleotide 254agctaccagc ggggcctgct
tgagggaga 2925529DNAArtificial SequenceSynthetic Oligonucleotide
255ctagctgtga agagcttcac tgagtagga 2925629DNAArtificial
SequenceSynthetic Oligonucleotide 256agcttcctac tcagtgaagc
tcttcacag 2925729DNAArtificial SequenceSynthetic Oligonucleotide
257ctagtgcaga tgtagtgttt ccacagggt 2925829DNAArtificial
SequenceSynthetic Oligonucleotide 258agctaccctg tggaaacact
acatctgca 2925926DNAArtificial SequenceSynthetic Oligonucleotide
259gcgacacgga aatgttgaat actcat 2626025DNAArtificial
SequenceSynthetic Oligonucleotide 260ggagtcaggc aactatggat gaacg
2526160DNAArtificial SequenceSynthetic Oligonucleotide
261actgtgaaga
gcttcactga gtaggattaa gatattgcag atgtagtgtt tccacagggt
6026260DNAArtificial SequenceSynthetic Oligonucleotide
262actgtgaaga gcttcactga gtaggattaa gatattgaag atgtagtgtt
tccacagggt 6026360DNAArtificial SequenceSynthetic Oligonucleotide
263actgtgaaga gcttcactga gtaggattaa gatattgaag atgtagtgtt
tccactgggt 6026460DNAArtificial SequenceSynthetic Oligonucleotide
264actgtgaaga gcttcactga gtaggattaa gatattgcag atggagggtt
tccacagggt 6026560DNAArtificial SequenceSynthetic Oligonucleotide
265actgtgaaga gcttcactga gtaggattaa gatattgcag atgtagtgtt
accagagggt 6026660DNAArtificial SequenceSynthetic Oligonucleotide
266actgtgaaga gcttcactga gtaggattaa gatattgggg atgtagtgtt
tccactgggt 6026760DNAArtificial SequenceSynthetic Oligonucleotide
267tccctcaagc aggccccgct ggtgcactga agagccaccc tgtggaaaca
ctacatctgc 6026860DNAArtificial SequenceSynthetic Oligonucleotide
268tccctcaagc aggccccgct ggtgcactga agagccaccc tgtggaaaca
ctacatcttc 6026960DNAArtificial SequenceSynthetic Oligonucleotide
269tccctcaagc aggccccgct ggtgcactga agagccaccc agtggaaaca
ctacatcttc 6027060DNAArtificial SequenceSynthetic Oligonucleotide
270tccctcaagc aggccccgct ggtgcactga agagccaccc tgtggaaacc
ctccatctgc 6027160DNAArtificial SequenceSynthetic Oligonucleotide
271tccctcaagc aggccccgct ggtgcactga agagccaccc tctggtaaca
ctacatctgc 6027260DNAArtificial SequenceSynthetic Oligonucleotide
272tccctcaagc aggccccgct ggtgcactga agagccaccc agtggaaaca
ctacatcccc 6027362DNAArtificial SequenceSynthetic Oligonucleotide
273aatgatacgg cgaccaccga gatctacact ctttccctac acgacgctct
tccgatctaa 60ca 6227449DNAArtificial SequenceSynthetic
Oligonucleotide 274tgttagatcg gaagagcgtc gtgtagggaa agagtgtaga
tctcggtgg 4927562DNAArtificial SequenceSynthetic Oligonucleotide
275aatgatacgg cgaccaccga gatctacact ctttccctac acgacgctct
tccgatcttt 60ca 6227649DNAArtificial SequenceSynthetic
Oligonucleotide 276tgaaagatcg gaagagcgtc gtgtagggaa agagtgtaga
tctcggtgg 4927758DNAArtificial SequenceSynthetic Oligonucleotide
277aatgatacgg cgaccaccga gatctacact ctttccctac acgacgctct tccgatct
5827845DNAArtificial SequenceSynthetic Oligonucleotide
278agatcggaag agcgtcgtgt agggaaagag tgtagatctc ggtgg
4527915DNAArtificial SequenceSynthetic Oligonucleotide
279gacggcatac gagat 1528028DNAArtificial SequenceSynthetic
Oligonucleotide 280aacaatctcg tatgccgtct tctgcttg
2828128DNAArtificial SequenceSynthetic Oligonucleotide
281tcttatctcg tatgccgtct tctgcttg 2828228DNAArtificial
SequenceSynthetic Oligonucleotide 282agagatctcg tatgccgtct tctgcttg
2828328DNAArtificial SequenceSynthetic Oligonucleotide
283ttgtatctcg tatgccgtct tctgcttg 2828440DNAArtificial
SequenceSynthetic Oligonucleotide 284caagcagaag acggcatacg
agattgtgtt ctcggcaggt 4028540DNAArtificial SequenceSynthetic
Oligonucleotide 285caagcagaag acggcatacg agatagaaga ctcggcaggt
4028640DNAArtificial SequenceSynthetic Oligonucleotide
286caagcagaag acggcatacg agatttctct ctcggcaggt 4028740DNAArtificial
SequenceSynthetic Oligonucleotide 287caagcagaag acggcatacg
agatacacaa ctcggcaggt 4028820DNAArtificial SequenceSynthetic
Oligonucleotide 288aatgatacgg cgaccaccga 2028982DNAArtificial
SequenceSynthetic Oligonucleotide 289aatgatacgg cgaccaccga
gatctacact ctttccctac acgacgctct tccgatctnn 60nnacctacct gccgagaaca
ca 8229082DNAArtificial SequenceSynthetic Oligonucleotide
290aatgatacgg cgaccaccga gatctacact ctttccctac acgacgctct
tccgatctnn 60nnacctacct gccgagtctt ct 8229182DNAArtificial
SequenceSynthetic Oligonucleotide 291aatgatacgg cgaccaccga
gatctacact ctttccctac acgacgctct tccgatctnn 60nnacctacct gccgagagag
aa 8229282DNAArtificial SequenceSynthetic Oligonucleotide
292aatgatacgg cgaccaccga gatctacact ctttccctac acgacgctct
tccgatctnn 60nnacctacct gccgagttgt gt 8229324DNAArtificial
SequenceSynthetic Oligonucleotide 293caagcagaag acggcatacg agat
2429453DNAArtificial SequenceSynthetic Oligonucleotide
294acactctttc cctacacgac gctcttccga tctcaagtct agcaagcagg cca
5329553DNAArtificial SequenceSynthetic Oligonucleotide
295acactctttc cctacacgac gctcttccga tctcaggcac tgagtgggaa agt
5329653DNAArtificial SequenceSynthetic Oligonucleotide
296acactctttc cctacacgac gctcttccga tcttaacccc aagtcagcaa gca
5329753DNAArtificial SequenceSynthetic Oligonucleotide
297acactctttc cctacacgac gctcttccga tctttgctgg tcaataccct ggc
5329853DNAArtificial SequenceSynthetic Oligonucleotide
298acactctttc cctacacgac gctcttccga tcttgagtac ccctgaaatg ggc
5329953DNAArtificial SequenceSynthetic Oligonucleotide
299acactctttc cctacacgac gctcttccga tcttcgctac caatcagggc ttt
5330053DNAArtificial SequenceSynthetic Oligonucleotide
300acactctttc cctacacgac gctcttccga tctccattgc cacttgtttg cat
5330153DNAArtificial SequenceSynthetic Oligonucleotide
301acactctttc cctacacgac gctcttccga tctcctaccc ccacaacttt gct
5330253DNAArtificial SequenceSynthetic Oligonucleotide
302acactctttc cctacacgac gctcttccga tctgtgtaca tccagtgcac cca
5330357DNAArtificial SequenceSynthetic Oligonucleotide
303acactctttc cctacacgac gctcttccga tcttcggaaa ggactttgaa tacttgt
5730453DNAArtificial SequenceSynthetic Oligonucleotide
304acactctttc cctacacgac gctcttccga tctcggccca agacctcatt cac
5330553DNAArtificial SequenceSynthetic Oligonucleotide
305acactctttc cctacacgac gctcttccga tctgtcctct ctggggcaga agt
5330655DNAArtificial SequenceSynthetic Oligonucleotide
306acactctttc cctacacgac gctcttccga tctagctgag tcatgagttg tctcc
5530753DNAArtificial SequenceSynthetic Oligonucleotide
307acactctttc cctacacgac gctcttccga tctctgccag cttctcacac cat
5330853DNAArtificial SequenceSynthetic Oligonucleotide
308acactctttc cctacacgac gctcttccga tctctgaagg acaaaggcgg gaa
5330953DNAArtificial SequenceSynthetic Oligonucleotide
309acactctttc cctacacgac gctcttccga tctaaggtgc taaaggctcc acg
5331053DNAArtificial SequenceSynthetic Oligonucleotide
310acactctttc cctacacgac gctcttccga tctgaccatt ggtgagccca gag
5331153DNAArtificial SequenceSynthetic Oligonucleotide
311acactctttc cctacacgac gctcttccga tcttttttcg ggcaactgct cac
5331253DNAArtificial SequenceSynthetic Oligonucleotide
312acactctttc cctacacgac gctcttccga tctgcaagcc ttctctcctc aga
5331354DNAArtificial SequenceSynthetic Oligonucleotide
313acactctttc cctacacgac gctcttccga tctacacaaa cttccctgag accc
5431453DNAArtificial SequenceSynthetic Oligonucleotide
314acactctttc cctacacgac gctcttccga tcttgagtta gccctgctgt tca
5331555DNAArtificial SequenceSynthetic Oligonucleotide
315acactctttc cctacacgac gctcttccga tcttgaagag cttcactgag tagga
5531654DNAArtificial SequenceSynthetic Oligonucleotide
316acactctttc cctacacgac gctcttccga tcttcccctt acagccaatt tcgt
5431758DNAArtificial SequenceSynthetic Oligonucleotide
317acactctttc cctacacgac gctcttccga tcttgctgat gaaatgcaat taagaggt
5831853DNAArtificial SequenceSynthetic Oligonucleotide
318acactctttc cctacacgac gctcttccga tctggtccct gcaagccagt atg
5331955DNAArtificial SequenceSynthetic Oligonucleotide
319acactctttc cctacacgac gctcttccga tctatcaaag ccttgtatca cagtt
5532054DNAArtificial SequenceSynthetic Oligonucleotide
320acactctttc cctacacgac gctcttccga tctcccaaat aatgcaggag ccaa
5432155DNAArtificial SequenceSynthetic Oligonucleotide
321acactctttc cctacacgac gctcttccga tctctgcctt tagtgggaca gactt
5532254DNAArtificial SequenceSynthetic Oligonucleotide
322acactctttc cctacacgac gctcttccga tctagtaacc ctagtagccc tcca
5432354DNAArtificial SequenceSynthetic Oligonucleotide
323acactctttc cctacacgac gctcttccga tctcattgca gtgagccgag attg
5432454DNAArtificial SequenceSynthetic Oligonucleotide
324acactctttc cctacacgac gctcttccga tcttggcaaa gttcacttcc atgt
5432553DNAArtificial SequenceSynthetic Oligonucleotide
325acactctttc cctacacgac gctcttccga tcttgctctg tgatgtctgc cac
5332655DNAArtificial SequenceSynthetic Oligonucleotide
326acactctttc cctacacgac gctcttccga tcttgtgtag gattgtgaac cagca
5532753DNAArtificial SequenceSynthetic Oligonucleotide
327acactctttc cctacacgac gctcttccga tcttcccagc ccagcatttt tct
5332853DNAArtificial SequenceSynthetic Oligonucleotide
328acactctttc cctacacgac gctcttccga tctaggttgc tttgtgcaca gtc
5332953DNAArtificial SequenceSynthetic Oligonucleotide
329acactctttc cctacacgac gctcttccga tctcctggct tgggatgttg gaa
5333053DNAArtificial SequenceSynthetic Oligonucleotide
330acactctttc cctacacgac gctcttccga tctttgccca aggtcatact gct
5333156DNAArtificial SequenceSynthetic Oligonucleotide
331acactctttc cctacacgac gctcttccga tctacccact aggtagccat aatcca
5633253DNAArtificial SequenceSynthetic Oligonucleotide
332acactctttc cctacacgac gctcttccga tctcggtcat gtcgcttgga aga
5333356DNAArtificial SequenceSynthetic Oligonucleotide
333acactctttc cctacacgac gctcttccga tctttggccc atattgcttt atgctg
5633453DNAArtificial SequenceSynthetic Oligonucleotide
334acactctttc cctacacgac gctcttccga tctattaggg gttggctgca tga
5333553DNAArtificial SequenceSynthetic Oligonucleotide
335acactctttc cctacacgac gctcttccga tctccaagac gtgttgcatg ctg
5333657DNAArtificial SequenceSynthetic Oligonucleotide
336acactctttc cctacacgac gctcttccga tcttgggagg tgataaattc cctaaat
5733753DNAArtificial SequenceSynthetic Oligonucleotide
337acactctttc cctacacgac gctcttccga tctccagaga caaaggtggg gag
5333856DNAArtificial SequenceSynthetic Oligonucleotide
338acactctttc cctacacgac gctcttccga tcttcataca gaagagcaaa gtacca
5633953DNAArtificial SequenceSynthetic Oligonucleotide
339acactctttc cctacacgac gctcttccga tctcaaagag gggtatcggg agc
5334057DNAArtificial SequenceSynthetic Oligonucleotide
340acactctttc cctacacgac gctcttccga tctaaatgga agaaccaagt agatgaa
5734155DNAArtificial SequenceSynthetic Oligonucleotide
341acactctttc cctacacgac gctcttccga tctttttggt tgacagatgg ccaca
5534258DNAArtificial SequenceSynthetic Oligonucleotide
342acactctttc cctacacgac gctcttccga tcttcttact tgtgtgattt tagaacaa
5834353DNAArtificial SequenceSynthetic Oligonucleotide
343acactctttc cctacacgac gctcttccga tctgatggtt catgcagagg gct
5334453DNAArtificial SequenceSynthetic Oligonucleotide
344acactctttc cctacacgac gctcttccga tctgctggtc tttcctgagc tgt
5334555DNAArtificial SequenceSynthetic Oligonucleotide
345acactctttc cctacacgac gctcttccga tctctccatc agatacctgt accca
5534655DNAArtificial SequenceSynthetic Oligonucleotide
346acactctttc cctacacgac gctcttccga tctgggaaaa cactctctct ctgct
5534753DNAArtificial SequenceSynthetic Oligonucleotide
347acactctttc cctacacgac gctcttccga tctggaggcc acgacacaca ata
5334854DNAArtificial SequenceSynthetic Oligonucleotide
348gtgactggag ttcagacgtg tgctcttccg atctcacagg gtggctcttc agtg
5434954DNAArtificial SequenceSynthetic Oligonucleotide
349gtgactggag ttcagacgtg tgctcttccg atcttgcaca tgtttccaca gggt
5435054DNAArtificial SequenceSynthetic Oligonucleotide
350gtgactggag ttcagacgtg tgctcttccg atctagtgtt tccaggagcg gttt
5435154DNAArtificial SequenceSynthetic Oligonucleotide
351gtgactggag ttcagacgtg tgctcttccg atctaagcct caggcacaac tctg
5435253DNAArtificial SequenceSynthetic Oligonucleotide
352gtgactggag ttcagacgtg tgctcttccg atcttagggg aggggcaaag aca
5335354DNAArtificial SequenceSynthetic Oligonucleotide
353gtgactggag ttcagacgtg tgctcttccg atctgggaac agtggtatgc tggt
5435455DNAArtificial SequenceSynthetic Oligonucleotide
354gtgactggag ttcagacgtg tgctcttccg atctagtgtg gacactgaca aggaa
5535554DNAArtificial SequenceSynthetic Oligonucleotide
355gtgactggag ttcagacgtg tgctcttccg atcttcactg cctgggtgct ttag
5435654DNAArtificial SequenceSynthetic Oligonucleotide
356gtgactggag ttcagacgtg tgctcttccg atcttacccc agcctccagc ttta
5435754DNAArtificial SequenceSynthetic Oligonucleotide
357gtgactggag ttcagacgtg tgctcttccg atcttgacta ctggggagcg atga
5435856DNAArtificial SequenceSynthetic Oligonucleotide
358gtgactggag ttcagacgtg tgctcttccg atctaggctg ttatgcagga aaggaa
5635954DNAArtificial SequenceSynthetic Oligonucleotide
359gtgactggag ttcagacgtg tgctcttccg atctgcggtt gaggtggatg gaag
5436054DNAArtificial SequenceSynthetic Oligonucleotide
360gtgactggag ttcagacgtg tgctcttccg atctggcagc atcccttaca tcct
5436157DNAArtificial SequenceSynthetic Oligonucleotide
361gtgactggag ttcagacgtg tgctcttccg atctagaaaa agcttcccca gaaagga
5736254DNAArtificial SequenceSynthetic Oligonucleotide
362gtgactggag ttcagacgtg tgctcttccg atctctgcac caacctctac gtcc
5436354DNAArtificial SequenceSynthetic Oligonucleotide
363gtgactggag ttcagacgtg tgctcttccg atctctggag agggcatagt tggc
5436454DNAArtificial SequenceSynthetic Oligonucleotide
364gtgactggag ttcagacgtg tgctcttccg atcttggaag gctctttgtg ggtt
5436554DNAArtificial SequenceSynthetic Oligonucleotide
365gtgactggag ttcagacgtg tgctcttccg atctttccta gcgggaactg gaaa
5436654DNAArtificial SequenceSynthetic Oligonucleotide
366gtgactggag ttcagacgtg tgctcttccg atctaggcta atggggtagg ggat
5436754DNAArtificial SequenceSynthetic Oligonucleotide
367gtgactggag ttcagacgtg tgctcttccg atcttgtcca tgttggctga ggtg
5436854DNAArtificial SequenceSynthetic Oligonucleotide
368gtgactggag ttcagacgtg tgctcttccg atctcaggcc aaccttgaca actt
5436954DNAArtificial SequenceSynthetic Oligonucleotide
369gtgactggag ttcagacgtg tgctcttccg atctagcagg ccaaagatgt ctcc
5437057DNAArtificial SequenceSynthetic Oligonucleotide
370gtgactggag ttcagacgtg tgctcttccg atcttctgct cttgaggtta tttgtcc
5737156DNAArtificial SequenceSynthetic Oligonucleotide
371gtgactggag ttcagacgtg tgctcttccg atctgggacc aatttgctac tcatgg
5637254DNAArtificial SequenceSynthetic Oligonucleotide
372gtgactggag ttcagacgtg tgctcttccg atcttggagg ctgtaaacgt cctg
5437359DNAArtificial SequenceSynthetic Oligonucleotide
373gtgactggag ttcagacgtg tgctcttccg atcttgctat gatttgctga attactcct
5937455DNAArtificial SequenceSynthetic Oligonucleotide
374gtgactggag ttcagacgtg tgctcttccg atctgcaatt ttgcagacca ccatc
5537554DNAArtificial SequenceSynthetic Oligonucleotide
375gtgactggag ttcagacgtg tgctcttccg atctggcagc ttgcaacctt cttg
5437654DNAArtificial SequenceSynthetic Oligonucleotide
376gtgactggag ttcagacgtg tgctcttccg atcttcatga gagtttcccc aaca
5437758DNAArtificial SequenceSynthetic Oligonucleotide
377gtgactggag ttcagacgtg tgctcttccg atctacttga gggggaaaaa gtttctta
5837854DNAArtificial SequenceSynthetic Oligonucleotide
378gtgactggag ttcagacgtg tgctcttccg atcttggtcc ctgtctgtca ttgg
5437954DNAArtificial SequenceSynthetic Oligonucleotide
379gtgactggag ttcagacgtg tgctcttccg atctaagcga gtgactgtct ggga
5438054DNAArtificial SequenceSynthetic Oligonucleotide
380gtgactggag ttcagacgtg tgctcttccg atctcatggg tgggacacgt agtt
5438155DNAArtificial SequenceSynthetic Oligonucleotide
381gtgactggag ttcagacgtg tgctcttccg atctggcttt cctggacacc ctatc
5538253DNAArtificial SequenceSynthetic Oligonucleotide
382gtgactggag ttcagacgtg tgctcttccg atctagagcg agggagcgat gta
5338355DNAArtificial SequenceSynthetic Oligonucleotide
383gtgactggag ttcagacgtg tgctcttccg atctttgtgg accactgctt agtgc
5538453DNAArtificial SequenceSynthetic Oligonucleotide
384gtgactggag ttcagacgtg tgctcttccg atctcaacta ccctgaggcc acc
5338554DNAArtificial SequenceSynthetic Oligonucleotide
385gtgactggag ttcagacgtg tgctcttccg atctggtcag cactcctcag cttt
5438654DNAArtificial SequenceSynthetic Oligonucleotide
386gtgactggag ttcagacgtg tgctcttccg atcttggagg atgcatgcca catt
5438754DNAArtificial SequenceSynthetic Oligonucleotide
387gtgactggag ttcagacgtg tgctcttccg atctcccagc ctctttgacc cttc
5438853DNAArtificial SequenceSynthetic Oligonucleotide
388gtgactggag ttcagacgtg tgctcttccg atctcccaca ccaggctgta agg
5338958DNAArtificial SequenceSynthetic Oligonucleotide
389gtgactggag ttcagacgtg tgctcttccg atcttagata tatgggtgtg tctgtacg
5839054DNAArtificial SequenceSynthetic Oligonucleotide
390gtgactggag ttcagacgtg tgctcttccg atctttccaa agtggctgaa ccat
5439154DNAArtificial SequenceSynthetic Oligonucleotide
391gtgactggag ttcagacgtg tgctcttccg atctcccaca gggctgatgt ttca
5439257DNAArtificial SequenceSynthetic Oligonucleotide
392gtgactggag ttcagacgtg tgctcttccg atctttgtaa tgcaacctct gtcatgc
5739354DNAArtificial SequenceSynthetic Oligonucleotide
393gtgactggag ttcagacgtg tgctcttccg atctccagct ccagcaatcc atga
5439455DNAArtificial SequenceSynthetic Oligonucleotide
394gtgactggag ttcagacgtg tgctcttccg atcttttggg aaagatagcc ctgga
5539554DNAArtificial SequenceSynthetic Oligonucleotide
395gtgactggag ttcagacgtg tgctcttccg atctcaatga aacagcgggg aggt
5439654DNAArtificial SequenceSynthetic Oligonucleotide
396gtgactggag ttcagacgtg tgctcttccg atctacaatc acgtgtcctt cact
5439754DNAArtificial SequenceSynthetic Oligonucleotide
397gtgactggag ttcagacgtg tgctcttccg atctcagatc cctcctgggc aatg
5439854DNAArtificial SequenceSynthetic Oligonucleotide
398gtgactggag ttcagacgtg tgctcttccg atctgtcagg aggcaaggag gaac
5439958DNAArtificial SequenceSynthetic Oligonucleotide
399gtgactggag ttcagacgtg tgctcttccg atctacttcc ttccttttga gaccaagt
5840054DNAArtificial SequenceSynthetic Oligonucleotide
400gtgactggag ttcagacgtg tgctcttccg atctgcggca gattcctggt gatt
5440154DNAArtificial SequenceSynthetic Oligonucleotide
401gtgactggag ttcagacgtg tgctcttccg atctggtcac catcagcaca gtca
5440256DNAArtificial SequenceSynthetic Oligonucleotide
402caagcagaag acggcatacg agatatatca gtgtgactgg agttcagacg tgtgct
5640356DNAArtificial SequenceSynthetic Oligonucleotide
403caagcagaag acggcatacg agattttcac cggtgactgg agttcagacg tgtgct
5640456DNAArtificial SequenceSynthetic Oligonucleotide
404caagcagaag acggcatacg agatccactc atgtgactgg agttcagacg tgtgct
5640556DNAArtificial SequenceSynthetic Oligonucleotide
405caagcagaag acggcatacg agattacgta cggtgactgg agttcagacg tgtgct
5640656DNAArtificial SequenceSynthetic Oligonucleotide
406caagcagaag acggcatacg agatcgaaac tcgtgactgg agttcagacg tgtgct
5640756DNAArtificial SequenceSynthetic Oligonucleotide
407caagcagaag acggcatacg agatatcagt atgtgactgg agttcagacg tgtgct
5640857DNAArtificial SequenceSynthetic Oligonucleotide
408aatgatacgg cgaccaccga gatctacaca ttactcgaca ctctttccct acacgac
5740957DNAArtificial SequenceSynthetic Oligonucleotide
409aatgatacgg cgaccaccga gatctacact ccggagaaca ctctttccct acacgac
5741057DNAArtificial SequenceSynthetic Oligonucleotide
410aatgatacgg cgaccaccga gatctacacc gctcattaca ctctttccct acacgac
57
* * * * *